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Abstract
Background
In 2017 approximately 50 million people worldwide were living with dementia. With
Alzheimer’s disease (AD), accounting for 50-70% of dementia cases making this debilitating
disease, with no current effective prevention, treatment or cure, a critical healthcare concern.
Genome wide association studies (GWAS) have identified a number of risk genes for late
onset AD (LOAD); Apolipoprotein E (APOE), a gene involved in the cholesterol/lipid pathway
is considered the gene with the greatest risk. The third most associated AD risk gene is
Clusterin (CLU), is also involved in the cholesterol/lipid pathway. CLU has been implicated in
both a protective and aggravating role in AD making it a compelling gene for further study.
The identification of a fluid-based AD biomarker/s has become an increasingly important area
of study to assist in the identification of individuals before substantial pathological or
cognitive symptoms arise. Plasma clusterin is one such biomarker showing promise as levels
differ between healthy individuals and those with mild cognitive impairment (MCI) and AD.
Methylation of CLU, from brain samples, has been associated with A pathology and lower
risk of AD diagnosis. In addition, methylation of other AD associated risk genes has been
shown to be altered in the periphery. These factors make CLU a prime candidate for
peripheral methylation study.
Aims
The overarching aim of the study was to investigate methylation within the CLU promoter
region in peripheral blood samples. Specifically, to determine whether there is a relationship
between specific methylation sites and AD-related phenotypes. The first study aimed to crosssectionally assess CLU promoter region methylation and its association with clinical
classification, genetic variation in CLU (rs9331888/rs11136000), and pathological biomarkers
(Chapter 3.2). The second study aimed to analyse the influence of methylation on longitudinal
cognitive performance (Chapter 3.3).
Methods
Utilising DNA samples collected as part of the Australian Imaging, Biomarkers and Lifestyle
Flagship Study of Ageing (AIBL). Methylation analysis was conducted on an initial 768 samples
comprised of healthy controls (HC), MCI and AD participants. Methylation data was collected
VI

using the Agena MassArray platform across the CLU promoter region.

Percentage

methylation was determined by the EpiTYPER software. ANCOVA’s were used to study
association between methylation levels and clinical classifications as well as genetic variants,
whilst Spearman’s Partial correlations were used to investigate the relationship between
methylation and brain imaging and fluid biomarker data (Chapter 3.2). Linear mixed models
(LMMs) were employed to assess associations between methylation and cognitive
performance, both at baseline and over 7.5 years (Chapter 3.3). Analyses were first conducted
across the whole sample, followed by HC only, then HC with high brain A burden (A+). All
P-values were corrected for the false discovery rate (FDR).
Results
Analysis revealed an association between clinical classification and methylation. After FDR
correction significant decreases in methylation from HC to MCI was seen at 3 loci, with
CpG_14 and CpG_15 showing a significant decrease from HC to AD. CpG_25_26_27_28 also
showed a decrease in methylation between HC and AD. When analysing methylation patterns
with respect to rs11136000 a significant difference in methylation levels were observed
between non-carriers and carriers of the protective T allele at CpG_14, CpG_16 and
CpG_23_24. This was only observed when assessed across all participants, whilst no
significant differences in methylation were observed with respect to rs9331888.
An increased percentage methylation at CpG_16 was associated with elevated plasma
clusterin (⍴=0.1858, p=0.0034, q=0.0157) within the HC group, which remained as a trend in
the HC A+ after FDR correction (=0.2704, p=0.0043, q=0.0817). With respect to
cerebrospinal fluid (CSF) biomarkers no sites survived FDR correction in the whole cohort.
CpG_37 was inversely correlated with phosphorylated tau (P-tau; ⍴=-0.4585, p=0.001,
q=0.0155) within the HC cohort. Whilst with the A+ HC group higher percentage methylation
at CpG_1 (⍴=-0.6584, p=0.0016, q=0.0028), CpG_8_9 (⍴=-0.4704, p=0.0363, q=0.0297) and
CpG_10 (⍴=-0.4433, p=0.0503, q=0.0297) was associated with elevated A42 CSF levels.
Increased methylation at CpG_1, CpG_2_3, CpG_8_9, CpG_14, CpG_16, CpG_19 and
decreased methylation at CpG_20_21, CpG_23_24, CpG_25_26_27_28, CpG_34, CpG_36,
CpG_38_39 and CpG_41 were associated with a higher brain A burden across the whole
cohort. Whilst methylation at CpG_15 positively correlated with cortical grey matter volume.
VII

Within HC’s, increased methylation at CpG_1, CpG_2_3, CpG_8_9, CpG_14, CpG_16, CpG_19,
and decreased methylation at CpG_20_21, CpG_23_24, CpG_25_26_27_28, CpG_36,
CpG_38_39 and CpG_41 were associated with a higher brain A burden. Whilst methylation
at CpG_15, CpG_36 and CpG_41 positively correlated with cortical grey matter volume. Again,
within the A+ HC group, increased methylation at CpG_8_9, CpG_14, CpG_16, CpG_19, and
decreased methylation at CpG_20_21, CpG_25_26_27_28, CpG_34, CpG_36, and CpG_41
were associated with a higher brain A burden. Whilst a significant positive correlation
between methylation at CpG_37 and cortical white matter volume was observed.
Whilst several methylation sites within the CLU promoter reached a nominal level of
significance with respect to both baseline cognitive performance and change in cognitive
performance over 7.5 years no sites retained significance after FDR correction. This finding
was consistent when investigated across the entire cohort, within the HC and within the A+
HC group.
Conclusions
Differential methylation was seen across the CLU promoter region in relation to clinical
classification, SNP’s and both fluid and brain imaging biomarkers. These observations seen in
the periphery provide further evidence of methylation, and specifically of methylation in the
CLU promoter region, having the potential to be a biomarker in early AD diagnosis. Of
particular interest is the decrease in methylation seen between clinical classifications and the
associated impact on gene expression. Another area of noted interest is the association seen
between CLU promoter region methylation and A burden in the brain. Further exploration
is warranted to validate and further examine these results by generating longitudinal
methylation data to assess whether changes in methylation track with changes in AD clinical
and pathological characteristics.
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Chapter 1: Literature review
1.1 Introduction
Alzheimer’s disease (AD), the most common cause of dementia, is a debilitating condition
that currently has no effective prevention, cure and/or treatment (Lord & Cruchaga, 2014;
Scheltens et al., 2016). It is estimated that in 2017 there were 50 million people living with
dementia worldwide (Alzheimer’s Disease International, 2017) . Dementia typically affects
individuals over the age of 60 years and is not considered a normal part of aging (World Health
Organization, 2016). Dementia Australia estimates that in this year, 2018, the total cost to
Australia of dementia, including care and research, will be more than $15 billion (Alzheimer’s
Australia, 2017; Dementia Australia, 2018).
AD is neurodegenerative in nature, causing increasingly severe cognitive decline that results
in loss of independence and consequently, death (Lunnon & Mill, 2013). AD pathology is
characterized by accumulation of A-amyloid (A) plaques, intracellular hyper
phosphorylated tau tangles, gliosis, synaptic dysfunction and eventually death of neuronal
cells (Lunnon et al., 2014). The neuropathological hallmarks of AD are well characterized in
the post mortem brain, with different areas showing altered levels of neurodegeneration
(Lunnon et al., 2014). The neurodegeneration indicative of AD is thought to start many years
before the onset of clinical symptoms (Lunnon & Mill, 2013). Individuals with AD commonly
suffer from behavioural and psychological symptoms, with each patient experiencing
cognitive decline at different and unpredictable rates (Lopez et al., 2010). More than 50% of
patients suffer from these symptoms which are distressing for both the patient and
caregiver/s (Hersch & Falzgraf, 2007).
Risk factors for AD can be divided into two categories; modifiable and non-modifiable. The
predominant non-modifiable risk factor, after age, is genetics (Scheltens et al., 2016).
Mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin (PSEN2)
genes are autosomal dominantly inherited and cause autosomal dominant AD (ADAD)
(Ballard et al., 2011; Karch & Goate, 2015). There is also data to suggest these 3 genes are
involved in the more common late onset AD (LOAD), where the strongest risk factor is the
Apolipoprotein E (APOE) gene (Bekris, Yu, Bird, & Tsuang, 2010). Genome wide association
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studies (GWAS) have identified several further genetic loci associated with AD risk (Karch &
Goate, 2015). Through the association of the genes with AD risk, several biological pathways
have been implicated in the pathomechanisms of AD, including the inflammatory response,
cholesterol metabolism and endocytosis (J. Hardy et al., 2014).
A further genomic factor that has been implicated in AD is epigenetic alteration. Epigenetic
alterations are a modification brought about to gene regulation through altering DNA
packaging proteins or the DNA molecules themselves without actually changing the
underlying DNA sequence (Lord & Cruchaga, 2014). DNA methylation is a form of epigenetic
alteration that involves the attachment of methyl groups at certain sites that results in the
silencing or down regulation of a gene (Lord & Cruchaga, 2014). Epigenome wide association
studies (EWAS) are a means of identifying methylation loci (Lunnon & Mill, 2013). Several loci
have been identified as points of methylation related to AD phenotypes (De Jager et al., 2014).

1.2 Dementia
1.2.1 Dementia
Dementia is an umbrella term used to describe a range of neurodegenerative, vascular,
metabolic and infectious diseases (Josephs et al., 2009). They are characterized by the decline
of a range of cognitive functions including thinking and memory skills, behaviours and the
ability to participate in normal daily activities (American Psychiatric Association. & American
Psychiatric Association. DSM-5 Task Force., 2013). The most common forms of dementia are
Alzheimer’s disease (AD), frontotemporal dementia (FTD), vascular dementia (VD) and Lewy
body dementia (LBD) (Prince et al., 2013). Both the incidence and prevalence of dementia
increases with advancing age, with 70% of affected individuals being greater than 75 years
old (Mangialasche, Kivipelto, Solomon, & Fratiglioni, 2012).
1.2.1.1 The impact of dementia
In their 2015 report, Alzheimer’s Disease International stated that 48.6 million people
worldwide were living with dementia, with that number set to double every 20 years;
reaching 131.5 million in 2050, with estimates for 2017 believed to be close to 50 million
people (Alzheimer’s Disease International, 2017). These projections are continually being
revised with numbers being increased by 12-13% from the 2009 World Alzheimer Report
(Alzheimer's Disease International, 2015). With specific regard to Australia, 342,000
3

individuals are estimated to be suffering from dementia, with that number set to rise to
900,000 in 2050 (Australian Institute of Health and Welfare, 2015). Further, in 2016 dementia
was the second leading cause of death in Australia (Australian Bureau of Statistics, 2017).
Rates of dementia related deaths have risen from 5.3% in 2007 to 8.3% in 2017 (Australian
Bureau of Statistics, 2017). As the population continues to age and individuals live to older
ages (attributed to better medical intervention resulting in longer life expectancies),
dementia will pose a greater threat to population health as well as impacting on social and
economic development (Australian Bureau of Statistics, 2017; Mangialasche et al., 2012).

1.3 Alzheimer’s disease
Worldwide, Alzheimer’s disease (AD) accounts for 50-70% of all dementia cases (Australian
Institute of Health and Welfare, 2017). AD, like a wide variety of neurodegenerative diseases,
is characterized by the accumulation of extracellular and intracellular protein aggregates. AD
is distinctly defined by the presence of extracellular amyloid plaques, predominantly
consisting of A peptides, and neurofibrillary tangles, which are the result of intracellular
accumulation of hyper-phosphorylated tau (Forman, Trojanowski, & Lee, 2004; Z.-G. Zhang,
Li, Ng, & Song, 2015).
1.3.1 Forms of Alzheimer’s Disease
From a genetic perspective, AD can be classified into two categories; autosomal dominant AD
(ADAD) and sporadic late onset AD (LOAD). Currently, mutations leading to ADAD have been
identified in three genes, namely the amyloid precursor protein (APP), presenilin 1 (PSEN1)
and presenilin 2 (PSEN2) genes (Suárez‐Calvet et al., 2014). A wide variety of risk factors have
been identified for LOAD including age, gender and head trauma (Foster, 2002). There are
several genetic factors involved in LOAD, but genes associated with this form of the disease
are considered risk factors rather than causative – the most significant of which is the 4 allele
of the Apolipoprotein E (APOE) gene (Ashford & Mortimer, 2002; Foster, 2002).
ADAD is more commonly associated with an earlier age of onset with the majority being
diagnosed younger than 65 years of age, with some as young as their mid-twenties (Bateman
et al., 2011; Rossor, Fox, Mummery, Schott, & Warren, 2010). Contrasting with LOAD cases,
those diagnosed are typically above the age of 65, with diagnoses below 50 very rare
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(Bateman et al., 2011; Rossor et al., 2010). Ringman et al. (2016) determined that there were
higher degrees of A plaques, neurofibrillary tangles and cerebral amyloid angiopathy in
individuals with ADAD compared to those with LOAD.
1.3.2 Clinical characteristics
Apart from the behavioural and psychological symptoms of dementia, including delusions,
aggressive behaviour, wandering and anxiety, the major clinical characteristic of AD is
cognitive impairment (American Psychiatric Association. & American Psychiatric Association.
DSM-5 Task Force., 2013). There are 5 cognitive domains that are used for the assessment of
neurocognitive and neurodegenerative diseases, these being; complex attention, executive
function, learning and memory (episodic, semantic and implicit), language and perceptualmotor skills (American Psychiatric Association., 2013). Symptoms within these domains are
then classified as mild or major. Rate of decline is specific to the individual and there are some
factors that are recognized to increase the rate of decline such as initial age of onset, higher
level of education, greater baseline cognitive and functional impairment, pre-existing
language impairment, attention deficit issues, presence of disruptive behaviour or psychotic
symptoms and established motor skill impairments (Lopez et al., 2010). The initial cognitive
impairment in individuals with AD is the deterioration of episodic memory, which only
continues to decline with the progression of the disease (Albert et al., 2011; Silverberg et al.,
2011). Previous studies have observed that this decline occurs 4-8 years prior to executive
function and up to 7-10 years prior to other cognitive domains (Derby et al., 2013; Elias et al.,
2000; Grober et al., 2008).
1.3.2.1 Mild cognitive impairment
Mild cognitive impairment (MCI) refers to a stage of cognitive function that is abnormal for
an individual’s age and education but as yet does not interfere with the ability to conduct
daily activities (Gauthier et al., 2006). There are two subtypes of MCI; amnestic and nonamnestic (Dementia Australia, 2014). Within amnestic MCI the most prominent symptom is
memory impairment whereas within non-amnestic MCI another cognitive skill is most
commonly impaired, such as, language or visual perception (Dementia Australia, 2014).
Not all individuals with MCI will progress to AD or another form of dementia although the
amnestic subtype of MCI is considered to have a high risk of progression to AD (Gauthier et
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al., 2006). To further predict an individual’s risk of progression from MCI to AD and to develop
a diagnosis of “MCI due to AD” the National Institute on Aging and the Alzheimer’s
Association, both within the US, observed current biomarker and clinical criteria determining
that biomarkers could provide an important diagnostic tool for the prediction of the
development of AD from MCI but greater refinement and validation in a clinical setting is
required (Albert et al., 2011).
1.3.3 Pathological characteristics
The amyloid cascade hypothesis (Figure 1.1), first
proposed by J. A. Hardy and Higgins (1992) is believed
central to AD pathogenesis. It states that deposition of
A peptide is the main causative agent of AD and the
secondary neurofibrillary tangles, cell death, cerebral
amyloid angiopathy (CAA) and dementia are a direct
result of its deposition. The following sections describe
the

macroscopic

and

microscopic

pathological

characteristics of AD.

Figure 1.1. The Amyloid Hypothesis
(right) How the pathogenesis of AD is proposed to occur
according to the amyloid cascade hypothesis. Diagram
retrieved from (Selkoe & Hardy, 2016)

1.3.3.1 Macroscopic changes
1.3.3.1.1 Brain Atrophy
Whilst neither specific nor diagnostic for AD when in isolation, atrophy or shrinkage is a
notable macroscopic change in the AD brain (Perl, 2010; Serrano-Pozo, Frosch, Masliah, &
Hyman, 2011). The annual global brain atrophy in AD amounts to 2-3% compared to 0.2-0.5%
in healthy controls (Fox & Schott, 2004). Although neurodegeneration and consequently
atrophy and volumetric loss are not unique to AD, there is a pattern and degree of atrophy
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that is unique to AD (Mueller et al., 2005). Atrophy is initially most pronounced in the medial
temporal lobe, followed by the temporal neocortex becoming involved in the atrophy pattern
then extending to the parietal and frontal lobes (Luiz K. Ferreira & Busatto, 2011). Importantly
this pattern corresponds to the data acquired from post-mortem study of AD atrophy
progression (Braak & Braak, 1995; Luiz K. Ferreira, Diniz, Forlenza, Busatto, & Zanetti, 2011).
The primary motor, sensory, and visual cortices are typically spared from atrophy; this trait
being explicitly associated with AD specific dementia (Serrano-Pozo et al., 2011). Brain tissue
loss resulting in dilation of the lateral ventricles (ex vacuo hydrocephalus) is also observed but
differentiation of this feature between AD and healthy controls cannot usually be made (de
la Monte, 1989; Perl, 2010). Importantly, although cerebral atrophy is not enough alone to
diagnose AD it is a clinically relevant marker for AD progression (Schott et al., 2008). The
structural changes caused by atrophy can be observed utilising magnetic resonance imaging
(MRI). Atrophy is best visualized with T1 weighted volumetric sequences similar to the ones
shown in Figure 1.2 (Bourgeat, Villemagne, et al., 2015; Johnson, Fox, Sperling, & Klunk, 2012;
Mueller et al., 2005; Vemuri & Jack, 2010).

Figure 1.2. Magnetic Resonance Images (MRI)
MRI displaying progressive atrophy in the medial temporal lobes of a cognitively normal (CN)
individual, an individual with amnestic mild cognitive impairment (aMCL) and an individual
with Alzheimer’s disease (AD). Image courtesy of Vemuri and Jack (2010).
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1.3.3.2 Microscopic changes
It is the microscopic changes that provide a more definitive diagnosis of AD (Perl, 2010). These
microscopic changes can be detected in the brains of elderly individuals who have normal
cognitive function making the area of the brain affected by the microscopic changes
particularly important, as those definitive of AD have a stereotypical presentation (Perl,
2010).
1.3.3.2.1 Amyloid plaques
Formed by aggregated A, amyloid plaques (Figure 1.3) are a well-known hallmark of AD (R.
H. Takahashi et al., 2011). A is a 40-42 amino acid fragment of the amyloid precursor protein
(APP) (Games et al., 1995). APP undergoes proteolytic cleavage by -secretase and a secretase complex that produces a 4 kDa A peptide (Murphy & LeVine, 2010; Vassar et al.,
1999). This pathway is referred to as the amyloidogenic pathway where only 10% of APP is
processed by -secretase, the remaining 90% being cleaved via -secretase in the nonamyloidogenic pathway (Murphy & LeVine, 2010). A40 is the most abundant at 80-90% and
A42 at 5-10% (Schmidt et al., 2009). In contrast, within the actual amyloid plaque itself, A42
is more abundant because of its propensity to aggregate and form fibrils (Ahmed et al., 2010).
Amyloid plaques predominantly accumulate in the isocortex of the brain (Serrano-Pozo et al.,
2011).
Figure 1.3. A -amyloid (A ) plaques
Yellow arrows point to amyloid plaques stained
with silver from a brain section.
Adapted from O’Brien and Wong (2011)

Positron emission tomography (PET) with the use of radiolabelled markers allows for the
imaging of amyloid deposition within the brain (Luiz K. Ferreira & Busatto, 2011). Carbon-11
labelled Pittsburgh compound B (PiB) was the first such radiolabelled marker (Figure 1.4). It
is designed to bind to amyloid  plaques as first reported by Klunk et al. (2004). PiB binds
specifically to fibrillar A and is a sensitive marker in cognitively normal, MCI and AD
individuals (Rabinovici & Jagust, 2009). Crucially, amyloid detected using PiB-PET is closely
mirrored in post mortem autopsy of the brain (Rabinovici & Jagust, 2009).
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Figure 1.4. A -amyloid (A ) Positron emission tomography (PET)
Pittsburgh compound B (PiB) PET standardised uptake value (SUV) comparison between a
healthy control and an AD brain. The ‘warmer’ the colour (i.e. red) the higher the
concentration of amyloid load within that area. Image adapted from Klunk et al. (2004)

PiB has since established itself as a major advancement in the understanding of A deposition
in AD (Cohen et al., 2012). PiB-PET was a major advancement in AD research, allowing
recognition that A accumulation commences 15-20 years prior to the onset of clinical
symptomology (Villemagne et al., 2013). However, it does have limitations, principal of which
is its short radioactive half-life (about 20 minutes) (Cohen et al., 2012), which has led to the
development of Fluorine-18 (F-18) labelled compounds such as Flutemetamol and Florbetapir
(Adlard et al., 2014; Cohen et al., 2012).
1.3.3.2.2 Cerebral amyloid angiopathy
Another microscopic feature of AD involving A, is cerebral amyloid angiopathy (CAA) where
A is deposited on the walls of arteries, arterioles and less often capillaries and veins of the
central nervous system (Revesz et al., 2002). In AD it is mostly the cortical capillaries, small
arterioles, medium sized arteries and leptomeningeal arteries that are affected, with
posterior parietal and occipital areas being more predominantly affected than frontal and
temporal lobes (Revesz et al., 2002; Serrano-Pozo et al., 2011). CAA pathology is also very
common in cognitively healthy older individuals (Arvanitakis et al., 2011). CAA’s most serious
complication is haemorrhage, with other problems being infarcts and chronic brain
haemorrhages called micro bleeds (Arvanitakis et al., 2011; Martinez-Ramirez, Greenberg, &
Viswanathan, 2014).
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1.3.3.2.3 Neurofibrillary tangles
Hyperphosphorylated tau, the protein that comprises the neurofibrillary tangles, is a neuronal
microtubule associated protein (MAP) that is most commonly found in axons (Medeiros,
Baglietto-Vargas, & LaFerla, 2011). In non-pathological instances, tau is a highly soluble and
unfolded protein, that along with tubulin promotes the formation of microtubules that assist
in structure stabilisation (Medeiros et al., 2011). In AD and other neurodegenerative diseases,
tau is abnormally hyperphosphorylated and aggregated into bundles of filaments (Figure 1.5)
(Iqbal, Liu, Gong, & Grundke-Iqbal, 2010). Hyperphosphorylated tau is oligomeric and most
likely causes neurodegeneration by isolating normal MAPs and disrupting the microtubule
network (Iqbal et al., 2010).
Figure 1.5. Neurofibrillary tangles (NFT)
A NFT stained with silver. Adapted from O’Brien and Wong
(2011)

1.3.3.3 Fluid based biomarkers in AD
The identification of a fluid-based biomarker, or more likely a set of fluid-based biomarkers,
to assist in the identification of individuals who have not developed substantial pathology or
cognitive issues is an important area in AD research (Craig-Schapiro, Fagan, & Holtzman,
2009). A vast array of fluid-based biomarkers have been observed with altered levels of total
tau protein (T-tau), phosphorylated tau (P-tau) and A 42 in cerebrospinal fluid (CSF) proving
to be the most promising candidates, as they can identify individuals with mild cognitive
impairment and also individuals likely to progress into AD (Blennow, 2017; Craig-Schapiro et
al., 2009; Q.-X. Li et al., 2015; Palmqvist et al., 2015). Whilst these CSF markers have proved
helpful, the act of acquiring a sample is still an invasive and potentially risky procedure.
Due to the invasive nature of CSF collection, the targeting of biomarkers in the blood has
gained significant impetus. Blood based biomarkers have the significant advantage of being
less invasive and being more time and cost effective, making them a significant area of
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interest of AD research (O’Bryant et al., 2017). A number of different analytes have been
investigated including autoantibodies and proteins such as clusterin (DeMarshall et al., 2016;
Gupta et al., 2016). MicroRNA’s have also been investigated as potential AD biomarkers
showing promising results (Geekiyanage, Jicha, Nelson, & Chan, 2012). Whilst there are quite
a few different potential blood based biomarkers, focus needs to concentrate on validation
and reproducibility (DeMarshall et al., 2016).

1.4 Modifiable and non-modifiable risk factors for AD
The risk factors for the development of AD can be divided into two groups; modifiable and
non-modifiable (Flicker, 2010; Østergaard et al., 2015). Norton, Matthews, Barnes, Yaffe, and
Brayne (2014) determined that, after considering non-independence of modifiable risk
factors, up to one third of AD cases in Europe and the UK can be attributed to modifiable risk
factors. These modifiable risk factors are type 2 diabetes mellitus, hypertension, obesity,
dyslipidemia, smoking, physical inactivity, depression and low educational attainment
(Østergaard et al., 2015). Alzheimer's Disease International (2015) agrees with these
modifiable risk factors having an influence on the acquisition of AD.
Including age, the major non-modifiable risk factor is genetics. ADAD is genetically associated
with mutations in APP, PSEN1 and PSEN2 (Bird, 2008) whilst APOE is associated with increased
risk for the more common late onset AD (Bird, 2008). GWAS have been an important tool for
the identification of several other polymorphisms in or near multiple genes that are
associated with increased risk for developing AD (Kamboh et al., 2012; Karch & Goate, 2015).
The genetic component of AD will be more thoroughly discussed in the following section.

1.5 Alzheimer’s disease and Genetics
1.5.1 Autosomal dominant Alzheimer’s disease (ADAD)
Autosomal dominantly inherited mutations in three currently identified genes, the amyloid
precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2), are the cause of the
ADAD component of early onset AD (Karch & Goate, 2015). The mutations cause an increase
in extracellular concentration of A42 and therefore the deposition of A42 in the brain
(Scheuner et al., 1996). These mutations and their resultant pathological impact were central
to the previously discussed amyloid cascade hypothesis.
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APP is a type-1 integral membrane protein that resembles a signal-transduction receptor and
although it is expressed in many tissues and is particularly concentrated around synapses, its
exact function is unknown (Bekris et al., 2010; Storey & Cappai, 1999). It is hypothesized by
some, rather controversially, that APP has a neuroprotective effect (M. Takahashi et al.,
2000). Mutations, of which there are over 32 different specific missense mutations, cause an
elevation of A production and deposition (Bekris et al., 2010; Bodendorf et al., 2002; Goate,
Chartier-Harlin, & et al., 1991). An exception is the APP A673T (Icelandic) mutation which is
the first variant within APP to be associated with protection against the accumulation of A
(Peacock, Warren, Roses, & Fink, 1993). The elevation of A production and deposition has
been modelled in transgenic mice (Games et al., 1995). Korenberg, Pulst, Neve, and West
(1989) mapped APP on chromosome 21q21.105–q21.05 linking individuals with trisomy 21,
who often display pathological signs of AD (CAA, amyloid plaques and neurofibrillary tangles)
(Arai, Suzuki, Mizuguchi, & Takashima, 1997).
PSEN1 is located on chromosome 14 position q24.2 and contains 12 exons that encode a 467
amino acid (Bekris et al., 2010) protein. Point mutations in PSEN1, the expressed protein
which is a member of the -secretase complex, result in a selective increase in the production
of the amyloidogenic peptide A(1-42) (De Strooper, Saftig, Craessaerts, Vanderstichele, & et
al., 1998; Murphy & LeVine, 2010; Vassar et al., 1999). The PSEN2 gene is located on
chromosome 1 position q42.13 (Bekris et al., 2010). PSEN2 is 67% homologous with PSEN1
and they appear to be ubiquitously expressed (Diehlmann et al., 1999; Kovacs et al., 1996).
Feng et al. (2004) using PSEN1 and PSEN2 double knockout mice found that the proteins the
presenilin genes code for are synergistic and the deficiency of the presenilin genes
contributes to the pathogenesis (loss of neuronal function, cortical shrinking) of early onset
AD.
1.5.2 Sporadic late onset of Alzheimer’s disease (LOAD)
The advent of GWAS has resulted in the identification of multiple genes associated with LOAD.
However, no genetic variant discovered to date through GWAS has approached the relative
risk that is attributed to the major genetic risk factor for LOAD, Apolipoprotein E (APOE),
which is associated with the pathway of cholesterol/lipid metabolism (National Institute on
Aging, Alzheimer’s Association Working Group, & Relkin, 1996). APOE codes for a major
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cholesterol carrier that supports inflammation and neuroplasticity (Liu, Kanekiyo, Xu, & Bu,
2013). There are 3 allelic forms of APOE, the most common of which is the APOE-3 allele.
Individuals who carry the APOE-4 allele have an increased risk of AD, whilst comparatively
the 2 allele decreases overall AD risk (Liu et al., 2013). The grouping of genes, identified in
GWAS, by their involvement in biological pathways, has allowed for the identification of
several pathways believed to play integral roles in disease development (Figure 1.6), of
particular note are cholesterol/lipid metabolism, endocytosis and the immune response
(Rosenthal & Kamboh, 2014). The cholesterol/lipid metabolism is of particular interest due
to the association of APOE. Another apolipoprotein of note, Clusterin, which is also involved
in cholesterol metabolism is amongst the strongest genetic risk factors identified through
GWAS and is of major interest to the AD research field.

Figure 1.6. Rare and common genetic variants which contribute to Alzheimer’s disease risk.
Distributed by frequency in population and AD risk effect size. Genes are colour coded by
probable pathway through which they are involved in AD pathogenesis. Modified from Karch
and Goate (2015).
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1.5.3 Clusterin in Alzheimer’s disease
The Clusterin (CLU) gene, also known as apolipoprotein J, is located on chromosome 8p21p12 and spans approximately 18kb (Zhu, Liu, & He, 2018). The protein (Clu) consists of  and
 chains that are linked by 5 disulphide bonds and can be found across an array of bodily
fluids and in extracellular space (Matukumalli, Tangirala, & Rao, 2017). As a multifunctional
stress induced chaperone glycoprotein, Clu is involved in a number of processes, including
apoptosis, lipid transport, membrane protection, complement regulation and cell-cell
interactions (Calero et al., 2000; Karch & Goate, 2015).
1.5.3.1 Clusterin Genetics and Alzheimer’s disease
No causal gene has so far been identified for LOAD but a number of genes have been
identified as contributing to increasing the risk of acquiring LOAD. CLU is currently considered
the third most associated LOAD risk gene, after APOE and Bridging intregator-1 (BIN1) (De
Rossi et al., 2017; J.-T. Yu & Tan, 2012). In 2009, Harold and colleagues conducted a GWAS
that identified the first single nucleotide polymorphism (SNP) (rs11136000) within CLU
associated with AD. Since then, numerous SNPs have been identified, including rs9331888,
rs7012010, rs2279590, rs7982 and the originally identified rs11136000 (Harold et al., 2009;
Jun et al., 2010; Lambert et al., 2013; Seshadri et al., 2010). In addition to risk for developing
AD, rs11136000 has been shown to be associated with both longitudinal changes in brain
function in asymptomatic individuals and faster cognitive decline in the pre-symptomatic
stages of disease progression (Thambisetty et al., 2013). Whilst alternative slicing potentially
resulting in a pathological outcome has been attributed to another one of the risk alleles,
rs9331888 (Szymanski, Wang, Bassett, & Avramopoulos, 2011).
1.5.3.2 Plasma clusterin as an AD Biomarker
Plasma Clu has been shown to be an interesting area of study in AD but there is a lack of
consensus on its viability as a peripheral biomarker. Plasma Clu levels have been associated
with prevalence and severity of AD, although it was not shown to be associated with the
incidence of AD (Schrijvers, Koudstaal, Hofman, & Breteler, 2011; Weinstein et al., 2016). In
2010, Thambisetty et al. discovered that an increase in plasma Clu concentration is associated
with a greater burden of fibrillary A in the brain but did not deem it robust enough to be
used as a stand-alone biomarker. Silajdžić, Minthon, Björkqvist, and Hansson (2012) makes
an even firmer statement, believing plasma Clu has no diagnostic value for AD. Conversely,
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Hsu, Lee, Liao, Wang, and Fuh (2017) did show plasma Clu to be a potential biomarker for the
severity of cognitive decline. Furthermore within the Australian Imaging, Biomarkers and
lifestyle study of ageing (AIBL), plasma Clu was shown to be elevated in individuals with MCI
and AD (Gupta et al., 2016). The efficacy of Clu protein levels as a biomarker requires
clarification in further studies. However, the potential that CLU gene expression is associated
with disease pathogenicity provides support for the study of the means by which CLU gene
expression may be moderated. One such mechanism, and the primary focus of this thesis, is
the epigenetic process of DNA methylation.

1.6 Epigenetics and Alzheimer’s disease
The term ‘epigenetics’ encompasses changes in DNA expression that are not coded for in the
DNA sequence itself and the changes are meiotically and mitotically heritable (Egger, Liang,
Aparicio, & Jones, 2004; Portela & Esteller, 2010). Epigenetic mechanisms can be involved in
non-pathological instances such as X-inactivation and be pathological in instances such as AD
and Fragile X syndrome (Egger et al., 2004). Types of epigenetic modification work together
to influence DNA expression in the form of histone modification, nucleosome positioning and
methylation; mediated by histone acetyltransferases (HATs) and histone deacetylases
(HDACs), blocking access to activators and transcription factors and methyl groups,
respectively (Portela & Esteller, 2010). As identified, this thesis will focus specifically on
methylation.
1.6.1 DNA Methylation
DNA methylation occurs predominantly at the sites of CpG dinucleotides; the CpG
dinucleotides tend to cluster in areas called CpG islands (Portela & Esteller, 2010). CpG islands
are most often found in the promoter regions and first exons of genes but can also be present
in areas close to the 3’ end of the DNA strand (Jones & Takai, 2001). Jones and Takai (2001)
and Portela and Esteller (2010) define CpG islands as regions of more than 200 bases with a
G + C content of at least 50% and the observed statistically expected CpG frequency is at least
0.6.
DNA methyltransferases (DNMTs) transfer a methyl group from a S-adenyl methionine to the
5th carbon of a cytosine residue to form 5-methylcytosine (5-mC) (Moore, Le, & Fan, 2013). In
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one instance, DNMT’s in particular DNMT3A and DNMT3B, act as de novo enzymes during
embryonic development, putting initial patterns of methylation in place (Jin, Li, & Robertson,
2011). The second instance utilizes DNMT1 in a form of maintenance whereby the pattern of
methylation from one strand is copied to the new strand during DNA replication (Jin et al.,
2011; Portela & Esteller, 2010). The roles of the DNMTs are not always so clear cut, with Jones
and Liang (2009) suggesting DNMT3A and DNMT3B also assist in methylation maintenance
along with DNMT1 but they act in a proof reading fashion. The binding of 5-mC disrupts the
cells transcriptional machinery by blocking the binding of transcription factors and attracting
methyl-binding proteins that initiate chromatin compaction and bring about gene silencing
(Lunnon & Mill, 2013).
1.6.2 DNA Methylation and Alzheimer’s disease
Studying methylation in AD is complicated by the fact that methylation increases with age
(age being a compounding risk factor in AD) and methylation patterns naturally differ across
cell types (comparing neurons, astrocytes and other glia collected in a brain biopsy) (Lord &
Cruchaga, 2014). Despite these difficulties previously complicating the conducting and
replicating of epigenome wide association studies (EWAS), De Jager et al. (2014) and Lunnon
et al. (2014) have found compounding evidence for differentially methylated regions and a
relationship with AD. L. Yu et al. (2015) did not conduct an EWAS but targeted previously
reported methylated loci and confirmed those results, finding DNA brain methylation in
SORL1, BIN1, ABCA7, SLC24A4 and HLA-DRB5 were associated with pathological AD. Chibnik
et al. (2015) added to the research on BIN1 and ABCA7, whilst also observing methylations
correlation with neuritic plaques in MS4A6A, CD2AP and APOE utilizing brain tissue samples.
Smith et al. (2016) identified in a meta-analysis of 3 independent studies increased DNA
methylation in the superior temporal gyrus in the brains of individuals with AD at a CpG site
located 289 bp upstream of the transcription start site of the TREM2 gene. The exact role
methylation with 5mC plays in the brain is not entirely clear but there is evidence to suggest
synapse plasticity, learning and memory, all implicated in AD, are regulated by 5mC (Day &
Sweatt, 2011).
1.6.2.1 DNA Methylation in Clusterin
CLU has a CpG rich promoter region that has been associated with an increase in gene
expression after neuronal injuries, degeneration, aging and neurodegenerative diseases (J.-T.
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Yu & Tan, 2012). Methylation study has been limited within the CLU loci in relation to AD. The
previously stated study by Chibnik et al. (2015) tested a total of 40 CpG loci within CLU with
only 5 reaching statistical significance in association with A pathology. Rather interestingly,
4 of those 5 showed a negative correlation with A pathology; meaning higher methylation
levels were associated with a lower burden of A plaque’s and lower odds of AD. CLU
methylation has also been studied outside the context of AD, it has been observed in other
instances such as tumour angiogenesis (Hellebrekers et al., 2007) and in particular types of
prostate cancer (Rauhala, Porkka, Saramäki, Tammela, & Visakorpi, 2008).
1.6.2.2 Identification of methylation in peripheral samples
The previously mentioned studies by De Jager et al. (2014), Lunnon et al. (2014), L. Yu et al.
(2015), Chibnik et al. (2015) and Smith et al. (2016) all used brain biopsy tissue samples to
identify areas of methylation. This obviously presents an obstacle for early biomarker
identification as the brain is a relatively inaccessible tissue (Davies et al., 2012). Blood, an
easily accessible peripheral tissue, is showing promise in the identification of methylation
with corresponding brain methylation (Chang et al., 2014; Chouliaras et al., 2013; Davies et
al., 2012). A study by Di Francesco et al. (2015) provided evidence for increased DNA
methylation in the peripheral cells (peripheral blood mononuclear cells) of individuals with
AD and that DNA hypermethylation correlates with worse cognitive impairment and the APOE

4 polymorphism. With specific regard to genes associated with AD, Yamazaki et al. (2017)
studied methylation of ABCA7 in relation to education, age of onset and duration of illness
and found no correlations. Peripheral hypermethylation of brain derived neurotrophic factor
(BDNF) has also been observed which resulted in silencing of gene expression (Chang et al.,
2014).
A potential usage for peripheral methylation analysis is as a biomarker. For methylation
analysis to work as an efficient biomarker it must be detected in the preclinical stages of the
disease; a way to study this would to be to follow a large cohort of initially healthy individuals
over an extended period to track methylation patterns and AD associated symptoms
(Fransquet et al., 2018).
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1.7 Hypothetical Framework
As the literature review highlighted, research into the genetic components of AD has been
extensive and provided great insight into the genetic contribution to AD pathogenesis.
Through the identification of specific genetic contributions, ADAD and LOAD could be
attributed to certain genes; ADAD has been attributed to highly penetrant mutations in three
genes; APP, PSEN1 and PSEN2, whilst risk for LOAD has been linked to an array of genes
identified through GWAS studies. The analysis of GWAS data has identified several biological
pathways that the identified genes are associated with. A prime example of which is the
cholesterol/lipid metabolism pathway, which in addition to the role of APOE is supported
through the association of leading genetic-risk candidates, including CLU and ABCA7.
Epigenetic study of AD, specifically methylation, has revealed a new, promising area of study.
However, there is a lack of research into the potential use of methylation as a biomarker of
AD. Additionally, to date methylation studies have primarily looked at methylation as a risk
factor rather than, as proposed in this research, the association with AD phenotypes
(cognition, imaging and established biomarkers). Research into these areas may provide
insight into potential new genomic markers of disease progression. As identified, for this goal
to be reached requires the study of large highly characterised cohorts with extensive
longitudinal data (Fransquet et al., 2018). This thesis will present a targeted approach to this
principle by focussing on methylation in the promoter region of a leading gene-candidate,
CLU. The importance of the proposed research is only strengthened by the increasing burden
AD will have both socially and economically as the population ages.
1.7.1 Study Aims, Hypotheses and Expected Outcomes
The overarching aim of this thesis is to identify methylation units/sites in the CLU promoter
region and investigate them with respect to AD-related phenotypes. Analyses undertaken
within this thesis are divided into two related studies.
The aim of study one is to undertake a cross-sectional analysis of methylation patterns in the
CLU promoter region to determine their association with disease classification, genotypes and
AD-related imaging and fluid-based biomarkers.
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Hypothesis 1: Differential methylation is present in the CLU promoter across clinical
classifications.
Hypothesis 2: Differential methylation occurs in the CLU promoter relative to variation in
CLU rs9331888 and rs11136000 genotypes.
Hypothesis 3: Differential methylation within the CLU promoter region is associated with
AD-related imaging and fluid-based biomarkers.
Expected Outcome:
1. The identification of specific methylation units/sites relative to:
a. individual genotypes,
or that are associated with differences in
b. imaging biomarkers, e.g. brain volumetrics and brain A burden, and
c. fluid biomarkers, e.g. CSF and blood-based biomarkers.
The aim of study two is to determine if there is an association with the methylation units/sites
within the CLU promoter region and cross-sectional and longitudinal cognition.
Hypothesis 4: Differential methylation within the CLU promoter region is associated with
poorer cognition.
Hypothesis 5: Differential methylation within the CLU promoter region is associated with
altered longitudinal cognitive performance.
Expected Outcomes
1. The identification of specific methylation units/sites associated with differences in
a. cross-sectional performance in specific cognitive domains, and
b. longitudinal decline in performance in specific cognitive domains.
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Chapter 2: Methods and Materials
2.1 Research Design
Cross sectional and longitudinal analyses were applied over generated methylation data and
previously accrued data. All data were generated from the study participants of the AIBL study
(detailed below). Previously accrued data including demographic, genetic, biomarker and
phenotypic data outlined in Section 2.3 were accessed and utilised under approval from the
AIBL integrated data system (IDS; http://aibl.csiro.au/awd).

2.2 Study Participants
The research project utilised blood samples and accrued data from the longitudinal Australian
Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). Ellis et al. (2009) detailed
the participant requirements and recruitment for the AIBL study. Participants were assessed
by a clinical review panel, blinded to neuroimaging data, and classified with either AD, per
NINCDS-ADRDA criteria (McKhann et al., 1984), mild cognitive impairment (MCI) (Winblad et
al., 2004) or as being as healthy controls (HC). Ethics approval was granted before volunteers
were originally recruited and informed consent was again acquired before the assessment
stage (Ellis et al., 2009). For this specific research study, the inclusion criteria were accessible
blood samples, cognitive data and neuroimaging data at the same cross-sectional time point.
AIBL currently consists of 1811 registered participants (as of September 2018). Data collection
was conducted on 768 DNA samples for the purpose of this thesis.

2.3 Accessed Datasets
2.3.1 Fluid-based Biomarker Data
2.3.1.1 Plasma Clusterin Levels
Plasma Clu was obtained utilising a commercial quantitative sandwich enzyme-linked
immunosorbent assay (ELIZA; R&D Systems, USA). Plasma samples were initially thawed on
ice then centrifuged for 10 minutes at 12,000 X g and diluted 4000-fold using the supplied
diluent. Care was taken to ensure all reagents were brought to room temperature before use.
100 µL of Assay Diluent RD1-19 was added to each well of the apoJ (Clu) specific monoclonal
antibody precoated microplate. 50 µL of either sample or standard was subsequently added
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and the plate was kept at room temperature on a horizontal orbital microplate shaker for a
2-hour incubation. Once the plate was washed to remove any unbound substances, an
enzyme-linked monoclonal antibody was added to the wells. The plate was then again washed
to remove any leftover enzyme-linked monoclonal antibody. A substrate was added which
aids in the development of colour in proportion to the amount of bound ApoJ (Clu). Once
colour development was stopped the intensity of the colour was read using a BMG microplate
reader calibrated to 50nm. The above is as described by Gupta et al. (2016).
2.3.1.2 CSF Biomarker Data
At the baseline timepoint of the study, participants underwent a lumbar puncture to collect
a CSF sample utilising a similar protocol to that recommended by the Alzheimer’s Biomarkers
Standardisation Initiative (Vanderstichele et al., 2012). Enzyme-linked immunosorbent assays
(ELISA): INNOTEST Aβ (1–42; Aβ42), INNOTEST hTAU Ag (total-tau), and INNOTEST Phosphotau (phospho-tau181P; P-tau181P) (Fujirebio, Belgium), were used to analyse the samples as
per standard methods. All samples were analysed in duplicate and mean intra-assay
coefficients of variation for these assays are as previously published (Q.-X. Li et al., 2015).
A 42, total-tau and phospho-tau were quantified as previously described by Q.-X. Li et al.
(2015). Resultant data was accessed from the AIBL IDS.
2.3.2 Genotype data
Genotype data was determined for rs11136000 (Assay ID: C___11227737_10) and rs9331888
(Assay ID: C___1522425_10) using TaqMan® genotyping assays which were analysed on the
QuantStudio 12K Flex real-time PCR system (Applied Biosystems, USA) in a 384-well format.
Both assays were performed using the “Fast” thermocycling conditions and included the
TaqMan® GTXpress™ Master Mix (#4401892, Applied Biosystems). This mix contains a 2-times
mix of AmpliTaq® Fast DNA Polymerase, dNTPs, a tracking dye and a ROX™ Dye. Likewise,
APOE genotype data was previously assessed using TaqMan® genotyping assays (Life
Technologies, USA) for rs7412 (Assay ID: C____904973_10) and rs429358 (Assay ID:
C___3084793_20).
2.3.3 Neuroimaging Data
All neuroimaging data used for the purpose of this project was obtained from the AIBL cohort
database and interpreted by a suitable AIBL-affiliated researcher. Two forms of neuroimaging
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were utilised, magnetic resonance imaging (MRI) for brain atrophy and positron emission
tomography (PET) for observing amyloid load.
2.3.3.1 MRI Data Collection and Analysis
All MRI imaging was performed for AIBL research purposes and has been obtained using
Alzheimer’s Disease Neuroimaging Initiative (ADNI) 3-dimensional (3D) Magnetisation
Prepared Rapid Gradient Echo (MPRAGE) sequence, with 1 X 1 mm in-plane resolution and
1.2 mm slice thickness, TR/TE/T1 = 2300/2.98/900, flip angle 9°, and a field view of 240 X 256
and 160 slices. In addition, T2 fast spin echo (FSE) and fluid attenuation recovery (FLAIR)
sequences have been obtained. Volumetric estimates (expressed in cm3) of the hippocampus,
cortical grey matter (GM), white matter (WM) and ventricular volume were determined using
Computational qUantification of mRi from AIBL (CurAIBL) (Bourgeat, Doré, et al., 2015).
2.3.3.2 PET Data Collection and Analysis
All PET imaging was performed for AIBL research purposes using one of the following amyloid tracers; 11C-Pittsburgh Compound B (PiB), 18F-florbetapir or 18F-flutemetamol. Each
-amyloid tracer has a different and distinct cut off threshold and reference region (Bourgeat,
Villemagne, et al., 2015; Ellis et al., 2009). All images were processed using Computational
Analysis of PET (CapAIBL) to estimate PET signals in the cerebral cortex and displays the result
on a standard brain surface in relation to Z-scores and the Standardised Uptake Volumetric
Ratio (SUVR), a commonly used unit of measurement to quantify PET signals (Bourgeat, Doré,
et al., 2015). Briefly, the SUVR is calculated by summing the standardised uptake volume
(SUV) value then normalising them to their respective reference region. Based on tracer
specific thresholds of ≥1.4, ≥1.05 and ≥0.55 SUVR for PiB, florbetapir and flutemetamol,
respectively (Clark et al., 2011; Rowe et al., 2013; Vandenberghe et al., 2010), individuals were
classified as having either low (Αβ-) or high (Αβ+) brain Αβ burden. Tracer specific SUVR
thresholds are typically only used for binary measures (high versus low amyloid), however
multiple tracers can be combined for cross-sectional analysis as a continuous variable after
transformation to PiB-like SUVR using a simple linear regression transformation known as the
“Before the Centiloid Kernel Transformation” (BeCKet) (Villemagne et al., 2014). After the
BeCKet transformation participants are then classified as Αβ- or Αβ+ if a PiB/BeCKet threshold
of ≥1.4 is measured at any time point (Rowe et al., 2013).
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2.3.4 Cognitive Data
For the purposes of this research project, AD-related cognitive phenotypes of participants
were assessed using a set of novel statistically-derived cognitive composites developed by
Burnham et al (2015) using the measures from tests involved in the AIBL Neuropsychological
Testing Battery. The AIBL Neuropsychological Testing Battery was selected on the basis that
it covered the main domains of cognition that are affected by AD and other dementias (Ellis
et al., 2009). The full battery incorporated the Mini Mental State examination (MMSE),
California Verbal Learning Test 2nd edition (CVLT-II), Logical Memory I and II (WMS; Story A
only), D-KEFS verbal fluency, 30-item Boston naming Test (BNT), Wechsler Test of Adult
Reading (WTAR), Digital Span and Digit Symbol-Coding subtests of the Wechsler Adult
Intelligence Scale 3rd edition (WAIS-III), the Stroop task (Victoria version) and the Rey Complex
Figure Test (RCFT) (Ellis et al., 2009). All participants were also rated using the Clinical
Dementia rating scale (CDR) (Ellis et al., 2009). The composites defined by Burnham et al
(2015) utilise the best measures of change from baseline in functional and multiple cognitive
domains; two global and four domain-specific (verbal episodic memory, visual episodic
memory, executive function and language) cognitive composites.
For this study, the executive function composite (CDRSb: clinical dementia rating sum of boxes,
Stroop: Stroop task, FAS: Verbal fluency for letters F, A, S, CatSwTot: Category Switch Total)
and the verbal episodic memory composite (CDRSb, LMII: logical memory II, CVLTFP: California
Verbal Learning Test false positives, CVLTLDFR: California Verbal Learning Test long delayed
free recall) were chosen as they represent the domains of cognition that are first observed to
decline (Albert et al., 2011; Derby et al., 2013; Elias et al., 2000; Grober et al., 2008; Silverberg
et al., 2011). To provide an overall measure of cognitive performance, global cognition (CDRSb,
MMSE, LMII, CVLTFP, Clock: Clock drawing test) was also included in analyses. Finally, the
Preclinical Alzheimer’s Cognitive Composite (PACC; CVLT-IILDFR, , LMII, MMSE, Digit SymbolCoding) was also included as it was specifically developed to detect early signs of cognitive
decline (Donohue et al., 2014). Cognitive data has been collected from the AIBL cohort over
a period of 7.5 years.
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2.4 Clusterin Promoter Methylation Data
2.4.1 In Silico Target Region Identification and Primer Design
The specific focus of this thesis was the study of methylation in the promoter region of the
clusterin gene. Utilising the UCSC Genome browser’s table browser function
(genome.ucsc.edu/cgi-bin/hgGateway) a portion of Clusterin’s promoter region, spanning
from 27614425 to 27615250 of chromosome 8 (Genome Reference Consortium Human Build
38 (GRCh38/hg38)), was taken and entered into the online EMBOSS Cpgplot software
(www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/-(Rice, Longden, & Bleasby, 2000). Cpgplot
identified two putative CpG Islands, the first of 217 base pairs (bp) (228-444bp relative to
input sequence) and the second of 170bp (450-619bp; Figure 2.1). The sequence was then
entered into the Agena EpiDesigner software (Agena Bioscience, www.epidesigner.com/cgibin/webseq/epidesigner.cgi) to design potential primer pairs.

Figure 2.1 Identification of putative CpG islands in Clusterin promoter region
CPGPLOT identifies two putative CpG Islands (bottom frame) of length 217bp and 170bp.
To maximise coverage of the target region a two-amplicon design was chosen (Figure 2.2),
these two amplicons being henceforth referred to as Amplicon 1 and Amplicon 2. The specific
sequence of each primer pair in each amplicon is also shown in Figure 2.2. Whilst the genomic
sequence is entered in the EpiDesigner program, it outputs a bisulphite converted primer
sequence to allow for annealing to the bisulphite converted DNA used in the methylation
analysis described below in Section 2.4.2. Primers were then produced by Integrated DNA
technologies (IDT, Singapore) with a T7 promoter tag (cagtaatacgactcactatagggagaaggct)
incorporated on the reverse primer. The T7 promoter is used to transcribe the PCR product
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from the reverse strand, yielding a single stranded RNA product that is specifically cleaved by
RNAse A (Suchiman et al., 2015). To balance the primer length a 10mer tag sequence
(aggaagagag) is added to the forward primer. Reverse primers underwent purification by
High-performance Liquid Chromatography (HPLC) and forward primers were purified using
standard desalting techniques. The location and coverage of these amplicons relative to the
Clusterin gene is presented in Figure 2.3. The EpiDesigner software also identifies the CpG
sites (a single differentiable CpG) and CpG units (a group of CpG sites that are analysed
together due to proximity) that will be able to analysed. Overall the two amplicon design
targets a total of 41 CpG sites across 26 differentiable loci (Table 2.1), consisting of 15 sites
and 11 units.

Figure 2.2. EpiDesigner Output
The two-amplicon design generated by the Agena EpiDesigner software. Boxes identify the
chosen amplicon designs with arrows indicating the specific primer designs and start positions
relative to the sequence entered (Chr8:27614425…27615250; hg38).
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Figure 2.3. Visualisation of the targeted region and assay design coverage
The targeted region in the clusterin gene (shaded green in top frame) was covered with 2
amplicons (bottom frame). Amplicon 1 (shaded blue) and Amplicon 2 (shaded red)

CpG Site/Unit
Amplicon 1
CpG_1
CpG_2_3
CpG_4_5
Cpg_6_7
CpG_8_9
CpG_10
CpG_11_12_13
CpG_14
CpG_15
CpG_16
CpG_17_18
CpG_19

CpG sites

Chr. Location*

1
2
2
2
2
1
3
1
1
1
2
1

27615006
27614997
27614970
27614941
27614934
27614892
27614879
27614858
27614847
27614833
27614805
27614789

CpG Site/Unit
Amplicon 2
CpG_20_21
CpG_22
CpG_23_24
CpG_25_26_27_28
CpG_29_30_31
CpG_32
CpG_33
CpG_34
CpG_35
CpG_36
CpG_37
CpG_38_39
CpG_40
CpG_41

CpG sites

Chr. Location*

2
1
2
4
3
1
1
1
1
1
1
2
1
1

27614745
27614734
27614723
27614701
27614681
27614664
27614657
27614643
27614608
27614600
27614558
27614541
27614532
27614500

Table 2.1. CpG sites covered by designed assay
CpG sites, and their *Chromosomal location (start site; hg38), that will be captured using the
chosen two amplicon design.
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2.4.2 Quantitation of DNA Methylation - Workflow and Protocols
2.4.2.1 Overview
The quantification of DNA methylation analysis undertaken as part of the research project
was conducted at the specific predetermined loci (Table 2.4) using bisulphite-PCR
amplification followed by matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) techniques.
In this section a brief overview of each planned procedure will be given. The appendices of
the thesis will provide more detailed step-by-step instructions of each procedure. The steps
were conducted in the order they are listed below. All referenced appendices can be found
at the end of the thesis. All equipment utilised was located at Edith Cowan University
Joondalup, in the School of Medical and Health Sciences Neuroscience Laboratories and as of
February 2018 laboratory equipment will be located at 8 Verdun Street, Nedlands on level 2
of the Ralph and Patricia Sarich Neuroscience Institute.
2.4.2.2 DNA Extraction, Bisulphite Conversion and PCR Amplification
DNA has previously been extracted from whole blood samples provided from the AIBL DNA
bank using either QIAamp DNA blood Maxi- or Midikit following the manufacturer’s protocol.
To allow for quantification of methylation, extracted DNA samples first underwent bisulphite
conversion. Bisulphite conversion is a commonly used method that converts non-methylated
cytosine into uracil and methylated cytosines remain untouched (Ehrich, Correll, & van den
Boom, 2006). The bisulphite conversion process creates a mass discrepancy between
methylated and unmethylated fragments that the MALDI-TOF relies on to determine the state
of methylation (Suchiman et al., 2015). Specifically, bisulphite conversion of extracted DNA
samples was undertaken using the Sequenom3 recommended protocol (SRP) for ZYMO
Research EZ DNA MethylationTM Kits (kit specifications can be found in Appendix 1). The SRP
contains small modifications from the ZYMO Research EZ DNA MethylationTM Kits (Appendix
2) for use with the Agena Bioscience MassArray4 Analyser platform and EpiTyper software.
Post bisulphite conversion, each Amplicon was amplified separately using the primers
designed in Section 2.4.1 using a ‘Touch Down Polymerase Chain Reaction (PCR)’ method to
optimise primer conditions.

Full methodology, including reagents and thermocycling

conditions are detailed in Appendix 3.
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2.4.2.3 SAP Incubation, Transcription and Mass Cleavage
Shrimp Alkaline Phosphatase (SAP) (Agena Bioscience) was used to remove any
unincorporated dNTPs that remain after PCR amplification to prevent them interfering with
any further polymerase reactions. The protocol for the SAP reaction is detailed in Appendix
4. Following the SAP incubation, in vitro RNA transcription and base specific cleavage
(MassCLEAVE) by RNAseA occurred simultaneously as detailed in Appendix 5. Mass cleavage
ensures all lengths of DNA are the same and only differ in composition (i.e. either methylated
or un-methylated), achieved through the incorporation of the T7 tag. The RNAseA relies on
the addition of dCTPs or dTTPs prior to cleavage ensuring that cleavage only occurs at sites 3’
of the dCTP or dTTP residues (Sant, Nahar, & Dolinoy, 2012).
2.4.2.4 Resin Addition, Chip Dispensing, Time of Flight Detection and EpiTyper Analysis
Subsequent to the MassCLEAVE reaction the samples were treated with CLEAN resin (Agena
Bioscience). The resin eliminates any salts that may interfere with the mass spectrometer
measurement. The automated Nanodispenser RS1000 (Agena Bioscience) was used to
dispense the samples onto a SpectroCHIP® II 384 (Agena Bioscience) for use on the Agena
Bioscience MassArray® Analyser 4 (MA4) MALDI TOF-MS platform. The detailed protocol can
be found in Appendix 6.
The MA4 relies on the RNA fragments deposited on the SpectroCHIP® II array absorbing
energy from the laser and becoming ionised, this ionisation allowing the fragments to be
drawn down the flight tube of the mass spectrometer with the assistance of an electric field
(Suchiman et al., 2015). The larger a fragment the longer the time of flight, which permits
methylated units that have avoided bisulphite conversion to be distinguished from one
another, as fragments with a CpG unit are 16 Da heavier than those without a CpG unit
(Suchiman et al., 2015). Results are displayed in peaks with DNA methylation percentage of a
given CpG determined by the EpiTyper software (Agena Bioscience) through dividing the
surface area of a peak representing a methylated peak by the total surface area of all peaks
(both methylated and unmethylated) (Suchiman et al., 2015).

2.5 Data Analysis
All data analysis was carried out using RStudio Version 1.1.453 – © 2009-2018 RStudio, Inc.
for Macintosh (R Development Core Team, 2015). Demographic data was determined;
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providing mean, standard deviation and percentage of population where applicable.
Demographic data was stratified by amplicon. Methylation data was determined to be
negatively skewed by the Shapiro-Wilks test. The non-parametric nature of the data was
considered when deciding relevant statistical tests and models.
2.5.1 Normalisation of methylation data
Normalisation of the data was also required to account for variation introduced during the
laboratory process, including samples being analysed from different PCR cycles and different
analysis chips. 10 samples from each plate were selected (10 x 8) and rerun for both amplicons
within the same PCR and assessed on the same chip. Analysis was then undertaken to
determine the average variation between original run and the normalisation run for the
selected samples. This then informed how sample methylation levels were adjusted for
normalisation.
2.5.2 Study One: CLU Promoter methylation, clinical classification and AD biomarkers
To determine whether methylation levels in the promoter region of Clusterin were associated
with clinical classification, cross sectionally, analyses of covariance (ANCOVA) were
conducted. An ANCOVA was chosen because it is robust enough to account for the
skewedness of the data (Portney & Watkins, 2000) and allows for the inclusion of covariates,
which are; age, sex, APOE ε4 and whether an individual is A positive or negative (A+/-).
Utilising the ‘aov’ function within the ‘Stats’ package version 3.5.0 a comparison was
conducted between HC and MCI, HC and AD, and MCI and AD. An ANCOVA with the same
covariates was conducted to determine a potential association between methylation
percentage levels and the CLU SNPs rs11136000 and rs9331888. An additive model was used
for both SNPs. Nominal or uncorrected values were reported as significant if p < 0.05. All
values then underwent correction for the false discovery rate (FDR), which is represented
with a q-value. The significance threshold for the q-value was q < 0.05 (Benjamini & Hochberg,
1995). Correction was performed across all p-values combined, using a web based program
called ‘q-value estimation for FDR control’ (http://qvalue.princeton.edu; (J. D. Storey, 2002).
Default settings (lambda range, 0–0.95 in 0.05 steps; π0 method, smoother) were used as
standard for the ‘q-value estimation for FDR control’ program unless otherwise specified,
where the lambda range was adjusted to reflect distribution of uncorrected p-values.
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Spearman’s partial correlations were used to analyse any correlation between blood, CSF and
brain biomarkers of AD in relation to methylation percentage levels. Spearman’s partial
correlation was appropriate in this case because it is a non-parametric test that considers
covariates (Kim, 2015). Applying the ‘pcor.test’ from the ‘ppcor’ R package the data was
analysed across all participants and subsequently in HC and HC with high brain Αβ burden
(A+ HC). Across all participants the covariates of clinical classification, sex, age, APOE ε4 and
A+/- were used. In HC analyses, sex, age, APOE ε4 and A+/- were used and within HC Αβ+,
sex, age and APOE ε4 were controlled for. All analyses were cross-sectional and FDR
correction was completed across each individual biomarker.
2.5.3 Study Two: CLU Promoter methylation and cognitive performance
Linear mixed model’s (LMM’s) were used to analyse associations between CLU promoter
region methylation levels and longitudinal cognition. The ‘lme’ function within R’s ‘nlme’
package was used to conduct the LMM’s. An LMM was chosen as it has the capacity to cope
with missing data, skewed data and include covariates (Cnaan, Laird, & Slasor, 1997). The
cognitive domains of global cognition, verbal episodic memory and executive function were
analysed as developed by S. C. Burnham et al. (2015). The preclinical Alzheimer’s disease
cognitive composite (PACC) was also investigated. The PACC combines tests that access global
cognition, timed executive function and episodic memory to determine signs of early
cognitive decline (Donohue et al., 2014).
As for Study One, data was analysed across all participants and HC and A+ HC groups.
Initially, a methylation x time interaction was modelled with the cognitive composites as the
dependent variable. The composites of global cognition, verbal episodic memory and
executive function were developed considering age, premorbid IQ, depression score and sex,
so it was not required to control for these factors in analysis. Therefore, only clinical
classification, APOE ε4 and A+/- were included as covariates in the analysis. For analysis
using the PACC, age, premorbid IQ, depression score, sex, clinical classification, APOE ε4 and
A+/- were controlled for. Covariates were also amended depending on the level of analysis.
The models were graphically presented as both baseline cognitive composite score and
change in composite score over time. Correction for the false discovery rate was performed
over all p-values.
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Chapter 3: Results
3.1 Methylation Data and Sample Quality Control
DNA Methylation data was generated as described in Section 2.4.2 Quantitation of DNA
Methylation - Workflow and Protocols. Call rates for the CpG sites/units captured in the assay
design, along with respective call rates (i.e. where a percentage of methylation at that
site/unit was determined per individual sample), are presented in Table 3.1. The initial step
of data selection was to exclude any site/unit from downstream analysis where a percentage
methylation could not be determined in greater than 25% of samples (i.e. site/unit call rate
>75%). This resulted in 7 CpG sites/units being excluded from downstream analyses (Table
3.1). In addition to the above quality control of DNA methylation data, sample quality control
was also performed. Samples were only included in downstream analyses when DNA
methylation data was available at all sites/units that passed quality control.

CpG Site/Unit
Amplicon 1
CpG_1
CpG_2_3
CpG_4_5
Cpg_6_7
CpG_8_9
CpG_10
CpG_11_12_13
CpG_14
CpG_15
CpG_16
CpG_17_18
CpG_19

Call Rate (%)
89.55
87.57
9.79
60.85
87.96
89.68
74.21
89.55
86.9
87.17
0
89.68

Excluded* CpG Site/Unit
Amplicon 2
CpG_20_21
CpG_22
excluded CpG_23_24
excluded CpG_25_26_27_28
CpG_29_30_31
CpG_32
excluded CpG_33
CpG_34
CpG_35
CpG_36
excluded CpG_37
CpG_38_39
CpG_40
CpG_41

Call Rate (%)
92.58
60.42
92.06
92.45
92.19
92.97
91.02
85.42
0
93.1
93.1
92.45
0
93.1

Excluded*

excluded

excluded

excluded

Table 3.1. CpG site/unit call rates
List of clusterin CpG sites and units and their associated call rates (%) in methylation analysis.
*Exclusion criteria = call rate <75%, excluded as noted. Unbolded sites and units carried
forward for further analysis
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3.2 Sample Demographics
Due to the separate amplification of the two amplicons and to remove this potential source
of variability, these were analysed separately. Demographic data is provided for all samples
included in Amplicon 1 (n=626) and Amplicon 2 (n=646) analyses in Table 3.2. No significant
differences were observed between the two “Amplicon groups” for any demographic
variable.

Age, mean (SD), years
Female, n. (%)
Clinical Classification, n. (%)

HC
MCI
AD
Years of Education, n. (%)
0-8 years
9-12 years
13-15 years
15+ years
Premorbid IQ (FSIQ), mean (SD)
Depressive Symptoms (GDS), mean (SD)
APOE ε4 carriage, n. (%)
Imaged*, n. (%)
Aβ+, n (%)
CSF (n)
Plasma CLU Levels, n
rs11136000, n
rs9331888, n

Amplicon 1
n=626
73.11 (6.90)
336 (53.67)
450 (71.88)
90 (14.38)
86 (13.74)
61 (9.8)
240 (38.59)
118 (18.97)
203 (32.64)
106.6 (8.12)
1.63 (1.92)
223 (36.92)
626 (100)
349 (55.75)
85
331
622
623

Amplicon 2
n=646
72.87 (6.78)
355 (54.95)
474 (73.37)
85 (13.16)
87 (13.47)
58 (9.03)
239 (37.23)
135 (21.03)
210 (32.71)
106.76 (7.97)
1.62 (1.93)
229 (36.64)
646 (100)
356 (55.1)
85
357
642
643

Table 3.2. Demographic Data
Baseline demographic information for Alzheimer’s disease (AD, n=73) and cognitively normal
older adults (CN, n=570) in the AIBL Study. CN older adults with high Aβ (Aβhigh, n=247) were
used to investigate changes in baseline and longitudinal cognition. All values represented as
mean ± standard deviation, unless otherwise stated. *Imaged = PET imaging data available
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3.2 Study One: CLU Promoter methylation, clinical classification and AD biomarkers
3.2.1 Methylation levels vs clinical classification
To determine if there was an association between clinical classification and methylation levels
within the clusterin promoter region an analysis of covariance (ANCOVA) was conducted. The
covariates of age, sex, APOE ε4 genotype and A status (+/-) were controlled for. Overall six
CpG sites/units presented with nominally significant p-values (Table 3.3), which all survived
correction for the false discovery rate (FDR); CpG_10 (F=2.285, p=0.034, q=0.040), CpG_14
(F=4.047, p=0.001, q=0.004), CpG_15 (F=2.453, p=0.024, q=0.040), CpG_16 (F=3.267,
p=0.004, q=0.012), CpG_20_21 (F=2.712, p=0.013, q=0.030) and CpG_25_26_27_28 (F=2.310,
p=0.033, q=0.040). Subsequent post-hoc analysis of the estimated marginal mean (EMM)
percentage methylation for these CpG sites/units, with correction for the FDR, is presented
in Table 3.3. The between group post-hoc comparisons for CpG_10 (MCI<AD (p=0.232,
q=0.315), AD>HC (p=0.890, q=0.616), AD>MCI (p=0.298, q=0.364)), CpG_16 (MCI<AD
(p=0.229, q=0.315, AD>HC (p=0.059, q=0.10), AD>MCI (p=0.517, q=0.453)) and CpG_20_21
(MCI<HC (p=0.907, q=0.616), AD>HC (p=0.359, q=0.371), AD>MCI (p=0.401, q=0.377)) were
not significant after FDR correction. However, CpG_14, CpG_15 and CpG_25_26_27_28
between group comparisons with nominal significance also survived FDR correction.
Individuals with mild cognitive impairment (MCI) when compared to healthy controls (HC)
were significant; CpG_14 (p=0.001, q=0.012), CpG_15 (p=0.008, q=0.025), CpG_25_26_27_28
(p=0.019, q=0.038). CpG_14 (p=0.004, q=0.025) and CpG_15 (p=0.008, q=0.025) were also
significant for a difference between HC and individuals with Alzheimer’s Disease (AD).
CpG_25_26_27_28 has a significant difference between HC and those with AD (p=0.010,
q=0.025). Notably the EMM percentage methylation at each of the significant loci decreased
from HC to MCI and also for CpG_ CpG_25_26_27_28 the EMM percentage methylation
decreased from MCI to AD.
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Analysis site/unit

ANCOVA F
(p-value)

q-value+

Amplicon 1
CpG_1
CpG_2_3

1.213(0.298)
0.701(0.649)

0.206
0.290

CpG_8_9
CpG_10
CpG_14
CpG_15

0.649(0.691)
2.285(0.034)
4.047(0.001)
2.453(0.024)

0.290
0.040
0.004
0.040

CpG_16
CpG_19
Amplicon 2

3.267(0.004)
1.837(0.090)

0.012
0.089

CpG_20_21
CpG_23_24
CpG_25_26_27_28
CpG_29_30_31

2.712(0.013)
1.673(0.125)
2.310(0.033)
0.909(0.488)

0.030
0.096
0.040
0.260

CpG_32
CpG_33
CpG_34
CpG_36

0.808(0.564)
0.516(0.796)
1.717(0.115)
0.563(0.760)

0.279
0.290
0.096
0.290

CpG_37
CpG_38_39

1.027(0.406)
0.563(0.760)

0.235
0.213

CpG_41

0.563(0.760)

0.290

HC
EMM (95% CI)
n=450

MCI
EMM (95% CI)
n=90

AD
EMM (95% CI)
n=86

MCI-HC
p (q-value)

AD-HC
p (q-value)

AD-MCI
p (q-value)

0.045 (0.005)
0.032 (0.003)
0.051 (0.004)

0.037 (0.012)
0.02 (0.007)*
0.038 (0.008)*

0.046 (0.013)
0.021 (0.007)*
0.037 (0.009)*

0.232(0.315)
0.001(0.012)
0.008 (0.025)

0.890 (0.616)
0.004 (0.025)
0.008 (0.025)

0.298 (0.364)
0.861 (0.616)
0.866 (0.616)

0.056 (0.004)

0.05 (0.008)

0.046 (0.009)

0.229 (0.315)

0.059 (0.103)

0.518 (0.453)

n=474

n=85

n=87

0.043 (0.002)

0.044 (0.005)

0.041 (0.005)

0.907 (0.616)

0.359 (0.371)

0.401 (0.377)

0.022 (0.002)

0.017 (0.004)*

0.017 (0.004)^

0.019 (0.038)

0.364 (0.371)

0.010 (0.025)

Table 3.3 Methylation vs Clinical Classification
ANCOVA model output and between group comparisons of EMM (estimated marginal means) percentage methylation. Italicised, nominal
significance; bold, significant after FDR correction; +lambda range adjusted to 0–0.80; 95% CI, = 95% confidence interval. * significantly
different to HC (Healthy Controls); ^ significantly different to MCI (Mild Cognitive Impairment)
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3.2.2 Impact of CLU genetic variation on Methylation
3.2.2.1 rs9331888
Results of the ANCOVA comparing CLU rs9331888 genotypes among all participants,
controlling for clinical classification, A+/-, age, sex and APOE ε4 genotype, are presented in
Table 3.4. Only CpG_14 and CpG_16 reached nominal significance and they both survived FDR
correction, F=3.427, p=0.001, q=0.007 and F=2.875, p=0.006, q=0.022, respectively. However,
between group comparisons of the EMM percentage methylation at these sites did not
survive correction for the FDR (Table 3.4). Post-hoc analysis was performed on these sites
however there was no significant difference. This may be explained by the exploratory nature
of an ANCOVA. The cohort was further stratified to healthy controls (HC) and then only those
HC that were amyloid beta positive (A+). These analyses covaried for A+/- (HC only), age,
sex and APOE ε4 genotype. CpG_19 (F=2.120, p=0.05, q=0.466) and CpG_20_21 (F=2.496,
p=0.022, q=0.409) were nominally significant for the ANCOVA models in the HC’s but the
values did not survive FDR correction (Table 3.5). Likewise, for the A+ HC’s CpG_1 (F=3.298,
p=0.007, q=0.133) was nominally significant but also did not survive FDR correction (Table
3.6).
3.2.2.2 rs11136000
Analyses, as described above, were then undertaken for CLU rs1136000. The ANCOVA
performed in all participants (Table 3.7) revealed 2 sites and 1 unit with nominally significant
differences in percentage methylation between genotypes that remained significant after
FDR correction (CpG_14 (F=3.364, p=0.002, q=0.0285), CpG_16 (F=3.095, p=0.003, q=0.0285)
and CpG_23_24 (F=2.788, p=0.007, q=0.0443)). Post-hoc analysis revealed that the
rs1136000-TC genotype was associated with a significantly lower EMM percentage
methylation than rs1136000-CC at CpG_14 when FDR correction was performed (p=0.097,
q=0.05 Table 3.7). Likewise, CpG_16 was also significant after FDR correction (TT<CC, q=0.05;
Table 3.7). Finally, significant differences in EMM percentage methylation were observed,
though in the inverse direction, for CpG_23_24 (TT>CC, p=0.001, q=0.002; TT>TC (p=0.013,
q=0.013). After stratification by clinical classification, analyses within HC only (Table 3.8)
revealed no significant differences. Further, whilst nominal significances at CpG_1 (F=2.275,
p=0.049, q=0.2092) and CpG_23_24 (F=2.330, p=0.0440, q=0.2092) were observed in the A+
HC’s this did not survive FDR correction (Table 3.9).
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Analysis site/unit

ANCOVA F
(p-value)

q-value*

Amplicon 1
CpG_1
CpG_2_3

1.242(0.278)
0.705(0.668)

0.182
0.294

CpG_8_9
CpG_10
CpG_14
CpG_15

0.468(0.858)
1.857(0.074)
3.427(0.001)
1.964(0.058)

0.337
0.092
0.007
0.088

CpG_16
CpG_19
Amplicon 2

2.875(0.006)
1.571(0.141)

0.022
0.130

CpG_20_21
CpG_23_24
CpG_25_26_27_28
CpG_29_30_31

1.956(0.059)
1.996(0.054)
1.216(0.292)
0.487(0.845)

0.088
0.088
0.182
0.337

CpG_32
CpG_33
CpG_34
CpG_36

1.722(0.101)
0.810(0.579)
1.522(0.157)
1.002(0.429)

0.108
0.286
0.130
0.229

CpG_37
CpG_38_39

0.771(0.612)
1.347(0.226)

0.286
0.169

CpG_41

1.002(0.429)

0.229

GG
EMM (95% CI)
n=337

CG
EMM (95% CI)
n=244

CC
EMM (95% CI)
n=42

CG vs GG
p (q-value)

CC vs GG
p (q-value)

CC vs CG
p (q-value)

0.028(0.003)

0.029(0.004)

0.037(0.009)

0.709(0.154)

0.074(0.066)

0.119(0.066)

0.052(0.004)

0.056(0.005)

0.057(0.012)

0.248(0.091)

0.421(0.116)

0.839(0.154)

n=347

n=251

n=45

Table 3.4 Effect of rs9331888 on CLU promoter methylation (All Participants)
ANCOVA model output and between group comparisons of EMM (estimated marginal means) percentage methylation. Italicised, nominal
significance; bold, significant after FDR correction; *lambda range adjusted to 0–0.85; 95% CI, = 95% confidence interval.

37

Analysis site/unit
Amplicon 1
CpG_1
CpG_2_3
CpG_8_9
CpG_10
CpG_14

ANCOVA F (p-value)

q-value

1.258(0.276)
0.349(0.910)
0.847(0.534)
1.661(0.129)
1.908(0.078)

0.734
0.944
0.838
0.569
0.486

CpG_15
CpG_16
CpG_19
Amplicon 2
CpG_20_21

0.727(0.628)
1.481(0.183)
2.120(0.050)

0.838
0.569
0.466

2.496(0.022)

0.409

CpG_23_24
CpG_25_26_27_28
CpG_29_30_31
CpG_32
CpG_33

0.899(0.495)
0.168(0.985)
0.368(0.899)
1.533(0.166)
0.900(0.495)

0.838
0.968
0.944
0.569
0.838

CpG_34
CpG_36
CpG_37
CpG_38_39
CpG_41

0.854(0.529)
0.760(0.602)
0.634(0.703)
0.569(0.755)
0.760(0.602)

0.838
0.838
0.874
0.881
0.838

Table 3.5 Effect of rs9331888 on CLU promoter methylation (Healthy Controls)
ANCOVA model output and between group comparisons of EMM (estimated marginal means)
percentage methylation. Italicised, nominal significance; bold, significant after FDR
correction. Amplicon 1: n(GG)=240, n(CG)=178, n(CC)=30. Amplicon 2: n(GG)=252,
n(CG)=188), n(CC)=32.
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Analysis site/unit
Amplicon 1
CpG_1

ANCOVA F (p-value)

q-value

3.298(0.007)

0.133

CpG_2_3
CpG_8_9
CpG_10
CpG_14
CpG_15

0.534(0.750)
0.271(0.928)
1.311(0.261)
1.402(0.225)
0.166(0.975)

0.968
0.975
0.743
0.743
0.975

CpG_16
CpG_19
Amplicon 2
CpG_20_21
CpG_23_24
CpG_25_26_27_28

0.568(0.724)
0.516(0.764)

0.968
0.968

1.211(0.305)
1.121(0.351)
1.155(0.333)

0.743
0.743
0.743

CpG_29_30_31
CpG_32
CpG_33
CpG_34
CpG_36

0.300(0.912)
1.768(0.121)
1.639(0.151)
0.242(0.944)
1.008(0.414)

0.975
0.743
0.743
0.975
0.743

CpG_37
CpG_38_39
CpG_41

0.926(0.465)
0.921(0.469)
1.008(0.414)

0.743
0.743
0.743

Table 3.6 Effect of rs9331888 on CLU promoter methylation (A + Healthy Controls)
ANCOVA model output and between group comparisons of EMM (estimated marginal means)
percentage methylation. A+, amyloid beta positive; italicised, nominal significance; bold,
significant after FDR correction. Amplicon 1: n(GG)=105, n(CG)=85, n(CC)=12. Amplicon 2:
n(GG)=111, n(CG)=89, n(CC)=13.
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Analysis site/unit

ANCOVA F
(p-value)

q-value

Amplicon 1
CpG_1
CpG_2_3

2.248(0.029) 0.1330
0.528(0.814) 0.9710

CpG_8_9
CpG_10
CpG_14
CpG_15

1.566(0.143)
1.747(0.096)
3.364(0.002)
2.175(0.035)

CpG_16
CpG_19
Amplicon 2

3.095(0.003) 0.0285
1.490(0.168) 0.3547

CpG_20_21
CpG_23_24
CpG_25_26_27_28
CpG_29_30_31

1.974(0.056) 0.1773
2.788(0.007) 0.0443
1.170(0.318) 0.5262
0.336(0.937) 0.971

CpG_32
CpG_33
CpG_34
CpG_36

1.136(0.338)
0.254(0.971)
1.359(0.220)
0.258(0.970)

CpG_37

0.991(0.437) 0.5931

CpG_38_39
CpG_41

1.102(0.360) 0.5262
0.258(0.970) 0.9710

0.3396
0.2606
0.0285
0.1330

CC
EMM (95% CI)
n=218

TC
EMM (95% CI)
n=296

TT
EMM (95% CI)
n=108

TC vs CC
p (q-value+)

TT vs CC
p (q-value+)

TT vs TC
p (q-value+)

0.032(0.004)

0.027(0.004*

0.029 (0.006)

0.097 (0.050)

0.460(0.113)

0.587 (0.128)

0.057(0.005)

0.053 (0.004)

0.049(0.007*

0.349 (0.098)

0.101(0.050)

0.328 (0.098)

n=222

n=307

n=113

0.028(0.004)

0.031 (0.004)

0.04(0.006)^

0.201 (0.079)

0.001(0.002)

0.013 (0.013)

0.5262
0.9710
0.4180
0.9710

Table 3.7 Effect of rs11136000 on CLU promoter methylation (All Participants)
ANCOVA model output and between group comparisons of EMM (estimated marginal means) percentage methylation. Italicised, nominal
significance; bold, significant after FDR correction. +lambda range adjusted to 0–0.58; * significantly different to CC; ^ significantly different to
TC
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Analysis site/unit
Amplicon 1
CpG_1
CpG_2_3
CpG_8_9
CpG_10
CpG_14
CpG_15

ANCOVA F (p-value)

q-value

2.206(0.042)
0.236(0.965)
1.954(0.071)
1.748(0.108)
1.823(0.093)
0.800(0.570)

0.337
0.998
0.337
0.342
0.342
0.884

CpG_16
CpG_19
Amplicon 2
CpG_20_21
CpG_23_24

1.524(0.169)
1.401(0.213)

0.459
0.506

2.677(0.015)
1.980(0.067)

0.285
0.337

CpG_25_26_27_28
CpG_29_30_31
CpG_32
CpG_33
CpG_34

0.253(0.958)
0.080(0.998)
1.055(0.389)
0.756(0.605)
0.781(0.585)

0.998
0.998
0.821
0.884
0.884

CpG_36
CpG_37
CpG_38_39
CpG_41

0.238(0.964)
0.884(0.506)
0.691(0.657)
0.238(0.964)

0.998
0.884
0.892
0.998

Table 3.8 Effect of rs11136000 on CLU promoter methylation (Healthy Controls)
ANCOVA model output and between group comparisons of EMM (estimated marginal means)
percentage methylation. Italicised, nominal significance; bold, significant after FDR
correction. Amplicon 1: n(CC)=150, n(TC)=212, n(TT)=85. Amplicon 2: n(CC)=155, n(TC)=226,
n(TT)=90.
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Analysis site/unit
Amplicon 1
CpG_1

ANCOVA F (p-value)

q-value

2.275(0.049)

0.2092

CpG_2_3
CpG_8_9
CpG_10
CpG_14
CpG_15

0.557(0.733)
1.301(0.265)
1.113(0.355)
1.580(0.168)
0.268(0.930)

0.4075
0.4075
0.4075
0.4075
0.4180

CpG_16
CpG_19
Amplicon 2
CpG_20_21
CpG_23_24
CpG_25_26_27_28

0.604(0.697)
0.598(0.702)

0.4075
0.4075

1.194(0.314)
2.330(0.0440
0.490(0.784)

0.4075
0.2092
0.4075

CpG_29_30_31
CpG_32
CpG_33
CpG_34
CpG_36

0.384(0.859)
1.057(0.386)
1.391(0.229)
0.433(0.825)
0.630(0.677)

0.4075
0.4075
0.4075
0.4075
0.4075

CpG_37
CpG_38_39
CpG_41

0.881(0.495)
0.669(0.648)
0.630(0.677)

0.4075
0.4075
0.4075

Table 3.9 Effect of rs11136000 on CLU promoter methylation (A + Healthy Controls)
ANCOVA model output and between group comparisons of EMM (estimated marginal means)
percentage methylation. A+, amyloid beta positive; italicised, nominal significance; bold,
significant after FDR correction. Amplicon 1: n(CC)=75, n(TC)=93, n(TT)=34. Amplicon 2:
n(CC)=79, n(TC)=95, n(TT)=39.
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3.2.3 Association of Clusterin promoter methylation with AD Biomarkers
3.2.3.1 Associations with Plasma Clusterin Levels
Associations between percentage methylation and plasma clusterin levels were assessed
using Spearman’s partial correlations, with A+/-, age, sex and APOE ε4 genotype controlled
for (Table 3.10; clinical classification was removed when only analysing the HC’s and the A+/was further removed when analysing A+ HC’s). Significant correlations were observed across
all stratifications (all participants, HC and HC A+groups). However, whilst nominal
significance was observed, when analysing all participants, CpG_14 (=-0.1092, p=0.0488,
q=0.0925) and CpG_34 (=0.1046, p=0.0496, q=0.0925), neither remained significant after
FDR correction. Within the HC’s, CpG_16 (⍴=0.1858, p=0.0034) also reached nominal
significance and survived correction for the FDR (q=0.0157). That same site remained
nominally significant in the A+ HC’s but did not survive FDR correction (=0.2704, p=0.0043,
q=0.0817). Another site, CpG_32, also attained only nominal significance (= 0.1799,
p=0.0473, q=0.4494).
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Analysis site/unit

All Participants

HC

A+ HC

⍴ (p)*

⍴ (p)

⍴ (p)

n=331

n=251

n=113

CpG_1
CpG_2_3
CpG_8_9
CpG_10

-0.0178 (0.7487)
-0.0769 (0.1658)
-0.057 (0.3051)
-0.0214 (0.7002)

-0.062 (0.332)
-0.067 (0.2946)
-0.0144 (0.8213)
0.0236 (0.712)

-0.0543 (0.5732)
-0.0558 (0.5625)
-0.0584 (0.5443)
-0.0572 (0.5527)

CpG_14

-0.1092 (0.0488)

0.0313 (0.6245)

-0.0376 (0.6965)

CpG_15
CpG_16
CpG_19
Amplicon 2
CpG_20_21

-0.0813 (0.1431)
0.0478 (0.3897)
-0.05 (0.3685)
n=357
0.0257 (0.6302)

0.0899 (0.159)
0.1858 (0.0034)
0.034 (0.5952)
n=277
0.0049 (0.9355)

0.0087 (0.9282)
0.2704 (0.0043)
-0.004 (0.9667)
n=125
-0.1131 (0.2149)

CpG_23_24
CpG_25_26_27_28
CpG_29_30_31
CpG_32
CpG_33

-0.0173 (0.7459)
0.0706 (0.1861)
0.092 (0.0848)
0.0585 (0.2738)
0.0535 (0.3172)

0.0232 (0.7025)
0.0963 (0.1124)
0.1115 (0.0659)
0.098 (0.1061)
0.035 (0.5653)

-0.0649 (0.4777)
-0.0337 (0.7125)
0.0688 (0.4513)
0.1799 (0.0473)
-0.0196 (0.8301)

CpG_34
CpG_36
CpG_37
CpG_38_39
CpG_41

0.1047 (0.0496)
0.0497 (0.353)
-0.0197 (0.712)
0.0829 (0.1207)
0.0497 (0.353)

0.0443 (0.4661)
0.0312 (0.6073)
-0.0406 (0.5045)
0.0403 (0.5076)
0.0312 (0.6073)

0.0184 (0.8409)
0.0282 (0.7576)
-0.0207 (0.8207)
0.0436 (0.6338)
0.0282 (0.7576)

Amplicon 1

Table 3.10 Relationship between CLU promoter methylation and Plasma Clusterin levels
Partial correlations between CLU promoter methylation and plasma Clusterin levels. A+,
amyloid beta positive; ⍴= Spearman’s partial correlation coefficient, p=nominal p-value,
italicised, nominal significance, bold, significant after FDR correction (q<0.05). *lambda range
adjusted to 0–0.80.
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3.2.3.2 Cerebrospinal Fluid (CSF) biomarkers
As described in Section 2.3.1.2, CSF biomarkers included; A42, total tau (T-tau),
phosphorylated tau (P-tau), the ratio between A42 and T-tau (A42/T-tau), and the ratio
between A42 and P-tau (A42/P-tau). The biomarkers were analysed against methylation
levels using Spearman’s partial correlations using the covariates of clinical classification, A+/, age, sex and APOE ε4 genotype, when analysed across all participants. Clinical classification
and A+/- were removed as appropriate for analyses within HC and HC A+ groups. Multiple
sites and a unit were correlated with CSF biomarkers prior to FDR correction for analyses
across all participants (Table 3.11). Specifically, CpG_1 (= -0.29, p=0.0135, q=0.1424) and
CpG_8_9 (=-0.278, p=0.018, q=0.1424) were correlated with A42; CpG_10 was correlated
with T-tau (=0.243, p=0.0411, q=0.4522) and A42/T-tau ( =-0.255, p=0.0318, q=0.4214);
CpG_37 was correlated with T-tau (=-0.236, p=0.0476, q=0.5422) and P-tau (=-0.2639,
p=0.0251, q=0.3431). However, no sites or units survived FDR correction.
For analyses within the HC group (Table 3.12), several sites and units reached nominal
significance. With respect to A42 levels, significant correlations were observed for
methylation at CpG_1 (=-0.2988, p=0.0437, q=0.2821) and CpG_8_9 (=-0.3887, p=0.0076,
q=0.0981). Nominally significant correlations between methylation and CSF T-tau levels were
observed at CpG_2_3 (=0.3377, p=0.0217, q=0.1976), CpG_10 (=0.3182, p=0.0312,
q=0.1976) and CpG_37 (=-0.389, p=0.0062, q=0.1178). Likewise, methylation was also
correlated with CSF P-tau levels at CpG_2_3 (=0.3552, p=0.0154, q=0.1150), CpG_23_24 (
=-0.3295, p=0.0222, q=0.1150) and CpG_37 (-0.4585, p=0.001, q=0.0155). With respect to CSF
ratios, methylation was correlated with A42/T-tau at CpG_2_3 (=-0.3193, p=0.0305,
q=0.0681), CpG_10 (=-0.3181, p=0.0312, q=0.0681), CpG_34 (=0.3092, p=0.0325,
q=0.0681) and CpG_37 (=0.299, p=0.039, q=0.0681) and with A42/P-tau at CpG_2_3 (=0.3038, p=0.0401, q=0.1155), CpG_10 (=-0.3021, p=0.0413, q=0.1155) and CpG_37
(=0.3825, p=0.0073, q=0.0613). However, only one site stayed significant after FDR
correction – being the correlation between methylation at CpG_37 with P-tau (⍴=-0.4585,
p=0.001, q=0.0155).
Analyses within the A+ HC group (Table 3.13) revealed significant correlations between
methylation at CpG_1 (⍴=-0.6584, p=0.0016, q=0.0028), CpG_8_9 (⍴=-0.4704, p=0.0363,
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q=0.0297) and CpG_10 (⍴=-0.4433, p=0.0503, q=0.0297) with A42 CSF levels. Methylation at
CpG_10 was also observed to be correlated with A42 /T-tau (⍴=-0.5657, p=0.0093,
q=0.1544) and A42 /P-tau (⍴=-0.587, p=0.022, q=0.2848), though this did not survive FDR
correction. Methylation at CpG_32 was observed to be correlated with T-tau (⍴=0.4713,
p=0.0417, q=0.3765) and A42 /P-tau (⍴=-0.4885, p=0.0338, q=0.2848), though this did not
survive FDR correction.
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Analysis site/unit

A 42
⍴ (p)
n=77

T-tau
⍴ (p)
n=76

P-tau
⍴ (p)
n=77

A 42/T-tau
⍴ (p)
n=76

A 42/P-tau
⍴ (p)
n=77

-0.29 (0.0135)

0.0285 (0.8136)

-0.0369 (0.7586)

-0.1874 (0.1176)

-0.1726 (0.1471)

CpG_2_3
CpG_8_9
CpG_10
CpG_14

0.0509 (0.6709)
-0.278 (0.018)
-0.1016 (0.3959)
-0.1568 (0.1884)

0.1998 (0.0948)
-0.0831 (0.4908)
0.243 (0.0411)
-0.1318 (0.2731)

0.2096 (0.0772)
-0.1182 (0.3227)
0.1565 (0.1893)
-0.0969 (0.4181)

-0.1793 (0.1346)
-0.1402 (0.2434)
-0.255 (0.0318)
0.0129 (0.9153)

-0.1685 (0.157)
-0.1419 (0.2343)
-0.2048 (0.0844)
-0.0553 (0.6442)

CpG_15
CpG_16
CpG_19
Amplicon 2

0.0409 (0.7332)
-0.1339 (0.2621)
-0.0813 (0.497)
n=77

-0.0244 (0.84)
0.1119 (0.3527)
0.1424 (0.2361)
n=76

0.0192 (0.8728)
0.0445 (0.7104)
0.1265 (0.2898)
n=77

0.0132 (0.913)
-0.1661 (0.1662)
-0.1964 (0.1008)
n=76

-0.0317 (0.7918)
-0.1465 (0.2193)
-0.198 (0.0954)
n=77

CpG_20_21
CpG_23_24
CpG_25_26_27_28

-0.0056 (0.9631)
-0.0845 (0.4804)
0.1371 (0.251)

0.19 (0.1124)
-0.0612 (0.6121)
-0.0039 (0.9744)

0.1264 (0.29)
-0.1593 (0.1815)
-0.0919 (0.4427)

-0.1393 (0.2467)
0.0118 (0.9219)
0.0539 (0.6554)

-0.0744 (0.5345)
0.0755 (0.5287)
0.1662 (0.163)

CpG_29_30_31
CpG_32
CpG_33
CpG_34

-0.142 (0.2341)
-0.1928 (0.1047)
-0.0127 (0.9155)
0.0938 (0.433)

-0.1596 (0.1836)
0.0032 (0.9791)
-0.0399 (0.7409)
-0.1073 (0.373)

-0.178 (0.1346)
-0.1621 (0.1738)
0.0041 (0.9731)
-0.1257 (0.2927)

0.0695 (0.5648)
-0.0889 (0.4608)
0.0292 (0.8092)
0.196 (0.1013)

0.0665 (0.5786)
0.0109 (0.9275)
-0.0396 (0.741)
0.2016 (0.0895)

CpG_36
CpG_37

-0.1711 (0.1506)
-0.1336 (0.2631)

0.041 (0.7342)
-0.236 (0.0476)

-0.0998 (0.4044)
-0.2639 (0.0251)

-0.0429 (0.7223)
0.1675 (0.1628)

0.0199 (0.8679)
0.2 (0.0921)

CpG_38_39
CpG_41

-0.1101 (0.3572)
-0.1711 (0.1506)

0.0324 (0.7883)
0.041 (0.7342)

-0.0725 (0.545)
-0.0998 (0.4044)

-0.0289 (0.8106)
-0.0429 (0.7223)

0.0095 (0.9368)
0.0199 (0.8679)

Amplicon 1
CpG_1

Table 3.11 Relationship between CLU promoter methylation and CSF Biomarkers (All Participants)
⍴= Spearman’s partial correlation coefficient; p, nominal p-value; italicised nominal significance; bold, significant after FDR; A42, amyloid beta
42; T-tau, total tau; P-tau, phosphorylated tau; A42/T-tau, ratio of A42 and T-tau; A42/P-tau, ratio of A42 and p- Tau.
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Analysis site/unit

A 42
⍴ (p)
n=50

T-tau
⍴ (p)

P-tau
⍴ (p)

n=50

CpG_1
CpG_2_3

-0.2988 (0.0437)
0.0247 (0.8705)

CpG_8_9
CpG_10
CpG_14
CpG_15

n=50

A 42/T-tau
⍴ (p)
n=50

A 42/P-tau
⍴ (p)
n=50

0.1673 (0.2664)
0.3377 (0.0217)

0.0653 (0.6665)
0.3552 (0.0154)

-0.2668 (0.0731)
-0.3193 (0.0305)

-0.2258 (0.1313)
-0.3038 (0.0401)

-0.3887 (0.0076)
-0.1322 (0.381)
-0.1782 (0.236)
-0.0815 (0.5902)

-0.0833 (0.5821)
0.3182 (0.0312)
-0.2504 (0.0932)
0.0745 (0.6226)

-0.1504 (0.3185)
0.2316 (0.1215)
-0.2143 (0.1528)
0.1104 (0.465)

-0.1802 (0.2309)
-0.3181 (0.0312)
0.112 (0.4589)
-0.1302 (0.3884)

-0.1823 (0.2253)
-0.3021 (0.0413)
0.0643 (0.6711)
-0.2357 (0.1148)

CpG_16
CpG_19
Amplicon 2

-0.0698 (0.645)
-0.0618 (0.6831)
n=52

0.2475 (0.0972)
0.1194 (0.4294)
n=52

0.1897 (0.2068)
0.0881 (0.5603)
n=52

-0.2669 (0.0729)
-0.1417 (0.3475)
n=52

-0.2548 (0.0874)
-0.1411 (0.3495)
n=52

CpG_20_21
CpG_23_24
CpG_25_26_27_28
CpG_29_30_31

-0.0315 (0.8317)
-0.0966 (0.5135)
0.1031 (0.4856)
-0.1568 (0.2872)

0.1413 (0.3381)
-0.2063 (0.1595)
0.1412 (0.3384)
-0.1308 (0.3754)

0.0031 (0.9836)
-0.3295 (0.0222)
0.0103 (0.9448)
-0.1336 (0.3655)

-0.0717 (0.6283)
0.1127 (0.4457)
-0.0987 (0.5045)
-0.0288 (0.8461)

0.0344 (0.8167)
0.2666 (0.0669)
0.0343 (0.8169)
-0.0352 (0.8121)

CpG_32
CpG_33
CpG_34
CpG_36

-0.2357 (0.1068)
0.0539 (0.7162)
0.1198 (0.4175)
0.0141 (0.9243)

0.0808 (0.585)
0.0103 (0.9444)
-0.1765 (0.23)
0.0028 (0.9847)

-0.1071 (0.4686)
0.0509 (0.7311)
-0.1022 (0.4894)
-0.1524 (0.3012)

-0.132 (0.3713)
0.0443 (0.7651)
0.3092 (0.0325)
0.0759 (0.608)

-0.0247 (0.8675)
-0.0214 (0.885)
0.248 (0.0892)
0.1999 (0.1732)

CpG_37
CpG_38_39

-0.0769 (0.6035)
-0.0548 (0.7114)

-0.389 (0.0062)
-0.0498 (0.7366)

-0.4585 (0.001)
-0.14 (0.3425)

0.299 (0.039)
0.0538 (0.7164)

0.3825 (0.0073)
0.0969 (0.5125)

CpG_41

0.0141 (0.9243)

0.0028 (0.9847)

-0.1524 (0.3012)

0.0759 (0.608)

0.1999 (0.1732)

Amplicon 1

Table 3.12 Relationship between CLU promoter methylation and CSF Biomarkers (Healthy Controls)
⍴= Spearman’s partial correlation coefficient; p, nominal p-value; italicised nominal significance; bold, significant after FDR; A42, amyloid beta
42; T-tau, total tau; P-tau, phosphorylated tau; A42/T-tau, ratio of A42 and T-tau; A42/P-tau, ratio of A42 and p- Tau.
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Analysis site/unit
Amplicon 1
CpG_1
CpG_2_3

A 42
⍴ (p)
n=23
-0.6584 (0.0016)
-0.2155 (0.3616)

T-tau
⍴ (p)
n=23
0.0377 (0.8747)
0.3604 (0.1186)

P-tau
⍴ (p)*
n=23
-0.1173 (0.6224)
0.4169 (0.0674)

A 42/T-tau
⍴ (p)
n=23
-0.2319 (0.3251)
-0.3084 (0.1859)

A 42/P-tau
⍴ (p)
n=23
-0.3651 (0.1134)
-0.4436 (0.0501)

CpG_8_9
CpG_10
CpG_14

-0.4704 (0.0363)
-0.4433 (0.0503)
-0.0888 (0.7096)

-0.164 (0.4895)
0.4302 (0.0583)
-0.2899 (0.2151)

-0.2639 (0.2609)
0.2273 (0.3352)
-0.3313 (0.1536)

0.0049 (0.9836)
-0.5657 (0.0093)
0.1863 (0.4316)

-0.0466 (0.8455)
-0.5087 (0.022)
0.1684 (0.4778)

CpG_15
CpG_16
CpG_19
Amplicon 2

-0.3411 (0.1411)
-0.1314 (0.581)
-0.0711 (0.7659)
n=22

-0.1279 (0.5909)
0.198 (0.4027)
-0.0946 (0.6916)
n=22

-0.1516 (0.5234)
-0.0523 (0.8266)
-0.1229 (0.6057)
n=22

0.029 (0.9033)
-0.3569 (0.1224)
-0.0555 (0.8161)
n=22

-0.0786 (0.7419)
-0.1715 (0.4697)
-0.0222 (0.9261)
n=22

CpG_20_21
CpG_23_24
CpG_25_26_27_28
CpG_29_30_31

-0.0608 (0.8047)
-0.1443 (0.5556)
-0.1916 (0.432)
-0.1827 (0.4541)

0.2648 (0.2733)
-0.2428 (0.3165)
0.0919 (0.7082)
-0.2939 (0.2219)

0.0658 (0.789)
-0.1642 (0.5017)
-0.1028 (0.6755)
-0.3792 (0.1094)

-0.3374 (0.1578)
0.139 (0.5704)
-0.1815 (0.4572)
0.0949 (0.6992)

-0.2214 (0.3624)
-0.0945 (0.7005)
-0.0649 (0.7917)
0.154 (0.529)

CpG_32
CpG_33
CpG_34

-0.2793 (0.2469)
-0.148 (0.5454)
0.0545 (0.8246)

0.4713 (0.0417)
-0.315 (0.189)
-0.2366 (0.3294)

0.2859 (0.2354)
-0.2939 (0.222)
-0.1798 (0.4615)

-0.426 (0.0689)
0.2355 (0.3318)
0.1721 (0.4811)

-0.4885 (0.0338)
0.1196 (0.6256)
0.1196 (0.6257)

CpG_36

-0.2056 (0.3984)

0.1763 (0.4702)

-0.1567 (0.5218)

-0.2199 (0.3656)

-0.0285 (0.9079)

CpG_37
CpG_38_39
CpG_41

0.1771 (0.4682)
-0.0687 (0.78)
-0.2056 (0.3984)

-0.3805 (0.1081)
0.0054 (0.9826)
0.1763 (0.4702)

-0.3913 (0.0976)
-0.1047 (0.6697)
-0.1567 (0.5218)

0.364 (0.1255)
-0.1255 (0.6088)
-0.2199 (0.3656)

0.4172 (0.0755)
0.0776 (0.752)
-0.0285 (0.9079)

Table 3.13 Relationship between CLU promoter methylation and CSF Biomarkers (A + Healthy Controls)
A+, amyloid beta positive; ⍴= Spearman’s partial correlation coefficient; p, nominal p-value; italicised, nominal significance; bold, significant
after FDR; *lambda range adjusted to 0–0.80; A42, amyloid beta 42; T-tau, total tau; P-tau, phosphorylated tau; A42/T-tau, ratio of A42 and
T-tau; A42/P-tau, ratio of A42 and p- Tau.
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3.2.3.3 Brain Imaging Biomarkers
As described in Section 2.3.3.1 and 2.3.3.2, brain Aβ burden (as measured by the PET
standardised uptake value ratio (SUVR)), cortical grey matter (GM) volume, cortical white
matter (WM) volume, ventricular volume and hippocampal volume comprise the brain
biomarkers analysed in this study. As per other biomarker analyses Spearman’s partial
correlations analyses were implemented using the covariates of clinical classification, A+/-,
age, sex and APOE ε4 genotype, when analysed across all participants. Clinical classification
and A+/- were removed as appropriate for analyses within HC and HC A+ groups. Across all
participants (Table 3.14), methylation at 13 CpG sites or units were significantly correlated
with brain A burden and all maintained significance after FDR correction. Specifically, CpG_1
(=0.1955, p=1e-04, q=0.0002), CpG_2_3 (=0.1178, p=0.0229, q=0.0216), CpG_8_9
(=0.225, p=<0.0001, q=<0.0001), CpG_14 (=0.1736, p=8e-04, q=0.0011), CpG_16
(=0.1991, p=1e-04, q=0.0002), CpG_19 (=0.299, p=<0.0001, q=<0.0001), CpG_20_21 (=0.302,

p=<0.0001,

q=<0.0001),

CpG_23_24

(=-0.185,

p=4e-04,

q=0.0006),

CpG_25_26_27_28 (=-0.3, p=<0.0001, q=<0.0001), CpG_34 (=-0.1182, p=0.0235,
q=0.0216), CpG_36 (=-0.1445, p=0.0055, q=0.006), CpG_38_39 (=-0.2126, p=<0.0001,
q=<0.0001), and CpG_41 (=-0.1445, p=0.0055, q=0.006). Methylation at CpG_36 (= 0.1223,
p=0.0275, q=0.1649) and CpG_41 (= 0.1223, p=0.0275, q=0.1649) also reached a nominally
significant level of correlation with cortical grey matter volume, in addition to CpG_15,
although only CpG_15 (=0.1918, p=5e-04, q=0.009) survived FDR correction.
Within HC’s (Table 3.15) methylation at several loci previously identified across the entire
cohort remained significant whilst additional loci were observed to be significantly correlated
with brain A burden – namely; CpG_1 (=0.1386, p=0.0294, q=0.0312), CpG_2_3 (=0.1482,
p=0.0198, q=0.0230), CpG_8_9 (=0.1979, p=0.0018, q=0.0038), CpG_14 (=0.1866,
p=0.0032, q=0.0051), CpG_16 (=0.3175, p=<0.0001, q=<0.0001), CpG_19 (=0.3489,
p=<0.0001, q=<0.0001), CpG_20_21 (=-0.2256, p=3e-04, q=0.0008), CpG_23_24 (=-0.1919,
p=0.0024, q=0.0044), CpG_25_26_27_28 (=-0.3318, p=<0.0001, q=<0.0001), CpG_36 (=0.1761, p=0.0054, q=0.0069), CpG_38_39 (=-0.2317, p=2e-04, q=0.0006), and CpG_41 (=0.1761, p=0.0054, q=0.0069). With respect to volumetric measures, CpG_36 (=0.2147,
p=0.0011, q=0.0032) and CpG_41(=0.2147, p=0.0011, q=0.0032) were again significantly
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correlated with cortical grey matter volume and remained so after FDR. Further, CpG_15
(=0.1486, p=0.0254, q=0.0486) was also significant after correction for FDR in association
with cortical grey matter volume. CpG_34 (=0.1385, p=0.0366, q=0.0525) was nominally
significant in association with cortical grey matter volume but did not remain so after
correction for FDR. With respect to hippocampal volume, methylation at CpG_10 (=0.1357,
p=0.0416, q=0.3952) and CpG_14 (=-0.1388, p=0.037, q=0.3952) reached a nominal level of
significant correlation but did not remain so after FDR correction.
Finally, analysis of the A+ HC group (Table 3.16), revealed methylation at a number of loci to
be significantly correlated with brain A burden; CpG_8_9 (=0.1507, p=0.1267, q=0.0429),
CpG_14 (=0.3037, p=0.0017, q=0.0021), CpG_16 (=0.2983, p=0.0021, q=0.0021), CpG_19
(=0.3544,

p=2e-04,

q=0.0006),

CpG_20_21

(=-0.2071,

p=0.0377,

q=0.0144),

CpG_25_26_27_28 (=-0.2562, p=0.0097, q=0.0059), CpG_34 (=-0.2748, p=0.0054,
q=0.0041), CpG_36 (=-0.2097, p=0.0353, q=0.0144), and CpG_41 (=-0.2097, p=0.0353,
q=0.0144) were all significant after FDR correction. Nominally significant correlations were
also observed between methylation and other imaging biomarkers; methylation at CpG_14
(=0.2143, p=0.037, q=0.2343), CpG_15 (=0.2292, p=0.0254, q=0.2343) and CpG_34
(=0.2499, p=0.0157, q=0.2343) were correlated with cortical grey matter and at CpG_33 (=0.2806, p=0.0064, 0.1216) with ventricular volume, although these failed to remain significant
after FDR correction was applied. However, methylation at CpG_37 remained significant after
FDR correction with respect to correlation and cortical grey matter volume (=0.322,
p=0.0016, q=0.0182).
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Analysis site/unit
Amplicon 1
CpG_1
CpG_2_3

A burden
⍴ (p)
n=378
0.1955 (1e-04)
0.1178 (0.0229)

Grey Matter Vol.
⍴ (p)
n=334
0.0234 (0.6722)
0.0312 (0.5726)

White Matter Vol.
⍴ (p)
n=334
0.0325 (0.5566)
0.0467 (0.3987)

Ventricular Vol.
⍴ (p)
n=334
-0.0607 (0.2721)
-0.0745 (0.1776)

Hippocampal Vol.
⍴ (p)*
n=334
0.0477 (0.3888)
0.0379 (0.4933)

CpG_8_9
CpG_10
CpG_14

0.225 (<0.0001)
0.0132 (0.7998)
0.1736 (8e-04)

0.0578 (0.2962)
0.0672 (0.2238)
0.0227 (0.6812)

-0.0094 (0.8649)
-0.0193 (0.7274)
-0.0193 (0.7273)

-0.0043 (0.9376)
0.0081 (0.8841)
0.0539 (0.33)

0.0701 (0.2049)
0.0827 (0.1343)
-0.0502 (0.3639)

CpG_15
CpG_16
CpG_19
Amplicon 2

-0.04 (0.4411)
0.1991 (1e-04)
0.299 (<0.0001)
n=372

0.1918 (5e-04)
0.04 (0.4702)
0.0056 (0.92)
n=330

0.0053 (0.9243)
-0.018 (0.7448)
-0.0301 (0.5866)
n=330

-0.041 (0.4586)
-0.0501 (0.3648)
-0.0433 (0.4336)
n=330

0.0991 (0.0725)
-0.0201 (0.7162)
0.0231 (0.6767)
n=330

CpG_20_21
CpG_23_24
CpG_25_26_27_28
CpG_29_30_31

-0.302 (<0.0001)
-0.185 (4e-04)
-0.3 (<0.0001)
-0.0211 (0.6867)

-0.0098 (0.8598)
-0.0284 (0.6105)
2e-04 (0.9974)
0.0662 (0.2339)

-0.0352 (0.5271)
-0.0266 (0.6332)
0.0117 (0.8338)
0.0478 (0.3908)

0.0435 (0.4345)
0.0239 (0.6674)
-0.0557 (0.3165)
0.0494 (0.3743)

-0.0504 (0.3655)
-0.0824 (0.1385)
0.0251 (0.6528)
-0.0291 (0.6008)

CpG_32
CpG_33
CpG_34

-0.0981 (0.0604)
0.0496 (0.3433)
-0.1182 (0.0235)

0.0648 (0.2442)
0.0339 (0.5429)
0.0767 (0.1677)

0.0896 (0.1068)
0.0205 (0.7125)
-0.0135 (0.8088)

-0.1029 (0.0638)
-0.065 (0.2425)
0.0322 (0.5632)

0.0867 (0.1188)
0.0367 (0.5092)
0.0172 (0.7575)

CpG_36

-0.1445 (0.0055)

0.1223 (0.0275)

-0.0545 (0.3271)

0.0079 (0.887)

0.0188 (0.7355)

CpG_37
CpG_38_39
CpG_41

8e-04 (0.9873)
-0.2126 (<0.0001)
-0.1445 (0.0055)

-0.0285 (0.6092)
-0.0493 (0.3753)
0.1223 (0.0275)

0.0174 (0.7552)
-0.1077 (0.0525)
-0.0545 (0.3271)

-4e-04 (0.9947)
0.0479 (0.3899)
0.0079 (0.887)

-0.0164 (0.769)
0.0307 (0.5819)
0.0188 (0.7355)

Table 3.14 Relationship between CLU promoter methylation and Brain Imaging Biomarkers (All Participants)
A, amyloid beta; ⍴= Spearman’s partial correlation coefficient; p, nominal p-value; italicised, nominal significance; bold, significant after FDR;
*lambda range adjusted to 0–0.94; Vol., Volume.
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Analysis site/unit
Amplicon 1
CpG_1
CpG_2_3

A burden
⍴ (p)
n=251
0.1386 (0.0294)
0.1482 (0.0198)

Grey Matter Vol.
⍴ (p)
n=230
0.0583 (0.3834)
0.0659 (0.3237)

White Matter Vol.
⍴ (p)
n=230
0.0617 (0.3557)
0.0189 (0.7774)

Ventricular Vol.
⍴ (p)
n=230
-0.0723 (0.2791)
-0.0841 (0.208)

Hippocampal Vol.
⍴ (p)
n=230
0.0714 (0.2848)
0.0284 (0.6708)

CpG_8_9
CpG_10
CpG_14

0.1979 (0.0018)
0.0011 (0.9868)
0.1866 (0.0032)

0.0181 (0.7872)
0.0989 (0.1384)
0.046 (0.4916)

-0.0579 (0.3865)
0.0044 (0.948)
-0.0624 (0.3508)

0.0435 (0.5151)
-0.0075 (0.9108)
0.0632 (0.3446)

0.0489 (0.4641)
0.1357 (0.0416)
-0.1388 (0.037)

CpG_15
CpG_16
CpG_19
Amplicon 2

0.0251 (0.6942)
0.3175 (<0.0001)
0.3489 (<0.0001)
n=252

0.1486 (0.0254)
0.0384 (0.5658)
0.0241 (0.7191)
n=232

-0.069 (0.3017)
-0.0488 (0.4652)
-0.0782 (0.2415)
n=232

0.0405 (0.5449)
-0.0556 (0.4054)
0.002 (0.9756)
n=232

0.015 (0.8224)
-0.053 (0.4278)
-0.0296 (0.6586)
n=232

CpG_20_21
CpG_23_24
CpG_25_26_27_28
CpG_29_30_31

-0.2256 (3e-04)
-0.1919 (0.0024)
-0.3318 (<0.0001)
-0.082 (0.1982)

-0.0233 (0.7266)
-0.0315 (0.6357)
-0.0179 (0.7885)
0.095 (0.1526)

-0.0359 (0.5901)
0.0149 (0.8233)
0.0021 (0.9754)
0.0226 (0.7347)

0.0593 (0.3731)
-0.0646 (0.3312)
-0.0392 (0.556)
-0.0151 (0.8203)

0.0012 (0.9855)
-0.0296 (0.6562)
0.0492 (0.4596)
-0.0034 (0.9596)

CpG_32
CpG_33
CpG_34

-0.1214 (0.0561)
-0.032 (0.616)
-0.1079 (0.0899)

0.0196 (0.7689)
0.0716 (0.2818)
0.1385 (0.0366)

0.0611 (0.3586)
-0.0063 (0.9247)
-0.0112 (0.8666)

-0.0932 (0.1607)
-0.0807 (0.2248)
-0.0237 (0.7219)

0.0877 (0.1871)
-0.003 (0.9636)
0.1008 (0.1293)

CpG_36

-0.1761 (0.0054)

0.2147 (0.0011)

-0.0286 (0.668)

-0.0445 (0.5034)

0.1124 (0.0905)

CpG_37
CpG_38_39
CpG_41

-0.0125 (0.8453)
-0.2317 (2e-04)
-0.1761 (0.0054)

-0.0336 (0.6137)
0.0049 (0.9416)
0.2147 (0.0011)

0.1294 (0.0511)
-0.1074 (0.1057)
-0.0286 (0.668)

-0.0032 (0.9618)
0.0591 (0.3745)
-0.0445 (0.5034)

0.0092 (0.8897)
0.1023 (0.1237)
0.1124 (0.0905)

Table 3.15 Relationship between CLU promoter methylation and Brain Imaging Biomarkers (Healthy Controls)
A, amyloid beta; ⍴= Spearman’s partial correlation coefficient; p, nominal p-value; italicised, nominal significance; bold, significant after FDR;
Vol., Volume.
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Analysis site/unit
Amplicon 1
CpG_1
CpG_2_3

A burden
⍴ (p)
n=107
0.0631 (0.5242)
0.0833 (0.4006)

Grey Matter Vol.
⍴ (p)
n=98
-0.056 (0.5897)
0.1254 (0.226)

White Matter Vol.
⍴ (p)
n=98
0.182 (0.0775)
-0.0373 (0.7194)

Ventricular Vol.
⍴ (p)
n=98
-0.0676 (0.5149)
-0.0478 (0.6455)

Hippocampal Vol.
⍴ (p)
n=98
0.158 (0.1262)
0.1156 (0.2647)

CpG_8_9
CpG_10
CpG_14

0.1507 (0.1267)
0.0645 (0.5157)
0.3037 (0.0017)

0.0833 (0.4224)
0.1079 (0.2978)
0.2143 (0.037)

-0.0316 (0.7614)
0.027 (0.7952)
-0.1437 (0.1647)

-0.1206 (0.2445)
-0.1261 (0.2233)
-0.0119 (0.9087)

0.1957 (0.0573)
0.1596 (0.1223)
-0.1478 (0.1529)

CpG_15
CpG_16
CpG_19
Amplicon 2

-0.0708 (0.4752)
0.2983 (0.0021)
0.3544 (2e-04)
n=104

0.2292 (0.0254)
-0.0727 (0.4839)
-0.0479 (0.6449)
n=96

-0.0623 (0.5485)
-0.0388 (0.7086)
-0.0353 (0.7342)
n=96

-0.0363 (0.7271)
-0.0894 (0.3888)
-0.0186 (0.8583)
n=96

0.0069 (0.9468)
-0.0969 (0.3502)
0.0763 (0.4625)
n=96

CpG_20_21
CpG_23_24
CpG_25_26_27_28
CpG_29_30_31

-0.2071 (0.0377)
-0.0889 (0.3765)
-0.2562 (0.0097)
-0.0315 (0.7546)

-0.0549 (0.601)
0.0589 (0.5748)
0.0301 (0.7743)
-0.0239 (0.8203)

-0.1987 (0.0562)
-0.0102 (0.9227)
0.0996 (0.3424)
-0.0076 (0.9424)

0.1081 (0.3025)
-0.0788 (0.4526)
-0.0783 (0.4554)
0.0561 (0.5934)

-0.1686 (0.1062)
-0.0618 (0.5559)
0.0242 (0.8179)
-0.1586 (0.129)

CpG_32
CpG_33
CpG_34

-0.0262 (0.7946)
0.0138 (0.8911)
-0.2748 (0.0054)

0.014 (0.8943)
0.1056 (0.3135)
0.2499 (0.0157)

0.043 (0.6825)
0.0691 (0.5103)
-0.0308 (0.7695)

0.0046 (0.9649)
-0.2806 (0.0064)
0.0058 (0.9559)

-0.025 (0.8123)
0.0037 (0.9716)
0.1813 (0.082)

CpG_36

-0.2097 (0.0353)

0.0908 (0.3868)

-0.1087 (0.2995)

0.1771 (0.0894)

0.0378 (0.7191)

CpG_37
CpG_38_39
CpG_41

0.0273 (0.7864)
-0.1181 (0.2395)
-0.2097 (0.0353)

0.0128 (0.9028)
-0.002 (0.9845)
0.0908 (0.3868)

0.322 (0.0016)
-0.0902 (0.3897)
-0.1087 (0.2995)

-0.0423 (0.6875)
0.0919 (0.3807)
0.1771 (0.0894)

0.0432 (0.6807)
0.1374 (0.189)
0.0378 (0.7191)

Table 3.16 Relationship between CLU promoter methylation and Brain Imaging Biomarkers (A + Healthy Controls)
A(+), amyloid beta (positive); ⍴= Spearman’s partial correlation coefficient; p, nominal p-value; italicised, nominal significance; bold, significant
after FDR; Vol., Volume.
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3.3 Study Two: CLU Promoter methylation and cognitive performance
As described in Section 2.5.3 Linear mixed model’s (LMM’s), as implemented by lme’ function
within R’s ‘nlme’ package, were used to analyse associations between CLU promoter region
methylation levels and cognitive performance, both at baseline and over time. The cognitive
domains of global cognition, verbal episodic memory and executive function as well as the
preclinical Alzheimer’s disease cognitive composite (PACC) were investigated.
The relationship between CLU promoter methylation and cognitive performance at baseline
was assessed within the LMM by interpreting the main effect of methylation on cognitive
performance at baseline – termed hereafter as alpha (). Likewise, the relationship between
methylation and change in cognition over 7.5 years was determined through the association
of the methylation x time interaction term with cognition – termed hereafter as beta ().
LMM analyses were implemented firstly across all participants and then subsequently
stratified by clinical classification and brain A status to investigate the relationship between
methylation in the CLU promoter and cognitive performance in healthy controls and then in
those healthy controls that have a high brain A burden.
3.3.1 CLU promoter methylation and cognitive performance in all participants
3.3.1.1 Cognitive Performance at Baseline
The respective ’s for each CpG site/unit in relation to performance at baseline for each of
the cognitive composite scores assessed is presented in Appendix 7, Table A7.1. Only two
CpG sites/units presented with nominally significant associations with cognitive performance
at baseline (Figure 3.1). Increasing percentage methylation at CpG_8_9 was associated with
poorer executive function (Figure 3.1A; CpG_8_9, =-1.246, p=0.049, q=0.625) whilst
increasing percentage methylation at CpG_32 was associated with an increase in baseline
executive function (Figure 3.1B; CpG_32, =3.783, p=0.025, q=0.625). However, neither
survived FDR correction.
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Figure 3.1. Relationship between CLU promoter methylation and Cognitive Performance at
Baseline (All Participants)
Association between (A) CpG_8_9 (n=626) and (B) CpG_32 (n=646) methylation levels (%) and
baseline (⍺) executive function composite (Standard Deviation; SD) in all participants. Shaded
regions represent methylation level dependent standard error of ⍺. q = false discovery rate
corrected p value.

3.3.1.2 Change in Cognitive Performance Over Time
The respective ’s for each CpG site/unit in relation to performance over time for each of the
cognitive composite scores assessed is presented in Appendix 7, Table A7.1. Four CpG
sites/units presented with nominally significant rate of change in cognitive performance over
7.5 years (Figure 3.2). An increase in percentage methylation at CpG_19 was associated with
a faster rate of decline in executive function (Figure 3.2A; =-0.604, p=0.006, q=0.625).
Likewise, an increase in percentage methylation at CpG_33 was associated with a faster rate
of decline in performance over time on the preclinical Alzheimer’s cognitive composite (PACC)
(Figure 3.2B; =-1.664, p=0.013, q=0.625). Whilst a decrease in methylation at CpG_36 (Figure
3.2C; =2.071, p=0.044, q=0.625) and CpG_41 (Figure 3.2D; =2.071, p=0.044, q=0.625) was
associated with an improvement in cognitive performance over time on the PACC. Again,
these associations failed remain significant after FDR correction.
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Figure 3.2. Relationship between CLU promoter methylation and change in Cognitive
Performance (All Participants)
Associations were observed between (A) CpG_19 (n=626) methylation levels (%) and rate of
change () in executive function over time (Standard Deviation, SD) in all participants.
Associations were also observed between (B) CpG_33, (C) CpG_36 and (D) CpG_41
methylation and rate of change in the preclinical Alzheimer’s cognitive composite (PACC; also
corrected for age; 4xSD) in all participants (n=646) Shaded regions represent methylation
level dependent standard error of . q = false discovery rate corrected p value.

57

3.3.2 CLU promoter methylation and cognitive performance in Healthy Controls
3.3.2.1 Cognitive Performance at Baseline
After stratification by clinical classification, the LMM analyses were repeated in the HC group.
The respective ’s for each CpG site/unit with respect to each of the cognitive composite
scores assessed is presented in Appendix 7, Table A7.2. Only two CpG sites/units presented
with nominally significant associations with cognitive performance at baseline (Figure 3.3).
Increasing percentage methylation at both CpG_36 (Figure 3.3A; =-8.908, p=0.049, q=0.563)
and CpG_41 (Figure 3.3B; =-8.908, p=0.049, q=0.563) was associated with poorer baseline
performance on the PACC. However, they did not remain significant after correction for the
FDR.

Figure 3.3. Relationship between CLU promoter methylation and Cognitive Performance at
Baseline (Healthy Controls)
Associations were observed between (A) CpG_36 and (B) CpG_41 methylation and
performance at baseline (⍺) on the preclinical Alzheimer’s cognitive composite (PACC; also
corrected for age; 4xSD) in Healthy Controls (n=474). Shaded regions represent methylation
level dependent standard error of ⍺. q = false discovery rate corrected p value.
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3.3.2.2 Change in Cognitive Performance Over Time
The respective ’s for each CpG site/unit in relation to performance over time for each of the
cognitive composite scores assessed in healthy controls is presented in Appendix 7, Table
A7.2. Four CpG sites/units presented with nominally significant rates of change in cognitive
performance over 7.5 years (Figure 3.4). An increase in percentage methylation at CpG_19
was associated with a faster rate of decline in executive function (Figure 3.4A; =-0.563,
p=0.006, q=0.563) and the PACC (Figure 3.4B; =-1.231, p=0.021, q=0.563), though this did
not remain significant after correction for the FDR. Additionally, an increase in percentage
methylation at CpG_23_24 (Figure 3.4C; =-0.576, p=0.028, q=0.563) was also only nominally
significantly associated with a faster rate of cognitive performance in executive function over
time. Further, an increase in percentage methylation at CpG_33 was observed to be
associated with a nominally significant reduced rate of performance on the PACC (Figure 3.4D;
=-1.183, p=0.035, q=0.563), but this also did not survive correction for the FDR.
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Figure 3.4. Relationship between CLU promoter methylation and changes in Cognitive
Performance (Healthy Controls)
A faster rate of decline in cognitive performance over time () was observed with increased
percentage methylation at (A) CpG_19 (n=450), with respect to executive function (standard
deviation, SD) and (B) change in the preclinical Alzheimer’s cognitive composite (PACC; also
corrected for age; 4xSD) in healthy controls (n=450). Associations were also observed
between (C) CpG_23_24 and (D) CpG_41 methylation and a faster rate of decline in executive
function and performance on the PACC in healthy controls (n=474), respectively. Shaded
regions represent methylation level dependent standard error of . q = false discovery rate
corrected p value.
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3.3.3 CLU promoter methylation and cognitive performance in A+ Healthy Controls
3.3.3.1 Cognitive Performance at Baseline
Healthy controls were then stratified by brain A burden and LMM analyses repeated in those
classified as having high brain A burden (A+ HC). The respective ’s for each CpG site/unit
with respect to each of the cognitive composite scores assessed is presented in Appendix 7,
Table A7.3. Only two CpG sites/units presented with nominally significant associations with
cognitive performance at baseline (Figure 3.5). A lower level of methylation at CpG_2_3 was
observed to be associated with poorer baseline performance across three cognitive
composites, Global cognition (Figure 3.5A; =3.016, p=0.02, q=0.309), verbal episodic
memory (Figure 3.5B; =3.016, p=0.02, q=0.309) and PACC (Figure 3.5C; =3.016, p=0.02,
q=0.309) though these were only nominally significant and did not survive FDR correction.
Likewise, despite not surviving correction for the FDR a lower level of methylation at
CpG_25_26_27_28 was nominally significantly associated with poorer executive function at
baseline (Figure 3.5D; =11.884, p=0.013, q=0.278).
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Figure 3.5. Relationship between CLU promoter methylation and Cognitive Performance at
Baseline (A + Healthy Controls)
Associations were observed between CpG_2_3 methylation levels (%) and baseline (⍺) (A)
global cognition (standard deviation, SD), (B) verbal episodic memory (SD) and (C)
performance at baseline on the preclinical Alzheimer’s cognitive composite (PACC; also
corrected for age; 4xSD) in healthy controls with high brain A burden (A+; n=204). An
association between (D) CpG_25_26_27_28 (n=214) methylation and baseline executive
function was also observed. Shaded regions represent methylation level dependent standard
error in ⍺. q = false discovery rate corrected p value.
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3.3.3.2 Change in Cognitive Performance Over Time
The respective ’s for each CpG site/unit in relation to performance over time for each of the
cognitive composite scores assessed in the A+ HC group are presented in Appendix 7, Table
A7.3. Two CpG sites/units presented with nominally significant rate of change in cognitive
performance over 7.5 years (Figure 3.6). An increase in percentage methylation at CpG_10
presented with nominally significant association with an improvement in performance over
time in 3 cognitive composites; global cognition (Figure 3.6A; =0.705, p=0.008, q=0.278),
verbal episodic memory (Figure 3.6B; =0.705, p=0.006, q=0.278) and PACC (Figure 3.6C;
=1.536, p=0.045, q=0.465). An increase in percentage methylation at CpG_23_24 (Figure
3.6D; =-1.029, p=0.015, q=0.278) was also significantly associated with a faster rate of
decline in executive function. However, all nominally significant associations did not survive
correction for the FDR.
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Figure 3.6. Relationship between CLU promoter methylation and changes in Cognitive
Performance (A + Healthy Controls)
Associations were observed between CpG_10 methylation levels (%) and rate of change over
time () in (A) global cognition (standard deviation, SD), (B) verbal episodic memory (SD) and
(C) performance on the preclinical Alzheimer’s cognitive composite (PACC; also corrected for
age; 4xSD) in healthy controls with high brain A burden (A+; n=204). An association
between (D) CpG_23_24 (n=214) methylation and rate of change in executive function over
time was also observed. Shaded regions represent methylation level dependent standard
error in . q = false discovery rate corrected p value.
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Chapter 4: Discussion
4.1 Introduction
Alzheimer’s disease (AD) is characterised by a number of clinical and pathological
characteristics. The pathology of AD is characterised by an accumulation of amyloid beta (A)
plaques and intracellular hyper phosphorylated tau tangles (Lunnon et al., 2014). Individuals
with AD suffer from a variety of psychological symptoms, most notably cognitive decline
(Lopez et al., 2010). Both the incidence and prevalence of dementia increases with advancing
age and, as of, 2017 AD accounted for 50-70% of the estimated 50 million dementia cases
worldwide (Alzheimer’s Disease International, 2017; Australian Institute of Health and
Welfare, 2017). Considering the public health issue AD currently presents and will increasingly
impose going forward, further research into early detection and treatment is imperative.
One such area of development into AD diagnosis/prognosis is fluid based biomarkers.
Peripheral methylation has the potential to be a fluid based biomarker, used for detection in
the preclinical stages of AD (Fransquet et al., 2018). Previously conducted epigenome wide
studies (EWAS) and more targeted studies have reported AD risk genes having differing
methylation levels (De Jager et al., 2014; Lunnon et al., 2014; L. Yu et al., 2015).The identified
AD risk genes can be grouped into 3 pathways; lipid/cholesterol metabolism, the immune
response and endocytosis (Rosenthal & Kamboh, 2014). Clusterin (CLU) is the third most
associated AD risk gene and is primarily involved in the lipid/cholesterol metabolic pathway.
CLU plays a complex role in the pathogenesis of AD; with evidence suggesting it plays both a
protective and an aggregating role in the disease process (X. Li et al., 2013; J.-T. Yu & Tan,
2012). This thesis focused on methylation within the promoter region of CLU in two studies.
The first study focused on the association of methylation with clinical classification (i.e. AD
risk), fluid and imaging biomarkers and whether previously identified SNPs in CLU had any
impact on methylation. The second study focused on the relationship between CLU
methylation and both cross-sectional and longitudinal cognition.
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4.2 Study One: CLU Promoter methylation, clinical classification and AD biomarkers
4.2.1 Differential methylation in the CLU promoter is associated with clinical classification
Comparison of methylation levels across clinical classifications revealed a reduced level of
percentage methylation at significant loci, therefore supporting hypothesis 1. Methylation
levels decreased at CpG_14, CpG_15 and CpG_25_26_27_28 between healthy controls (HC)
and individuals with mild cognitive impairment (MCI). CpG_14 and CpG_15 also showed a
significant methylation decline between HC and those with Alzheimer’s disease (AD).
Additionally, CpG_25_26_27_28 had a decrease in methylation levels between HC and AD. A
decline in methylation levels is a state termed hypomethylation. Hypomethylation allows the
structure of the DNA to be prime for binding of transcription factors and a subsequent
increase in gene expression. An increase in gene expression would suggest an increase in the
protein product of the gene, which in this case would imply an increase in the production of
the clusterin protein from HC to the MCI, HC to AD and at CpG_25_26_27_28 from MCI to AD.
This has previously been observed in several studies (Hsu et al., 2017; Schrijvers et al., 2011;
Thambisetty et al., 2010), including within the AIBL cohort (Gupta et al., 2016). There does
not appear to be any research, known to the author, that studies a link between CLU
methylation and clinical classification. The apparent focus has been on methylation, globally
and gene specific, and the pathological features of AD. The majority of studies have consisted
of cohorts composed of healthy controls and those with AD (Fransquet et al., 2018).
4.2.2 The rs11136000 SNP is associated with altered promoter methylation patterns
The single nucleotide polymorphism (SNP) rs11136000, located at position 27607002 on
chromosome 8, revealed some association with methylation levels, supporting hypothesis 2.
The C allele of this SNP is associated with an increased risk for AD whilst the T allele confers a
decreased risk of developing late onset AD (Braskie et al., 2011). Percentage methylation at
the CpG unit CpG_23_24 was increased in individuals’ homozygote for the T allele. This
observed increase in relation to the rs11136000-T allele and conversely decreased
methylation in relation to the AD risk allele, rs11136000-C, is consistent with the observed
decrease in methylation observed in MCI/AD participants compared to HC. However, the
opposite was observed for CpG sites CpG_14 and CpG_16. Methylation at these CpG sites was
increased in individuals homozygote for the AD risk associated allele, although this was of
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borderline significance after FDR correction. The two SNPs, rs11136000 and rs93331888, are
in linkage disequilibrium with one another (Mengel-From et al., 2013). However, they have a
high D’ and low r2, the low correlation of the respective alleles may therefore account for an
association being found in rs11136000 and no association being identified between
methylation and rs9331888 (located on chr8: 27611345) (Zerbino et al., 2018).
An association between methylation within CLU and rs11136000 has been previously
identified by Chibnik et al. (2015), however Chibnik and colleagues did not specify which
particular genotype/s held greater association compared to others. Both Chibnik et al. (2015)
and the current study have studied methylation in different regions than where rs11136000
presides but both have found methylation to be associated with the SNP regardless. One
possibility is that rs11136000 is in linkage with a SNP in the vicinity of these CpG sites in the
CLU promoter. The functional implications of both analysed SNPs are yet to be determined
(Thambisetty et al., 2010) however the T allele within rs11136000 has been shown to
decrease risk which aligns with the increase in methylation at CpG_23_24 in genotypes with
a C allele. This result is suggestive of a potential relationship between the risk allele and
decrease in methylation which has been reported in this thesis to be associated with the AD
clinical classification.
4.2.3 Lack of association between CLU promoter methylation and plasma clusterin levels
Gupta et al. (2016) previously reported elevated levels of plasma clusterin in MCI and AD
individuals in the AIBL cohort. The findings in this thesis of a lower average percentage
methylation in the CLU promoter in MCI and AD, when compared with HC, aligns with an
increased level of expression and thus the elevated levels of plasma clusterin previously
observed in the AIBL cohort (Gupta et al., 2016).
However, no sites or units reached statistical significance for a correlation between all
participants and healthy controls with high brain A burden (A+ HC) when observing the
relationship between plasma clusterin levels and methylation levels. There was one
significant CpG site, though only the HC group, CpG_16, at which a positive correlation
between methylation levels and plasma clusterin levels was observed. As only one site
presented with a significant association with plasma clusterin levels, it’s difficult to draw a
firm conclusion from the result. However, the result is somewhat counter intuitive, as a higher
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level of methylation would be expected to result in a decrease in gene expression and a
subsequent decrease in protein product. This finding may be representative of the complex
mechanisms that control gene expression pre and post transcription, such as mRNA
modification, that mean methylation alone is not the only influence on plasma clusterin
levels. In this instance these findings do not support this aspect of hypothesis 3.
4.2.4 Methylation in CLU promoter is associated with cerebrospinal fluid (CSF) biomarkers in
healthy controls
The CSF biomarkers analysed in this study were amyloid beta 42 (A42), total tau (T-tau),
phosphorylated tau (P-tau), the ratio between A42 and T-tau and the ratio between A42
and P-tau. When the relationship between CLU methylation and CSF biomarkers was
examined across the entire cohort, no significant associations were observed after FDR
correction. In the HC group, one site, CpG_37, presented with a negative correlation with CSF
P-tau. Suggesting that a decrease in methylation levels is associated with an elevation in Ptau levels in the CSF. This result aligns with the presented findings within clinical
classifications; that methylation levels decrease from HC through to AD and as previously
reported in the literature, that P-tau is increased in individuals with AD (Pawlowski, Meuth,
& Duning, 2017).
When observing only healthy controls with high brain A burden (A+ HC), which could be
classified as the preclinical cohort, a relationship was seen between a number of loci and
levels of CSF A42; as such supporting hypothesis 3 with regard to CSF A42. Three CpG
sites/units, namely CpG_1, CpG_8_9 and CpG_10 from amplicon one, were inversely
correlated with CSF A42. So as methylation within the CLU promoter increased, CSF A42
decreases. This finding is somewhat counter intuitive as if a lower level of methylation is
suggestive of risk for MCI/AD then a positive correlation would have been expected as CSF
A42 typically decreases in AD patients (Pawlowski et al., 2017). However, this
counterintuitive association may be explained by the fact it was observed in HC and may
reflect the much earlier stage of the disease process.
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4.2.5 Differential methylation in the CLU promoter is associated with elevated brain A burden
Several brain imaging biomarkers were investigated in this thesis, including brain A burden,
cortical grey matter volume, cortical white matter volume, ventricular volume and
hippocampal volume. The findings from this study support this aspect of hypothesis 3 as a
considerable number of sites and units were correlated with amyloid burden. An interesting
pattern emerged, in that the significant sites of amplicon one (CpG_1, CpG_2_3, CpG_8_9,
CpG_14, CpG_16 and CpG_19) were all positively correlated with methylation levels.
Conversely, the

sites

of significance

in amplicon 2 (CpG_20_21, CpG_23_24,

CpG_25_26_27_28, CpG_34, CpG_36, CpG_38_39 and CpG_41) exhibited an inverse
correlation between methylation levels and amyloid burden. In the HC group the pattern
continued; the sites and units of significance in amplicon one (CpG_1, CpG_2_3, CpG_8_9,
CpG_14, CpG_16 and CpG_19) are all positively correlated with amyloid burden and the sites
and units of significance in amplicon two (CpG_20_21, CpG_23_24, CpG_25_26_27_28,
CpG_36, CpG_38_39 and CpG_41) are all inversely correlated with amyloid burden. Whilst, in
the A+ HC group the pattern across amplicons was maintained, the number of significant
loci was decreased.
These findings suggest a difference in the effects of methylation at different parts of the
promoter region. Chibnik et al. (2015) found a similar phenomenon when studying
methylation of brain tissue and its association with A plaques; 4 of the 5 significant loci were
inversely correlated with A plaques and the other locus was positively correlated. Whilst
Chibnik et al. (2015) studied different sites of methylation and a different tissue type, it does
indicate that methylation patterns influence on phenotype are more complex than all sites or
units having the same effect. In mice, clusterin has been shown to be a chaperone protein for
A (Thambisetty et al., 2010). Whilst this thesis cannot draw conclusions on whether
peripheral methylation in CLU reflects that seen in the brain, it could be hypothesised that an
increase in plasma clusterin, which could potentially be caused by low levels of methylation,
would result in an increased brain A burden or be a response to it. A potential mechanism
for the latter is the peripheral sink hypothesis, which suggests that brain and peripheral A
are in equilibrium and that the peripheral clearance of plasma A will result in a reduction in
brain A (DeMattos et al., 2001; Y. Zhang & Lee, 2011). It could be speculated that
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hypomethylation of the CLU promoter is a response to elevating A as this would thus
increase expression of this A chaperone and potentially promote peripheral clearance.
With respect to brain volumetrics, only methylation levels at CpG_15 was associated with any
measure, specifically a positive correlation with cortical grey matter volume when studied
across the entire cohort. CpG_15 was again significantly positively correlated with cortical
grey matter volume along with CpG_36 and CpG_41 in the HC group. No associations with
cortical grey matter were observed in the A+ HC, however there was a positive correlation
between methylation at CpG_37 and cortical white matter volume. Plasma clusterin, which
would be expected to be increased with hypomethylation (observed in this study to be
associated with brain atrophy) has previously been associated with brain volume cross
sectionally, indicating that it could potentially influence or be indicative of atrophy related to
AD (Thambisetty et al., 2010).

4.3 Study Two: CLU Promoter methylation and cognitive performance
The results of study one informed the focus of study two. Due to the significant decrease in
methylation being most apparent between HC and MCI group the focus was placed on the
cognitive domain composites that appear to be affected earliest in the disease process;
episodic memory being the initial domain to be affected (Albert et al., 2011; Silverberg et al.,
2011) and then executive function 4-8 years later (Derby et al., 2013; Elias et al., 2000; Grober
et al., 2008). The composites were developed as outlined in S. C. Burnham et al. (2015). The
preclinical Alzheimer’s cognitive composite (PACC) was also included as it was developed to
measure the first signs of cognitive decline (Donohue et al., 2014).
4.3.1 Reduced methylation is suggestive of poorer cognition in individuals at greatest risk of AD
After FDR correction no CpG sites/units were significantly associated with cognition at
baseline, as such hypothesis 4 was not supported. Observing the uncorrected results, in study
one, in all participants at baseline revealed a pattern. Executive function was nominally
significant at CpG_8_9, where at baseline more methylation was associated with poorer
executive function in all participants. CpG_32 was also nominally significant within executive
function but instead greater levels of methylation are associated with better executive
function. These loci come from different amplicons, and therefore different areas of the
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promoter region, which may suggest that transcription is altered depending on the location
of the methylation in the promoter region, however to determine whether this is the case
would require the analysis of gene expression from the same time-point from which
methylation levels were determined.
In the healthy controls at baseline a poor PACC score was seen in individuals with higher levels
of methylation at CpG_36 and CpG_41. Conversely, in only the A+ HC, representing those at
greatest disease risk, high levels of methylation were associated with better cognitive
performance at CpG_2_3 in global cognition, verbal episodic memory and the PACC and then
at CpG_25-26_27_28 regarding executive function. Thambisetty et al. (2010) observed a
negative correlation between plasma clusterin and mini mental state examination (MMSE)
score. Whilst this study didn’t look directly at MMSE, the MMSE does compose part of the
global cognition composite and PACC. The nominally significant inverse relationships seen in
this study and that of Thambisetty and colleagues suggests that excess clusterin and its
implications with AD pathology may influence cognitive performance, however further study
is needed before firm conclusions can be drawn.
4.3.2 CLU promoter methylation lacks prognostic utility for future cognitive performance
No associations between CpG sites/units and rates of change in cognitive performance over
time survived correction for the FDR, which does not support hypothesis 5. However, there
were some sites where nominally significant associations were observed. Within the whole
cohort, at CpG_19, in amplicon 1, an increase in percentage methylation was nominally
associated with a faster rate of decline in executive function. Likewise, at CpG_33 a similar
pattern of association was observed with respect to performance over time in the PACC. Two
other sites within amplicon 2, CpG_36 and CpG_41, both saw an increase in percentage
methylation associated with an improvement in performance over time in the PACC. The
former sites are further along amplicon 2 than CpG_33 which may contribute to the differing
outcome. In healthy controls a higher percent methylation was associated with a faster rate
of performance in executive function over time at CpG_19 and CpG_23_24. The same was
seen for performance over time in the PACC with respect to percentage methylation at
CpG_19 and also at CpG_33. In the A+ HC’s a decrease in percentage methylation at CpG_10
was associated with improvement in performance in global cognition, verbal episodic
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memory and PACC. The one nominally significant site in amplicon 2, CpG_23_24, observed
increased percentage methylation to be associated with a faster rate of performance in
executive function. A deposition and memory impairment and rate of cognitive decline have
previously been found to be associated with the non-demented population, a stage which is
representative of the earliest stages of preclinical AD (Villemagne et al., 2008). Furthermore
it has been shown that A deposition precedes the development of cognitive impairment in
those non-demented individuals (Villemagne et al., 2011). The results seen in the A+ HC
cohort - the preclinical cohort - of this study show that in the majority of nominally significant
results, a lower level of methylation is associated with a decreased rate of improvement in
the cognitive measures.

4.4 Overall Discussion
As methylation is tissue specific, it can be difficult to compare the pathological process within
the brain and what is being observed in the periphery, however that does not exclude
peripheral methylation as potential biomarker. CLU, being a recognised risk gene for AD
makes it a prime candidate for methylation analysis. Chibnik et al. (2015) established an
association between rs11136000 and methylation but did not establish whether there was an
increase or decrease in methylation or whether certain genotypes held different associations.
This study ascertained in our cohort, consisting of all participants, that at two significant CpG
sites a decrease in methylation was associated with individuals that had the T allele which
confers a protective effect (Braskie et al., 2011). One unit, however, has displayed an increase
in methylation, which would suggest a potential relationship between the risk allele and a
lower amount of methylation. The lower amount of methylation would, theoretically,
increase the amount of gene transcription and subsequent plasma clusterin levels.
Understanding the functional implications of rs11136000, or variants in linkage with it, would
further assist in explaining the results and an interactive model or network analysis would
need to be conducted to determine if there is an additive or cumulative effect in action
between specific genotypes and methylation.
As well as at the genetic level, levels of the protein in plasma have been studied as a candidate
clinical blood biomarker. In AD, plasma clusterin levels have been reported to be elevated
compared to healthy controls, this observation has also been made in the same cohort, the
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AIBL cohort, as studied in this thesis (Gupta et al., 2016). The elevated plasma clusterin levels
would be indicative of hypomethylation of the CLU promoter as the disease state progresses.
This has been demonstrated at 3 loci within the promoter region, furthermore there is a
significant difference in methylation decline between HC and individuals with MCI. This also
suggests an early stage change in methylation levels, potentially at the preclinical stage of
which biomarker detection would be optimum. To the authors knowledge there are no other
studies that have attempted to discern an association between peripheral CLU methylation
and clinical classification. Only one locus was observed to be significantly associated with
plasma clusterin, which was suggestive of a positive correlation between percentage
methylation and plasma clusterin levels. As only one CpG site in the promoter was associated
with plasma clusterin levels, drawing firm conclusions from this counterintuitive finding is
difficult. However, the result lends itself to the fact that more than just methylation influences
expression; complex interaction between DNA methylation, histone modification and RNA
interference all impact gene expression (Egger et al., 2004). In other diseases, such as cancer,
it has been reported that clusterin expression is predominantly regulated by histone
modifications (Moonmoon et al., 2015).
Across several analyses in this thesis, a differential pattern of association was observed. This
was particularly evident when the relationship between percentage methylation levels and
brain imaging biomarkers was investigated. The CpG sites of significance within amplicon 1
showed a positive correlation in relation to brain A burden and those within amplicon 2 had
an inverse correlation. Considering brain A burden increases with disease severity (i.e.
(HC<MCI<AD) and that a number of loci in this thesis were observed to have a decrease in
percentage methylation with increasing disease severity (i.e. HC>MCI/AD), the hypothesis
would be that there would be an inverse correlation between methylation and brain A
burden. Of significance is an important regulatory factor within the region covered by
amplicon 2; the TATA box. An increased level of methylation on or around the TATA box would
prevent necessary regulatory factors binding and would consequently result in an inhibition
of gene expression, as the TATA box is the site where transcription initiation is commenced,
marked by the formation of the preinitiation complex (Xu, Gonzalez-Hurtado, & Martinez,
2016). A visualization of where the TATA box resides in relation to the analysed region is
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shown in Figure 4.1; visible is how close many analysed CpG sites are, with CpG_23_24
immediately downstream.

Figure 4.1 Location of TATA Box in the CLU Promoter Region
Bold, amplicon 1 primers; underlined, amplicon 2 primers; Light blue box; TATA box,
highlighted in grey; CpG sites, red box; regions with CpG sites with hypermethylation
association with A, green box; regions with sites CpG sites with hypomethylation association
with A.

The presence of the TATA box within amplicon 2 may confer a greater effect of methylation
in that area on subsequent gene expression and potentially explain the patterns of differential
methylation associations observed in this thesis. Methylation would hypothetically have a
greater differential effect in the TATA box region because of the interruption of important
regulatory factors. Hypomethylation in this region may result in enhanced transcription,
which in turn would likely result in increased clusterin protein levels in the plasma – as
previously reported in MCI/AD individuals (Gupta et al., 2016; Hsu et al., 2017; Schrijvers et
al., 2011; Thambisetty et al., 2010). Moreover, a decrease in percentage methylation occurred
in individuals with reduced cortical grey matter volume, this correlation also occurred at the
most loci within the HC cohort. This finding suggests that reduced methylation in HC is
associated with a reduced brain volume, which would be suggestive of increased risk for AD.
There were only few significant observations when looking at methylation associations with
cerebrospinal fluid (CSF) biomarkers. Typically, in AD CSF A is decreased and both forms of
tau (T-tau and P-tau) are increased (Pawlowski et al., 2017). In this instance, in the few
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significant loci within the healthy controls, a higher level of P-tau was correlated with a lower
level of methylation, which again fits with the trend seen regarding methylation levels and
disease progression. However, when analysing only the A+ healthy controls the significant
loci are inversely correlated with methylation and CSF A42. A caveat of the findings
presented in relation to CSF biomarkers is that these analyses were undertaken in a
significantly reduced sub-sample of the entire study and as such need to be undertaken in
larger sample sizes before a firm conclusion can be drawn.
Whilst analyses of the relationship between CLU promoter methylation and cognition
revealed no significantly associated CpG sites (after FDR correction), there were several that
reached a nominal level of significance. The nominally significant results when observing all
participants showed both inverse and positive correlations at baseline and in rate of change
over time between methylation and cognition. Executive function and the preclinical
Alzheimer’s cognitive composite (PACC) were the two composites that had nominal levels of
significant association, in the cohort containing all participants. When the cohort is stratified
to only HC, executive function and the PACC were again observed as being the prominent
composites. The relationships observed in this case were inverse in nature - having lower
amounts of methylation are positive for both baseline executive function and the PACC at
certain loci. This an interesting result considering what was previously established in study
one regarding hypomethylation across the clinical classifications and in relation to brain A
burden. Brain A burden is also considered a pathological event that precedes cognitive
impairment (Villemagne et al., 2011) therefore it would have been expected to be observed
in this study, to observe a faster rate of cognitive decline in A+ HC’s, however this was only
observed at one particular CpG unit. Reasoning for this may be the demographics of the
cohort, AIBL is composed of volunteers which results in the enrolment of highly educated
individuals who do adapt to the cognitive testing over time, resulting in improved scores.
Overall, the results are suggestive that whilst assessing percentage methylation at a given
timepoint is suggestive of utility for current cognitive performance, it lacks prognostic utility
for future cognitive performance.
Further insight into these results would be garnered by testing methylation at different
timepoints, preferably at the same time as cognition data, and with increasing sample size of
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more diverse educational background. Since methylation is dynamic, studying how it changes
over time in relation to changing disease phenotypes would provide greater insight and offer
a potential dynamic genomic biomarker to monitor disease progression. Whilst there is a lack
of literature on CLU methylation and cognitive associations, Chouliaras et al. (2018) identified
multiple differently methylated loci within multiple gene regions, in the periphery, that are
associated with decline in cognitive performance giving strength to the concept that
methylation could be used as a blood based biomarkers to detect cognitive decline and
drawing from the current study CLU may be a good candidate.

4.5 Strengths and limitations
The advantages of this study are the use of the highly characterised AIBL cohort, of which a
plethora of data has been collected, analysed and further published; The AIBL cohort includes
a large number of imaged participants with different clinical classifications allowing the
current study to use brain volumetric measures developed from MRI and PET with A labelled
radioactive ligands to calculate A burden. AIBL also provides cognitive data from a large well
characterised cohort followed longitudinally over 7.5 years, which is a strength. The number
of samples of which methylation data was collected on was a considerable strength. To our
knowledge this study has the largest number of participants that methylation data has been
collected for and is one of the few studies that includes a cohort with mild cognitive
impairment. According to a systematic review by Fransquet et al. (2018) the mean number of
participants in AD methylation association studies is 91, where as we have collected data on
a total of 626 participants for amplicon 1 and 646 participants for amplicon 2. The use of the
AGENA MassArray platform is also a strength of the study due to the length of DNA it allows
to be interrogated which means a broader approach can be taken and more sites can be
analysed at once.
Although outside the scope of this study, one of its limitations is the lack of longitudinal
methylation data. Since methylation is a dynamic marker, observing its change over time
could certainly add important information. A further limitation of the study is that
participants are voluntarily enrolled into AIBL, which results in a high level of cognitive
performance and may not accurately represent the general population. Furthermore, the use
of different cognitive assessments to derive similar domain specific composites may alter
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association levels and make replication more difficult. The addition of gene expression data,
from the same timepoint as methylation data, would also provide another layer of
information.
The use of blood, a peripheral material, could be considered both a strength and a limitation.
The focus being on the identification of an easily accessible, cost effective and minimally
invasive biomarker makes differential CLU methylation detectable from a simple blood
sample greatly appealing and therefore a strength. However, because of the complex nature
of methylation, its tissue specificity and its dynamic evolution, extrapolation of peripheral
methylation patterns to that in the brain is not possible or whether the methylation is a cause
or product of the disease process. Whilst the formerly mentioned issues do prevent a direct
causal relationship being inferred, from a biomarker standpoint peripheral changes can be a
surrogate for changes in the brain- particularly if they track with those changes over time.

4.6 Future directions
Both studies presented in this thesis provide evidence that differential methylation in the CLU
promoter region is associated with the phenotypic characteristics of AD. To further
strengthen the research, gene expression data would provide another layer of complexity to
the analysis and provide a direct inference of methylation impact on expression. Primarily,
the best way to further strengthen the utility of CLU promoter methylation as a biomarker
would be the acquisition of longitudinal methylation data. This would significantly contribute
to gaining a greater understanding of how methylation levels change with disease progression
and phenotype changes over time. Also widening the methylation analysis across multiple
risk genes and potentially even epigenome wide analysis would beneficial (Fransquet et al.,
2018).

4.7 Conclusion
Studying methylation in the periphery for use as a biomarker presents an exciting and
promising area of research. Hypothesis one was proved correct as differential methylation
was identified across clinical classifications at specific CpG sites; namely hypomethylation
being associated with individuals with MCI or AD. As per hypothesis two, differential
methylation was identified in association with one of the CLU SNPs, rs11136000. Significantly,

78

specific methylation loci across the clusterin promoter region, were associated with
established AD fluid biomarkers, most markedly CSF A 42. Differential methylation was also
identified to be correlated with brain A burden and cortical white matter volume as was
postulated in hypothesis three. The association between methylation and cognition yielded
results in study two that warrant further study. Particularly that a difference in level of
methylation may occur, between healthy controls and healthy controls with high brain A
burden, at individual sites and units within the chosen cognitive domains both at baseline and
longitudinally. Overall, this project gives weight to the idea that methylation, and specifically
CLU promoter region methylation, could serve as a biomarker in the identification of
preclinical AD and further exploration is warranted.

79

Chapter 5: References
Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., &
Egan, G. F. (2014). A review of β-amyloid neuroimaging in Alzheimer's disease.
Frontiers in Neuroscience, 8, 327. doi:10.3389/fnins.2014.00327
Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., . . . Smith, S. O. (2010).
Structural conversion of neurotoxic amyloid-[beta]1-42 oligomers to fibrils. Nat
Struct Mol Biol, 17(5), 561-567.
doi:http://www.nature.com/nsmb/journal/v17/n5/suppinfo/nsmb.1799_S1.html
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., . . . Phelps, C.
H. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease:
Recommendations from the National Institute on Aging-Alzheimer’s Association
workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &
Dementia, 7(3), 270-279. doi:https://doi.org/10.1016/j.jalz.2011.03.008
Alzheimer's Disease International. (2015). World Alzheimer Report 2015. Retrieved from
https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf
Alzheimer’s Australia. (2017). Economic Cost of Dementia in Australia Retrieved from
https://www.dementia.org.au/files/NATIONAL/documents/The-economic-cost-ofdementia-in-Australia-2016-to-2056.pdf
Alzheimer’s Disease International. (2017). Dementia statistics Retrieved from
https://www.alz.co.uk/research/statistics
American Psychiatric Association. (2013). Neurocognitive Disorders. In Diagnostic and
Statistical Manual of Mental Disorders.
American Psychiatric Association., & American Psychiatric Association. DSM-5 Task Force.
(2013). Diagnostic and statistical manual of mental disorders : DSM-5 (5th ed.).
Washington, D.C.: American Psychiatric Association.
Arai, Y., Suzuki, A., Mizuguchi, M., & Takashima, S. (1997). Developmental and aging
changes in the expression of amyloid precursor protein in down syndrome brains.
Brain and Development, 19(4), 290-294. doi:http://dx.doi.org/10.1016/S03877604(97)00559-7
Arvanitakis, Z., Leurgans, S. E., Wang, Z., Wilson, R. S., Bennett, D. A., & Schneider, J. A.
(2011). Cerebral amyloid angiopathy pathology and cognitive domains in older
persons. Annals of Neurology, 69(2), 320-327. doi:10.1002/ana.22112
Ashford, J. W., & Mortimer, J. A. (2002). Non-familial Alzheimer's disease is mainly due to
genetic factors. Journal of Alzheimer's disease : JAD, 4(3), 169-177.
Australian Bureau of Statistics. (2017). Causes of Death, Australia, 2016. Retrieved from
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/3303.0~2015~Ma
in%20Features~Australia's%20leading%20causes%20of%20death,%202015~3
Australian Institute of Health and Welfare. (2015). Dementia Retrieved from
http://www.aihw.gov.au/dementia/
Australian Institute of Health and Welfare. (2017). About dementia Retrieved from
http://www.aihw.gov.au/dementia/about/
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011). Alzheimer's
disease. The Lancet, 377(9770), 1019-1031.
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., . . .
Xiong, C. (2011). Autosomal-dominant Alzheimer's disease: a review and proposal for

80

the prevention of Alzheimer's disease. Alzheimer's Research & Therapy, 3(1), 1-1.
doi:10.1186/alzrt59
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010). Genetics of Alzheimer Disease.
Journal of geriatric psychiatry and neurology, 23(4), 213-227.
doi:10.1177/0891988710383571
Benjamini, Y., & Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and
Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series
B (Methodological), 57(1), 289-300.
Bird, T. D. (2008). Genetic aspects of Alzheimer disease. Genet Med, 10(4), 231-239.
Blennow, K. (2017). A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF
to Blood. Neurology and Therapy, 6(Suppl 1), 15-24. doi:10.1007/s40120-017-0073-9
Bodendorf, U., Danner, S., Fischer, F., Stefani, M., Sturchler-Pierrat, C., Wiederhold, K.-H., . .
. Paganetti, P. (2002). Expression of human β-secretase in the mouse brain increases
the steady-state level of β-amyloid. Journal of Neurochemistry, 80(5), 799-806.
doi:10.1046/j.0022-3042.2002.00770.x
Bourgeat, P., Doré, V., Fripp, J., Ames, D., Masters, C. L., Rowe, C. C., . . . Salvado, O. (2015).
Web-based automated PET and MR quantification. Alzheimer's & Dementia: The
Journal of the Alzheimer's Association, 11(7), P698. doi:10.1016/j.jalz.2015.06.1549
Bourgeat, P., Villemagne, V. L., Dore, V., Brown, B., Macaulay, S. L., Martins, R., . . . Fripp, J.
(2015). Comparison of MR-less PiB SUVR quantification methods. Neurobiology of
Aging, 36, Supplement 1, S159-S166.
doi:http://doi.org/10.1016/j.neurobiolaging.2014.04.033
Braak, H., & Braak, E. (1995). Staging of alzheimer's disease-related neurofibrillary changes.
Neurobiology of Aging, 16(3), 271-278. doi:http://doi.org/10.1016/01974580(95)00021-6
Braskie, M. N., Jahanshad, N., Stein, J. L., Barysheva, M., McMahon, K. L., de Zubicaray, G. I.,
. . . Thompson, P. M. (2011). Common Alzheimer's disease risk variant within the CLU
gene affects white matter microstructure in young adults. The Journal of
neuroscience : the official journal of the Society for Neuroscience, 31(18), 6764-6770.
doi:10.1523/JNEUROSCI.5794-10.2011
Burnham, S. C., Raghavan, N., Wilson, W., Baker, D., Ropacki, M. T., Novak, G., . . . Maruff, P.
(2015). Novel statistically-derived composite measures for assessing the efficacy of
disease-modifying therapies in prodromal Alzheimer’s disease trials: an AIBL Study.
Journal of Alzheimer's Disease, 46(4), 1079-1089.
Burnham, S. C., Raghavan, N., Wilson, W., Baker, D., Ropacki, M. T., Novak, G., . . . Group, A.
R. (2015). Novel Statistically-Derived Composite Measures for Assessing the Efficacy
of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL
Study. J Alzheimers Dis, 46(4), 1079-1089. doi:10.3233/JAD-143015
Calero, M., Rostagno, A., Matsubara, E., Zlokovic, B., Frangione, B., & Ghiso, J. (2000).
Apolipoprotein J (clusterin) and Alzheimer's disease. Microscopy Research and
Technique, 50(4), 305-315. doi:10.1002/1097-0029(20000815)50:4<305::AIDJEMT10>3.0.CO;2-L
Chang, L., Wang, Y., Ji, H., Dai, D., Xu, X., Jiang, D., . . . Wang, Q. (2014). Elevation of
Peripheral BDNF Promoter Methylation Links to the Risk of Alzheimer's Disease.
PLOS ONE, 9(11), e110773. doi:10.1371/journal.pone.0110773

81

Chibnik, L. B., Yu, L., Eaton, M. L., Srivastava, G., Schneider, J. A., Kellis, M., . . . De Jager, P. L.
(2015). Alzheimer’s loci: epigenetic associations and interaction with genetic factors.
Annals of Clinical and Translational Neurology, 2(6), 636-647. doi:10.1002/acn3.201
Chouliaras, L., Mastroeni, D., Delvaux, E., Grover, A., Kenis, G., Hof, P. R., . . . van den Hove,
D. L. A. (2013). Consistent decrease in global DNA methylation and
hydroxymethylation in the hippocampus of Alzheimer's disease patients.
Neurobiology of Aging, 34(9), 2091-2099.
doi:http://dx.doi.org/10.1016/j.neurobiolaging.2013.02.021
Chouliaras, L., Pishva, E., Haapakoski, R., Zsoldos, E., Mahmood, A., Filippini, N., . . . Ebmeier,
K. P. (2018). Peripheral DNA methylation, cognitive decline and brain aging: pilot
findings from the Whitehall II imaging study. Epigenomics, 10(5), 585-595.
doi:10.2217/epi-2017-0132
Clark, C. M., Schneider, J. A., Bedell, B. J., Beach, T. G., Bilker, W. B., Mintun, M. A., . . . AV45A07 Study Group, f. t. (2011). Use of Florbetapir-PET for Imaging β-Amyloid
Pathology. JAMA, 305(3), 275-283. doi:10.1001/jama.2010.2008
Cnaan, A., Laird, N. M., & Slasor, P. (1997). Using the general linear mixed model to analyse
unbalanced repeated measures and longitudinal data. Statistics in Medicine, 16(20),
2349-2380. doi:10.1002/(SICI)1097-0258(19971030)16:20<2349::AIDSIM667>3.0.CO;2-E
Cohen, A. D., Rabinovici, G. D., Mathis, C. A., Jagust, W. J., Klunk, W. E., & Ikonomovic, M. D.
(2012). Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar AmyloidBeta. Advances in pharmacology (San Diego, Calif.), 64, 27-81. doi:10.1016/B978-012-394816-8.00002-7
Craig-Schapiro, R., Fagan, A. M., & Holtzman, D. M. (2009). Biomarkers of Alzheimer’s
Disease. Neurobiology of disease, 35(2), 128-140. doi:10.1016/j.nbd.2008.10.003
Davies, M. N., Volta, M., Pidsley, R., Lunnon, K., Dixit, A., Lovestone, S., . . . Mill, J. (2012).
Functional annotation of the human brain methylome identifies tissue-specific
epigenetic variation across brain and blood. Genome Biology, 13(6), R43-R43.
doi:10.1186/gb-2012-13-6-r43
Day, J. J., & Sweatt, J. D. (2011). Epigenetic mechanisms in cognition. Neuron, 70(5), 813829. doi:10.1016/j.neuron.2011.05.019
De Jager, P. L., Srivastava, G., Lunnon, K., Burgess, J., Schalkwyk, L. C., Yu, L., . . . Bennett, D.
A. (2014). Alzheimer's disease: early alterations in brain DNA methylation at ANK1,
BIN1, RHBDF2 and other loci. Nature Neuroscience, 17(9), 1156-1163.
doi:http://dx.doi.org/10.1038/nn.3786
de la Monte, S. M. (1989). Quantitation of cerebral atrophy in preclinical and end-stage
alzheimer's disease. Annals of Neurology, 25(5), 450-459.
doi:10.1002/ana.410250506
De Rossi, P., Buggia-Prevot, V., Andrew, R. J., Krause, S. V., Woo, E., Nelson, P. T., . . .
Thinakaran, G. (2017). BIN1 localization is distinct from Tau tangles in Alzheimer's
disease. Matters, 2017, 10.19185/matters.201611000018.
doi:10.19185/matters.201611000018
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., & et al. (1998). Deficiency of
presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature,
391(6665), 387-390. doi:http://dx.doi.org/10.1038/34910
DeMarshall, C. A., Nagele, E. P., Sarkar, A., Acharya, N. K., Godsey, G., Goldwaser, E. L., . . .
Nagele, R. G. (2016). Detection of Alzheimer's disease at mild cognitive impairment

82

and disease progression using autoantibodies as blood-based biomarkers.
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 3, 51-62.
doi:https://doi.org/10.1016/j.dadm.2016.03.002
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C., Paul, S. M., & Holtzman, D. M.
(2001). Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and
decreases brain A beta burden in a mouse model of Alzheimer's disease. Proceedings
of the National Academy of Sciences of the United States of America, 98(15), 88508855. doi:10.1073/pnas.151261398
Dementia Australia. (2014). Mild Cognitive Impairment (MCI). Retrieved from
https://www.dementia.org.au/files/helpsheets/Helpsheet-OtherInformation01MildCognitiveImpairment_english.pdf
Dementia Australia. (2018). Dementia: Key facts and statistics 2018. Retrieved from
https://www.dementia.org.au/files/documents/Key-facts-and-statistics.pdf
Derby, C. A., Burns, L. C., Wang, C., Katz, M. J., Zimmerman, M. E., L’Italien, G., . . . Lipton, R.
B. (2013). Screening for predementia AD: Time-dependent operating characteristics
of episodic memory tests. Neurology, 80(14), 1307-1314.
doi:10.1212/WNL.0b013e31828ab2c9
Di Francesco, A., Arosio, B., Falconi, A., Micioni Di Bonaventura, M. V., Karimi, M., Mari, D., .
. . D’Addario, C. (2015). Global changes in DNA methylation in Alzheimer’s disease
peripheral blood mononuclear cells. Brain, Behavior, and Immunity, 45, 139-144.
doi:http://dx.doi.org/10.1016/j.bbi.2014.11.002
Diehlmann, A., Ida, N., Weggen, S., Grünberg, J., Haass, C., Masters, C. L., . . . Beyreuther, K.
(1999). Analysis of presenilin 1 and presenilin 2 expression and processing by newly
developed monoclonal antibodies. Journal of Neuroscience Research, 56(4), 405-419.
doi:10.1002/(SICI)1097-4547(19990515)56:4<405::AID-JNR8>3.0.CO;2-F
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., . . .
the Alzheimer’s Disease Cooperative, S. (2014). The Preclinical Alzheimer Cognitive
Composite: Measuring Amyloid-Related Decline. JAMA neurology, 71(8), 961-970.
doi:10.1001/jamaneurol.2014.803
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004). Epigenetics in human disease and
prospects for epigenetic therapy. Nature, 429(6990), 457-463.
Ehrich, M., Correll, D., & van den Boom, D. (2006). Introduction to EpiTYPER for quantitative
DNA methylation analysis using the massARRAY system. Sequenom Application Note,
1, 18.
Elias, M. F., Beiser, A., Wolf, P. A., Au, R., White, R. F., & D'Agostino, R. B. (2000). The
preclinical phase of alzheimer disease: A 22-year prospective study of the
framingham cohort. Archives of neurology, 57(6), 808-813.
doi:10.1001/archneur.57.6.808
Ellis, K. A., Bush, A. I., Darby, D., De Fazio, D., Foster, J., Hudson, P., . . . Ames, D. (2009). The
Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and
baseline characteristics of 1112 individuals recruited for a longitudinal study of
Alzheimer's disease. International Psychogeriatrics, 21(4), 672-687.
doi:10.1017/S1041610209009405
Feng, R., Wang, H., Wang, J., Shrom, D., Zeng, X., & Tsien, J. Z. (2004). Forebrain
degeneration and ventricle enlargement caused by double knockout of Alzheimer's
presenilin-1 and presenilin-2. Proceedings of the National Academy of Sciences of the
United States of America, 101(21), 8162-8167. doi:10.1073/pnas.0402733101

83

Ferreira, L. K., & Busatto, G. F. (2011). Neuroimaging in Alzheimer's disease: current role in
clinical practice and potential future applications. Clinics, 66(Suppl 1), 19-24.
doi:10.1590/S1807-59322011001300003
Ferreira, L. K., Diniz, B. S., Forlenza, O. V., Busatto, G. F., & Zanetti, M. V. (2011).
Neurostructural predictors of Alzheimer's disease: A meta-analysis of VBM studies.
Neurobiology of Aging, 32(10), 1733-1741.
doi:http://doi.org/10.1016/j.neurobiolaging.2009.11.008
Flicker, L. (2010). Modifiable lifestyle risk factors for Alzheimer's disease. Journal of
Alzheimer's disease, 20(3), 803-811.
Forman, M. S., Trojanowski, J. Q., & Lee, V. M. Y. (2004). Neurodegenerative diseases: a
decade of discoveries paves the way for therapeutic breakthroughs. Nature
Medicine, 10(10), 1055-1063. doi:http://dx.doi.org/10.1038/nm1113
Foster, H. D. (2002). Why the preeminent risk factor in sporadic Alzheimer's disease cannot
be genetic. Medical hypotheses, 59(1), 57-61.
Fox, N. C., & Schott, J. M. (2004). Imaging cerebral atrophy: normal ageing to Alzheimer's
disease. The Lancet, 363(9406), 392-394.
Fransquet, P. D., Lacaze, P., Saffery, R., McNeil, J., Woods, R., & Ryan, J. (2018). Blood DNA
methylation as a potential biomarker of dementia: A systematic review. Alzheimer's
& Dementia, 14(1), 81-103. doi:https://doi.org/10.1016/j.jalz.2017.10.002
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., . . . Zhao, J.
(1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F
[beta]-amyloid precursor protein. Nature, 373(6514), 523-527.
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., . . . Chertkow, H.
(2006). Mild cognitive impairment. The Lancet, 367(9518), 1262-1270.
Geekiyanage, H., Jicha, G. A., Nelson, P. T., & Chan, C. (2012). Blood serum miRNA: Noninvasive biomarkers for Alzheimer's disease. Experimental Neurology, 235(2), 491496. doi:https://doi.org/10.1016/j.expneurol.2011.11.026
Goate, A., Chartier-Harlin, M.-C., & et al. (1991). Segregation of a Missense Mutation in the
Amyloid Precursor Protein Gene with Familial Alzheimer's Disease. Nature,
349(6311), 704-706.
Grober, E., Hall, C. B., Lipton, R. B., Zonderman, A. B., Resnick, S. M., & Kawas, C. (2008).
Memory impairment, executive dysfunction, and intellectual decline in preclinical
Alzheimer’s disease. Journal of the International Neuropsychological Society : JINS,
14(2), 266-278. doi:10.1017/S1355617708080302
Gupta, V. B., Doecke, J. D., Hone, E., Pedrini, S., Laws, S. M., Thambisetty, M., . . . Martins, R.
N. (2016). Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease:
Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimer's & Dementia:
Diagnosis, Assessment & Disease Monitoring, 3, 18-26.
doi:https://doi.org/10.1016/j.dadm.2015.12.001
Hardy, J., Bogdanovic, N., Winblad, B., Portelius, E., Andreasen, N., Cedazo‐Minguez, A., &
Zetterberg, H. (2014). Pathways to Alzheimer's disease. Journal of internal medicine,
275(3), 296-303.
Hardy, J. A., & Higgins, G. A. (1992). Alzheimer's Disease: The Amyloid Cascade Hypothesis.
Science, 256(5054), 184.
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., . . .
Williams, A. (2009). Genome-wide association study identifies variants at CLU and
PICALM associated with Alzheimer's disease. Nature genetics, 41(10), 1088-1093.

84

Hellebrekers, D. M. E. I., Melotte, V., Viré, E., Langenkamp, E., Molema, G., Fuks, F., . . . van
Engeland, M. (2007). Identification of Epigenetically Silenced Genes in Tumor
Endothelial Cells. Cancer Research, 67(9), 4138-4148. doi:10.1158/0008-5472.Can06-3032
Hersch, E. C., & Falzgraf, S. (2007). Management of the behavioral and psychological
symptoms of dementia. Clinical Interventions in Aging, 2(4), 611-621.
Hsu, J.-L., Lee, W.-J., Liao, Y.-C., Wang, S.-J., & Fuh, J.-L. (2017). The clinical significance of
plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer’s
disease. Alzheimer's Research & Therapy, 9(1), 91. doi:10.1186/s13195-017-0319-x
Iqbal, K., Liu, F., Gong, C.-X., & Grundke-Iqbal, I. (2010). Tau in Alzheimer Disease and
Related Tauopathies. Current Alzheimer research, 7(8), 656-664.
Jin, B., Li, Y., & Robertson, K. D. (2011). DNA Methylation: Superior or Subordinate in the
Epigenetic Hierarchy? Genes & Cancer, 2(6), 607-617.
doi:10.1177/1947601910393957
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012). Brain Imaging in Alzheimer
Disease. Cold Spring Harbor Perspectives in Medicine, 2(4), a006213.
doi:10.1101/cshperspect.a006213
Jones, P. A., & Liang, G. (2009). Rethinking how DNA methylation patterns are maintained.
Nature Reviews. Genetics, 10(11), 805-811. doi:http://dx.doi.org/10.1038/nrg2651
Jones, P. A., & Takai, D. (2001). The role of DNA methylation in mammalian epigenetics.
Science, 293(5532), 1068-1070.
Josephs, K. A., Ahlskog, J. E., Parisi, J. E., Boeve, B. F., Crum, B. A., Giannini, C., & Petersen, R.
C. (2009). Rapidly Progressive Neurodegenerative Dementias. Archives of neurology,
66(2), 201-207. doi:10.1001/archneurol.2008.534
Jun, G., Naj, A. C., Beecham, G. W., Wang, L.-S., Buros, J., Gallins, P. J., . . . Schellenberg, G. D.
(2010). Meta-Analysis confirms CR1, CLU, and PICALM as Alzheimer’s disease risk loci
and reveals interactions with APOE genotypes. Archives of neurology, 67(12), 14731484. doi:10.1001/archneurol.2010.201
Kamboh, M. I., Demirci, F. Y., Wang, X., Minster, R. L., Carrasquillo, M. M., Pankratz, V. S., . . .
Alzheimer's Disease Neuroimaging, I. (2012). Genome-wide association study of
Alzheimer's disease. Translational psychiatry, 2, e117.
Karch, C. M., & Goate, A. M. (2015). Alzheimer’s Disease Risk Genes and Mechanisms of
Disease Pathogenesis. Biological Psychiatry, 77(1), 43-51.
doi:http://dx.doi.org/10.1016/j.biopsych.2014.05.006
Kim, S. (2015). ppcor: An R Package for a Fast Calculation to Semi-partial Correlation
Coefficients. Communications for statistical applications and methods, 22(6), 665674. doi:10.5351/CSAM.2015.22.6.665
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., . . . Långström, B.
(2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
Annals of Neurology, 55(3), 306-319. doi:10.1002/ana.20009
Korenberg, J. R., Pulst, S.-M., Neve, R. L., & West, R. (1989). The Alzheimer amyloid
precursor protein maps to human chromosome 21 bands q21.105–q21.05.
Genomics, 5(1), 124-127. doi:http://dx.doi.org/10.1016/0888-7543(89)90095-5
Kovacs, D. M., Fausett, H. J., Page, K. J., KIM, T., MoR, R. D., Merriam, D. E., . . . Felsenstein,
K. M. (1996). Alzheimer-associated presenilins 1 and 2: Neuronal expression in brain
and localization. Nature Medicine, 2(2).

85

Lambert, J.-C., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., . . .
Amouyel, P. (2013). Meta-analysis of 74,046 individuals identifies 11 new
susceptibility loci for Alzheimer's disease. Nat Genet, 45(12), 1452-1458.
doi:10.1038/ng.2802
http://www.nature.com/ng/journal/v45/n12/abs/ng.2802.html#supplementaryinformation
Li, Q.-X., Villemagne, V. L., Doecke, J. D., Rembach, A., Sarros, S., Varghese, S., . . . Fowler, C.
J. (2015). Alzheimer’s disease normative cerebrospinal fluid biomarkers validated in
PET amyloid-β characterized subjects from the Australian Imaging, Biomarkers and
Lifestyle (AIBL) study. Journal of Alzheimer's disease, 48(1), 175-187.
Li, X., Ma, Y., Wei, X., Li, Y., Wu, H., Zhuang, J., & Zhao, Z. (2013). Clusterin in Alzheimer's
disease: a player in the biological behavior of amyloid-beta. Neuroscience bulletin,
30(1), 162-168. doi:10.1007/s12264-013-1391-2
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk,
mechanisms, and therapy. Nature reviews. Neurology, 9(2), 106-118.
doi:10.1038/nrneurol.2012.263
Lopez, O. L., Schwam, E., Cummings, J., Gauthier, S., Jones, R., Wilkinson, D., . . . Schindler, R.
(2010). Predicting cognitive decline in Alzheimer's disease: An integrated analysis.
Alzheimer's & Dementia, 6(6), 431-439.
doi:http://dx.doi.org/10.1016/j.jalz.2010.04.003
Lord, J., & Cruchaga, C. (2014). The epigenetic landscape of Alzheimer's disease. Nature
Neuroscience, 17(9), 1138-1140. doi:http://dx.doi.org/10.1038/nn.3792
Lunnon, K., & Mill, J. (2013). Epigenetic studies in Alzheimer's disease: Current findings,
caveats, and considerations for future studies. American Journal of Medical Genetics
Part B: Neuropsychiatric Genetics, 162(8), 789-799. doi:10.1002/ajmg.b.32201
Lunnon, K., Smith, R., Hannon, E., De Jager, P. L., Srivastava, G., Volta, M., . . . Mill, J. (2014).
Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease.
Nature Neuroscience, 17(9), 1164-1170. doi:http://dx.doi.org/10.1038/nn.3782
Mangialasche, F., Kivipelto, M., Solomon, A., & Fratiglioni, L. (2012). Dementia prevention:
current epidemiological evidence and future perspective. Alzheimer's Research &
Therapy, 4(1), 6. doi:10.1186/alzrt104
Martinez-Ramirez, S., Greenberg, S. M., & Viswanathan, A. (2014). Cerebral microbleeds:
overview and implications in cognitive impairment. Alzheimer's Research & Therapy,
6(3), 33-33. doi:10.1186/alzrt263
Matukumalli, S. R., Tangirala, R., & Rao, C. M. (2017). Clusterin: full-length protein and one
of its chains show opposing effects on cellular lipid accumulation. Scientific Reports,
7, 41235. doi:10.1038/srep41235
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984).
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group
under the auspices of Department of Health and Human Services Task Force on
Alzheimer's Disease. Neurology, 34(7), 939-944.
Medeiros, R., Baglietto-Vargas, D., & LaFerla, F. M. (2011). The Role of Tau in Alzheimer's
Disease and Related Disorders. CNS Neuroscience & Therapeutics, 17(5), 514-524.
doi:10.1111/j.1755-5949.2010.00177.x
Mengel-From, J., Thinggaard, M., Lindahl-Jacobsen, R., McGue, M., Christensen, K., &
Christiansen, L. (2013). CLU genetic variants and cognitive decline among elderly and
oldest old. PLOS ONE, 8(11), e79105.

86

Moonmoon, D., Dipta, S., Sandip Kumar, R., Swayamsiddha, K., Sabnam, P., Arunima, S., . . .
Samir Kumar, P. (2015). Clusterin gene is predominantly regulated by histone
modifications in human colon cancer and ectopic expression of the nuclear isoform
induces cell death. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease,
1852(8), 1630-1645. doi:https://doi.org/10.1016/j.bbadis.2015.04.021
Moore, L. D., Le, T., & Fan, G. (2013). DNA methylation and its basic function.
Neuropsychopharmacology, 38(1), 23-38.
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., . . . Beckett,
L. (2005). Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s
Disease Neuroimaging Initiative (ADNI). Alzheimer's & Dementia, 1(1), 55-66.
doi:http://doi.org/10.1016/j.jalz.2005.06.003
Murphy, M. P., & LeVine, H. (2010). Alzheimer’s Disease and the β-Amyloid Peptide. Journal
of Alzheimer's disease : JAD, 19(1), 311. doi:10.3233/JAD-2010-1221
National Institute on Aging, Alzheimer’s Association Working Group, & Relkin, N. R. (1996).
Apolipoprotein E genotyping in Alzheimer's disease. The Lancet, 347(9008), 1091.
Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K., & Brayne, C. (2014). Potential for primary
prevention of Alzheimer's disease: an analysis of population-based data. The Lancet
Neurology, 13(8), 788-794. doi:http://dx.doi.org/10.1016/S1474-4422(14)70136-X
O’Brien, R. J., & Wong, P. C. (2011). Amyloid Precursor Protein Processing and Alzheimer’s
Disease. Annual review of neuroscience, 34, 185-204. doi:10.1146/annurev-neuro061010-113613
O’Bryant, S. E., Mielke, M. M., Rissman, R. A., Lista, S., Vanderstichele, H., Zetterberg, H., . . .
the Biofluid Based Biomarker Professional Interest, A. (2017). Blood Based
Biomarkers in Alzheimer Disease: Current State of the Science and a Novel
Collaborative Paradigm for Advancing from Discovery to Clinic. Alzheimer's &
dementia : the journal of the Alzheimer's Association, 13(1), 45-58.
doi:10.1016/j.jalz.2016.09.014
Østergaard, S. D., Mukherjee, S., Sharp, S. J., Proitsi, P., Lotta, L. A., Day, F., . . . Scott, R. A.
(2015). Associations between Potentially Modifiable Risk Factors and Alzheimer
Disease: A Mendelian Randomization Study. PLoS Medicine, 12(6), e1001841.
doi:10.1371/journal.pmed.1001841
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Minthon, L., Blennow, K., . . .
Hansson, O. (2015). Detailed comparison of amyloid PET and CSF biomarkers for
identifying early Alzheimer disease. Neurology.
Pawlowski, M., Meuth, S., & Duning, T. (2017). Cerebrospinal Fluid Biomarkers in
Alzheimer’s Disease—From Brain Starch to Bench and Bedside. Diagnostics, 7(3), 42.
Peacock, M. L., Warren, J. T., Roses, A. D., & Fink, J. K. (1993). Novel polymorphism in the A4
region of the amyloid precursor protein gene in a patient without Alzheimer&#039;s
disease. Neurology, 43(6), 1254.
Perl, D. P. (2010). Neuropathology of Alzheimer's Disease. The Mount Sinai Journal of
Medicine, New York, 77(1), 32-42. doi:10.1002/msj.20157
Portela, A., & Esteller, M. (2010). Epigenetic modifications and human disease. Nat Biotech,
28(10), 1057-1068. doi:10.1038/nbt.1685
Portney, L. G., & Watkins, M. P. (2000). Foundations of clinical research (2 ed.): PrenticeHall, Inc.

87

Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013). The global
prevalence of dementia: A systematic review and metaanalysis. Alzheimer's &
Dementia, 9(1), 63-75.e62. doi:http://dx.doi.org/10.1016/j.jalz.2012.11.007
R Development Core Team. (2015). RStudio: Integrated Development for R. (Version
1.1.453).
Rabinovici, G. D., & Jagust, W. J. (2009). Amyloid imaging in ageing and dementia testing the
amyloid hypothesis in vivo. Behavioural neurology, 21(1), 117-128. doi:10.3233/BEN2009-0232
Rauhala, H. E., Porkka, K. P., Saramäki, O. R., Tammela, T. L. J., & Visakorpi, T. (2008).
Clusterin is epigenetically regulated in prostate cancer. International Journal of
Cancer, 123(7), 1601-1609. doi:10.1002/ijc.23658
Revesz, T., Holton, J. L., Lashley, T., Plant, G., Rostagno, A., Ghiso, J., & Frangione, B. (2002).
Sporadic and Familial Cerebral Amyloid Angiopathies. Brain Pathology, 12(3), 343357. doi:10.1111/j.1750-3639.2002.tb00449.x
Rice, P., Longden, I., & Bleasby, A. (2000). EMBOSS: the European Molecular Biology Open
Software Suite. Trends in genetics : TIG, 16(6), 276-277. doi:10.1016/s01689525(00)02024-2
Ringman, J. M., Monsell, S., Ng, D. W., Zhou, Y., Nguyen, A., Coppola, G., . . . Vinters, H. V.
(2016). Neuropathology of Autosomal Dominant Alzheimer Disease in the National
Alzheimer Coordinating Center Database. Journal of Neuropathology and
Experimental Neurology, 75(3), 284-290. doi:10.1093/jnen/nlv028
Rosenthal, S. L., & Kamboh, M. I. (2014). Late-Onset Alzheimer’s Disease Genes and the
Potentially Implicated Pathways. Current Genetic Medicine Reports, 2(2), 85-101.
doi:10.1007/s40142-014-0034-x
Rossor, M. N., Fox, N. C., Mummery, C. J., Schott, J. M., & Warren, J. D. (2010). The diagnosis
of young-onset dementia. Lancet neurology, 9(8), 793-806. doi:10.1016/S14744422(10)70159-9
Rowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., . . . Villemagne, V. L.
(2013). Predicting Alzheimer disease with beta-amyloid imaging: results from the
Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol, 74(6), 905913. doi:10.1002/ana.24040
Sant, K. E., Nahar, M. S., & Dolinoy, D. C. (2012). DNA Methylation Screening and Analysis.
Methods in molecular biology (Clifton, N.J.), 889, 385-406. doi:10.1007/978-1-61779867-2_24
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., &
Van der Flier, W. M. (2016). Alzheimer's disease. The Lancet, 388(10043), 505-517.
doi:http://dx.doi.org/10.1016/S0140-6736(15)01124-1
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., . . . Younkin, S. (1996).
Secreted amyloid [beta]-protein similar to that in the senile plaques of Alzheimer's
disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to
familial Alzheimer's disease. Nat Med, 2(8), 864-870.
Schmidt, M., Sachse, C., Richter, W., Xu, C., Fändrich, M., & Grigorieff, N. (2009).
Comparison of Alzheimer Aβ(1–40) and Aβ(1–42) amyloid fibrils reveals similar
protofilament structures. Proceedings of the National Academy of Sciences, 106(47),
19813-19818. doi:10.1073/pnas.0905007106

88

Schott, J. M., Crutch, S. J., Frost, C., Warrington, E. K., Rossor, M. N., & Fox, N. C. (2008).
Neuropsychological correlates of whole brain atrophy in Alzheimer's disease.
Neuropsychologia, 46(6), 1732-1737. doi:10.1016/j.neuropsychologia.2008.02.015
Schrijvers, E. C., Koudstaal, P. J., Hofman, A., & Breteler, M. B. (2011). Plasma clusterin and
the risk of alzheimer disease. JAMA, 305(13), 1322-1326. doi:10.1001/jama.2011.381
Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years.
EMBO Molecular Medicine, 8(6), 595-608. doi:10.15252/emmm.201606210
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011). Neuropathological
Alterations in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine:, 1(1),
a006189. doi:10.1101/cshperspect.a006189
Seshadri, S., Fitzpatrick, A. L., Arfan Ikram, M., DeStefano, A. L., Gudnason, V., Boada, M., . . .
Breteler, M. M. B. (2010). Genome-wide Analysis of Genetic Loci Associated with
Alzheimer’s Disease. JAMA : the journal of the American Medical Association,
303(18), 1832-1840. doi:10.1001/jama.2010.574
Silajdžić, E., Minthon, L., Björkqvist, M., & Hansson, O. (2012). No Diagnostic Value of Plasma
Clusterin in Alzheimer's Disease. PLOS ONE, 7(11), e50237.
doi:10.1371/journal.pone.0050237
Silverberg, N. B., Ryan, L. M., Carrillo, M. C., Sperling, R., Petersen, R. C., Posner, H. B., . . .
Ferman, T. J. (2011). Assessment of cognition in early dementia. Alzheimer's &
dementia : the journal of the Alzheimer's Association, 7(3), e60-e76.
doi:10.1016/j.jalz.2011.05.001
Smith, A. R., Smith, R. G., Condliffe, D., Hannon, E., Schalkwyk, L., Mill, J., & Lunnon, K.
(2016). Increased DNA methylation near TREM2 is consistently seen in the superior
temporal gyrus in Alzheimer's disease brain. Neurobiology of Aging, 47, 35-40.
doi:http://dx.doi.org/10.1016/j.neurobiolaging.2016.07.008
Storey, & Cappai. (1999). The amyloid precursor protein of Alzheimer’s disease and the Aβ
peptide. Neuropathology and Applied Neurobiology, 25(2), 81-97.
doi:10.1046/j.1365-2990.1999.00164.x
Storey, J. D. (2002). A direct approach to false discovery rates. Journal of the Royal
Statistical Society: Series B (Statistical Methodology), 64(3), 479-498.
doi:doi:10.1111/1467-9868.00346
Suárez‐Calvet, M., Belbin, O., Pera, M., Badiola, N., Magrané, J., Guardia‐Laguarta, C., . . .
Lleó, A. (2014). Autosomal‐dominant Alzheimer's disease mutations at the same
codon of amyloid precursor protein differentially alter Aβ production. Journal of
Neurochemistry, 128(2), 330-339. doi:10.1111/jnc.12466
Suchiman, H. E. D., Slieker, R. C., Kremer, D., Slagboom, P. E., Heijmans, B. T., & Tobi, E. W.
(2015). Design, measurement and processing of region-specific DNA methylation
assays: the mass spectrometry-based method EpiTYPER. Frontiers in Genetics, 6, 287.
doi:10.3389/fgene.2015.00287
Szymanski, M., Wang, R., Bassett, S. S., & Avramopoulos, D. (2011). Alzheimer's risk variants
in the clusterin gene are associated with alternative splicing. Translational
psychiatry, 1(7), e18. doi:10.1038/tp.2011.17
Takahashi, M., Doré, S., Ferris, C. D., Tomita, T., Sawa, A., Wolosker, H., . . . Snyder, S. H.
(2000). Amyloid Precursor Proteins Inhibit Heme Oxygenase Activity and Augment
Neurotoxicity in Alzheimer's Disease. Neuron, 28(2), 461-473.
doi:http://dx.doi.org/10.1016/S0896-6273(00)00125-2

89

Takahashi, R. H., Tobiume, M., Sato, Y., Sata, T., Gouras, G. K., & Takahashi, H. (2011).
Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques
in the Alzheimer's disease brain. Neuropathology, 31(3), 208-214.
doi:10.1111/j.1440-1789.2010.01158.x
Thambisetty, M., Beason-Held, L. L., An, Y., Kraut, M., Nalls, M., Hernandez, D. G., . . .
Resnick, S. M. (2013). Alzheimer risk variant CLU and brain function during aging.
Biological Psychiatry, 73(5), 399-405. doi:10.1016/j.biopsych.2012.05.026
Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., . . .
Lovestone, S. (2010). Association of plasma clusterin concentration with severity,
pathology, and progression in Alzheimer disease. Archives of general psychiatry,
67(7), 739-748. doi:10.1001/archgenpsychiatry.2010.78
Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., . . . Brooks, D. J.
(2010). 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive
impairment: A phase 2 trial. Annals of Neurology, 68(3), 319-329.
doi:doi:10.1002/ana.22068
Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., . . .
Blennow, K. (2012). Standardization of preanalytical aspects of cerebrospinal fluid
biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the
Alzheimer's Biomarkers Standardization Initiative. Alzheimer's & Dementia, 8(1), 6573. doi:https://doi.org/10.1016/j.jalz.2011.07.004
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., . . . Citron, M.
(1999). β-Secretase Cleavage of Alzheimer’s Amyloid Precursor Protein by the
Transmembrane Aspartic Protease BACE. Science, 286(5440), 735.
Vemuri, P., & Jack, C. R. (2010). Role of structural MRI in Alzheimer's disease. Alzheimer's
Research & Therapy, 2(4), 23. doi:10.1186/alzrt47
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., . . . Masters,
C. L. (2013). Amyloid β deposition, neurodegeneration, and cognitive decline in
sporadic Alzheimer's disease: a prospective cohort study. The Lancet Neurology,
12(4), 357-367. doi:https://doi.org/10.1016/S1474-4422(13)70044-9
Villemagne, V. L., Doré, V., Yates, P., Brown, B., Mulligan, R., Bourgeat, P., . . . Rembach, A.
(2014). En attendant centiloid.
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., . . . Rowe,
C. C. (2011). Longitudinal assessment of Aβ and cognition in aging and Alzheimer
disease. Annals of Neurology, 69(1), 181-192. doi:10.1002/ana.22248
Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P., Savage, G., Ng, S., . . . Rowe, C. C. (2008).
Aβ deposits in older non-demented individuals with cognitive decline are indicative
of preclinical Alzheimer's disease. Neuropsychologia, 46(6), 1688-1697.
doi:https://doi.org/10.1016/j.neuropsychologia.2008.02.008
Weinstein, G., Beiser, A. S., Preis, S. R., Courchesne, P., Chouraki, V., Levy, D., & Seshadri, S.
(2016). Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke.
Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring, 3, 103-109.
doi:10.1016/j.dadm.2016.06.005
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. O., . . . Petersen, R.
C. (2004). Mild cognitive impairment--beyond controversies, towards a consensus:
report of the International Working Group on Mild Cognitive Impairment. Journal of
internal medicine, 256(3), 240-246. doi:10.1111/j.1365-2796.2004.01380.x

90

World Health Organization. (2016). Dementia. Retrieved from
http://www.who.int/mediacentre/factsheets/fs362/en/
Xu, M., Gonzalez-Hurtado, E., & Martinez, E. (2016). Core promoter-specific gene regulation:
TATA box selectivity and Initiator-dependent bi-directionality of serum response
factor-activated transcription. Biochimica et biophysica acta, 1859(4), 553-563.
doi:10.1016/j.bbagrm.2016.01.005
Yamazaki, K., Yoshino, Y., Mori, T., Yoshida, T., Ozaki, Y., Sao, T., . . . Ueno, S.-i. (2017). Gene
expression and methylation analysis of ABCA7 in patients with Alzheimer’s disease.
Journal of Alzheimer's disease, 57(1), 171-181.
Yu, J.-T., & Tan, L. (2012). The Role of Clusterin in Alzheimer’s Disease: Pathways,
Pathogenesis, and Therapy. Molecular Neurobiology, 45(2), 314-326.
doi:10.1007/s12035-012-8237-1
Yu, L., Chibnik, L. B., Srivastava, G. P., Pochet, N., Yang, J., Xu, J., . . . Bennett, D. A. (2015).
Association of Brain DNA Methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and
BIN1 With Pathological Diagnosis of Alzheimer Disease. JAMA neurology, 72(1), 1524. doi:10.1001/jamaneurol.2014.3049
Zerbino, D. R., Achuthan, P., Akanni, W., Amode, M R., Barrell, D., Bhai, J., . . . Flicek, P.
(2018). Ensembl 2018. Nucleic Acids Research, 46(D1), D754-D761.
doi:10.1093/nar/gkx1098
Zhang, Y., & Lee, D. H. S. (2011). Sink Hypothesis and Therapeutic Strategies for Attenuating
Aβ Levels. The Neuroscientist, 17(2), 163-173. doi:10.1177/1073858410381532
Zhang, Z.-G., Li, Y., Ng, C. T., & Song, Y.-Q. (2015). Inflammation in Alzheimer’s Disease and
Molecular Genetics: Recent Update. Archivum Immunologiae et Therapiae
Experimentalis, 63(5), 333-344. doi:10.1007/s00005-015-0351-0
Zhu, R., Liu, X., & He, Z. (2018). Association between CLU gene rs11136000 polymorphism
and Alzheimer’s disease: an updated meta-analysis. Neurological Sciences, 39(4),
679-689. doi:10.1007/s10072-018-3259-8

91

Appendices
Appendix 1 – Bisulphite Treatment Protocol Bisulphite Treatment with EZ DNA
Methylation Kit (Sequenom Recommended Modified)

Day One
Before starting the conversion, prepare the CT Conversion Reagent and M-Wash Buffer.
Preparation of CT Conversion Reagent
The CT Conversion Reagent is light sensitive. Minimize exposure to light.
Prepare the CT Conversion Reagent by adding 750 l of H2O and 210 l of M-Dilution Buffer
to one tube of CT Conversion Reagent and then mix by vortexing on and off for a total of 10
minutes.
The CT Conversion Reagent is saturated, so it is normal for it to not be completely dissolved.
Store the prepared CT Conversion Reagent away from light and at room temperature (2030°C) until use. Each tube of prepared reagent is designed to treat 10 DNA samples.
For best results, the prepared CT Conversion Reagent should be used immediately. If the
reagent will not be used in less than an hour, then it can be stored for up to one week at 20°C. Once taken out of the freezer, it must be thawed at room temperature and vortexed
for 2 minutes.
Preparation of M-Wash Buffer
Add 24 ml of 100% EtOH to the M-Wash Buffer Concentrate to make final M-Wash Buffer.
AGENA Recommended Protocol for EZ DNA Methylation
1. 5 l M-Dilution Buffer + DNA + Make up with H2O.
Incubate the samples at 37°C for 15 minutes in the thermocycler.
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Add 100 l of the prepared CT Conversion Reagent to each sample and lightly vortex
Sequenom Recommendation “Alternative Cycling Protocol”:
Step 1: 95°C, 30 seconds
Step 2: 50°C, 15 minutes
Step 3: Repeat steps 1-2 for 20 cycles (Approx. duration ~ 5.5 hrs)
Step 4: 4°C infinite hold
Day Two
Incubate the sample on ice for 10 minutes.
Add 400 l of M-Binding Buffer to the sample and mix by pipetting up and down.
Load sample into a Zymo-Spin I Column and place column into a 2 ml collection tube.
Centrifuge at full speed (>10000 rpm) for 30 seconds. Discard the flow through. (Capacity of
the collection tube is 800 l with the column inserted. Empty whenever necessary to prevent
contamination by flow through.)
Add 200 l of M-Wash Buffer to the column and spin at full speed for 30 seconds.
Add 200 l of M-Desulphonation Buffer to the column and let column stand at room
temperature for 15 minutes. After the incubation spin at full speed for 30 seconds.
Add 200 l of M-Wash Buffer to the column and spin at full speed for 30 seconds.
Add another 200 l of M-Wash Buffer and spin at top speed for a minute. (A longer spinning
step is needed here to complete removal of wash buffer residues.)
Elute in 30-70 l of H2O. Spin at full speed for one minute.
Reload the eluate and incubate for 5 minutes and spin once more for a minute at full speed
for maximum concentration.
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Appendix 2 – ZYMO Research EZ DNA Methylation Kit Specifications DNA input
specifications adapted from ZYMO Research EZ DNA Methylation Kits

Instruction Manual.
DNA Input – Samples should contain 500 pg – 2 g of DNA (For optimal results, amount input
should be 200 to 500 ng)
Conversion Efficiency - > 99% of non-methylated C residues are converted to U
> 99% protection of methylated cytosines
DNA Recovery - > 80%

94

Appendix 3 – PCR Reaction and PCR Cocktail
PCR Reaction
Prepare the PCR mixture according to the table below. Include an additional 20% overhang
for errors in pipetting. Adjust values according to the number of reactions needed. Dispense
into either a 96-well plate, or a 384-well plate as needed.
PCR Mix Cocktail
Reagent

Final Concentration for

Volume for Single Reaction

Single Reaction
ddH2O

N/A

1.24 µl

10 X PCR Buffer, containing

1X

0.50 µl

dNTP mix 25 mM each

200 M

0.04 µl

5U/ L PCR Enzyme

0.2 unit/reaction

0.04 µl

PCR Cocktail Volume

N/A

2.0 µl

Bisulphite Converted DNA

10ng/reaction

1.0 µl

1 M Primer Mix (T7 Reverse

0.4 M

2.0 µl

N/A

5.00 µl

20mM MgCl2

& 10mer Forward)
Total Reaction Volume

Vortex and centrifuge after combining all reagents and dispense 5 L into each sample well
of your plate.
Seal, vortex and centrifuge the plate. Place the plate in the thermocycler and run the
following program:
‘Touch Down’ PCR Protocol
Step 1: 95 C for 10 minutes
Step 2: 95 C for 20 seconds
Step 3: 62 C (increment at -0.2 C/cycle) for 30 seconds
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Step 4: 72 C for 60 seconds
Step 5: Go to Step 2 for 29 cycles
Step 6: 95 C for 20 seconds
Step 7: 56 C for 30 seconds
Step 8: 72 C for 60 seconds
Step 9: Go to Step 6 for 16 cycles
Step 10: 72 C for 3 minutes
Step 11: 4 C infinite hold
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Appendix 4 - SAP Enzyme Reaction
Prepare the SAP mixture according to the table below. Include an additional 20% overhang
for errors in pipetting. Adjust values according to the number of reactions needed.
SAP Mix Cocktail
Reagent

Volume for Single Reaction

Nanopure Water, Autoclaved

1.7 µl

SAP Enzyme (1.7U/ L)

0.3 µl

Total Volume

2.0 µl

Vortex and centrifuge after combining all reagents and dispense 2 L into each sample well
containing your bisulphite converted DNA.
Seal, vortex and centrifuge the plate. Incubate sample plate on a thermocycler with the
following program:
Step 1: 37 C for 20 minutes
Step 2: 85 C for 5 minutes
Step 3: 4 C infinite hold
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Appendix 5 - MassCLEAVE Reaction
Prepare the Transcription/Cleavage mixture according to the table below. Include an
additional 20% overhang to account for errors in pipetting. Adjust values according to number
or reactions needed.
MassCLEAVE Mix Cocktail
T Cleavage

Final Concentration for

Volume for Single

Transcription/RNase A

Single Reaction

Reaction

RNase Free ddH2O

N/A

3.15 µl

5 X T7 Polymerase Buffer

0.64 X

0.89 µl

T Cleavage Mix

N/A

0.24 µl

DTT, 100 mM

3.15 mM

0.22 µl

Cocktail

T7 RNA & DNA Polymerase 22 Units/reaction

0.44 µl

RNase A

0.06 µl

Total Volume

0.09 mg/mL

5 µl

After SAP incubation, transfer 2 L from the PCR/SAP plate to the corresponding well of the
new 384-well MassCLEAVE reaction plate and vortex and centrifuge.
Incubate sample plate on a thermocycler with the following program:
Step 1: 37 C for 3 hours;
Step 2: 4 C infinite hold
After removal of plate, either store at -20 C overnight or proceed with resin conditioning.
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Appendix 6 - Resin Conditioning, Nanodispensing and MALDI-TOF MS
This procedure is optimised for one 384-well plate.
1- Spread out clean resin onto a 384/15mg dimple plate and allow at least 10 minutes of
drying time.
2- Add 16 L of water to each well of the sample plate, seal, vortex and centrifuge the plate.
3- Add 6mg of clean resin by turning the sample plate over and placing it on top of the dimple
plate. Turn it over, so that the dimple plate is on top and let the resin fall into the
corresponding wells. Rotate the plate for at least 30 minutes. Centrifuge at 2000 rpm for 3
minutes.
Nanodispensing
1- Condition and clean the pinhead (24 pins) as per instructions in the Agena Bioscience
NanoDispenser RS 1000 User Guide (UG 11558 version 2.1).
2- Place the 384-well plate and the SpectroCHIP II G-96 onto the instrument in the correct
positions and orient A1 correctly (top right hand corner).
3- Load the calibrant reservoir with 80 l of 4-point calibrant. Dispense calibrant at automatic
speed and volume.
4- Carry out volume check to find optimum dispensing speed and volume for samples
5- For detailed procedures, consult the Agena Bioscience NanoDispenser RS 1000 User Guide
(UG 11558 version 2.1).
MALDI-TOF MS
1- Set up the plate in the EpiTYPER Plate Editor Software. Import the DNA references and DNA
sample names into Plate Editor. Plate must be set up with reference sequences, samples and
reaction.
2- Using the Plate Editor software, export the plate to the RT-Workstation.
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3- Open the RT-Workstation
4- In SpectroACQUIRE, open the “Auto Run Setup” option and select the appropriate
experiment name.
5- Check the barcode and the “Auto Teach Geometry” and “Use Calibration Wells” options.
6- Double check the MassCLEAVE acquisition parameters.
7- Select “Start Autorun” to proceed with the data acquisition.
8- For detailed procedures, consult the Agena Bioscience NanoDispenser RS 1000 User Guide
(UG 11558 version 2.1).
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Appendix 7 Study Two: CLU Promoter Methylation and Cognitive Performance Tables
⍺

p-value

q-value



p-value

q-value

Global Cognition

0.455

0.743

0.692

-0.306

0.249

0.692

Verbal Episodic Memory

0.253

0.841

0.709

-0.142

0.56

0.692

Executive Function

-0.911

0.447

0.692

0.09

0.696

0.692

PACC

1.237

0.736

0.692

-0.693

0.346

0.692

Global Cognition

0.201

0.833

0.707

0.36

0.058

0.625

Verbal Episodic Memory

0.718

0.411

0.692

0.241

0.165

0.692

Executive Function

-0.422

0.612

0.692

-0.005

0.975

0.735

PACC

1.192

0.637

0.692

0.579

0.278

0.692

Global Cognition

0.644

0.382

0.692

-0.082

0.559

0.692

Verbal Episodic Memory

0.627

0.349

0.692

-0.047

0.715

0.692

Executive Function

-1.246

0.049

0.625

-0.059

0.631

0.692

PACC

0.951

0.641

0.692

-0.391

0.343

0.692

Global Cognition

0.123

0.915

0.723

0.207

0.333

0.692

Verbal Episodic Memory

0.264

0.801

0.703

0.151

0.441

0.692

Executive Function

-0.079

0.936

0.724

-0.339

0.071

0.625

PACC

-0.275

0.931

0.724

0.552

0.378

0.692

Global Cognition

0.655

0.742

0.692

0.211

0.555

0.692

Verbal Episodic Memory

1.198

0.508

0.692

0.167

0.608

0.692

Executive Function

-0.83

0.63

0.692

0.227

0.472

0.692

PACC

4.32

0.416

0.692

-0.307

0.76

0.692

Global Cognition

1.867

0.247

0.692

0.039

0.896

0.715

Verbal Episodic Memory

1.559

0.288

0.692

0.108

0.694

0.692

Executive Function

1.096

0.431

0.692

0.221

0.402

0.692

PACC

5.273

0.219

0.692

-0.714

0.414

0.692

Global Cognition

2.529

0.125

0.692

0.137

0.652

0.692

Verbal Episodic Memory

2.177

0.147

0.692

0.214

0.44

0.692

Executive Function

1.923

0.169

0.692

0.024

0.929

0.724

PACC

6.755

0.131

0.692

-0.277

0.755

0.692

CpG_1 (n= 626)

CpG_2_3 (n= 626)

CpG_8_9 (n= 626)

CpG_10 (n= 626)

CpG_14 (n= 626)

CpG_15 (n= 626)

CpG_16 (n= 626)

Table A7.1 continued over next page
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Table A7.1 continued
⍺

p-value

q-value



p-value

q-value

Global Cognition

0.816

0.57

0.692

-0.085

0.735

0.692

Verbal Episodic Memory

0.918

0.483

0.692

-0.07

0.76

0.692

Executive Function

1.586

0.202

0.692

-0.604

0.006

0.625

PACC

3.372

0.378

0.692

-0.954

0.174

0.692

Global Cognition

-0.594

0.821

0.706

-0.237

0.614

0.692

Verbal Episodic Memory

-0.639

0.862

0.711

-0.19

0.655

0.692

Executive Function

1.036

0.656

0.692

0.31

0.455

0.692

PACC

3.056

0.664

0.692

-1.942

0.174

0.692

Global Cognition

1.269

0.504

0.692

0.037

0.898

0.715

Verbal Episodic Memory

4.779

0.072

0.625

-0.311

0.233

0.692

Executive Function

0.533

0.754

0.692

-0.284

0.31

0.692

PACC

5.758

0.253

0.692

-0.858

0.302

0.692

Global Cognition

-3.272

0.32

0.692

-0.491

0.386

0.692

Verbal Episodic Memory

-0.869

0.85

0.711

-0.978

0.056

0.625

Executive Function

2.065

0.482

0.692

-0.743

0.135

0.692

PACC

-8.375

0.349

0.692

-2.097

0.243

0.692

Global Cognition

0.789

0.572

0.692

-0.332

0.129

0.692

Verbal Episodic Memory

1.337

0.495

0.692

-0.365

0.064

0.625

Executive Function

0.982

0.429

0.692

-0.127

0.507

0.692

PACC

2.895

0.424

0.692

-1.209

0.058

0.625

Global Cognition

0.359

0.861

0.711

0.159

0.636

0.692

Verbal Episodic Memory

1.47

0.608

0.692

0.205

0.5

0.692

Executive Function

3.783

0.025

0.625

0.003

0.993

0.738

PACC

4.096

0.42

0.692

-0.332

0.751

0.692

Global Cognition

1.595

0.254

0.692

-0.44

0.061

0.625

Verbal Episodic Memory

1.609

0.411

0.692

-0.051

0.809

0.703

Executive Function

-0.291

0.804

0.703

-0.122

0.552

0.692

PACC

0.904

0.792

0.703

-1.664

0.013

0.625

CpG_19 (n= 626)

CpG_20_21 (n= 646)

CpG_23_24 (n= 646)

CpG_25_26_27_28 (n= 646)

CpG_29_30_31 (n= 646)

CpG_32 (n= 646)

CpG_33 (n= 646)

Table A7.1 continued over next page
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Table A7.1 continued
⍺

p-value

q-value



p-value

q-value

Global Cognition

-1.604

0.437

0.692

0.396

0.264

0.692

Verbal Episodic Memory

-1.213

0.673

0.692

0.291

0.365

0.692

Executive Function

0.687

0.71

0.692

0.47

0.132

0.692

PACC

-8.452

0.121

0.692

2.071

0.044

0.625

Global Cognition

-1.618

0.231

0.692

-0.079

0.735

0.692

Verbal Episodic Memory

-1.282

0.497

0.692

0.006

0.976

0.735

Executive Function

-1.855

0.116

0.692

0.055

0.785

0.703

PACC

0.468

0.899

0.715

0.156

0.825

0.706

Global Cognition

0.058

0.983

0.735

-0.072

0.871

0.713

Verbal Episodic Memory

-0.943

0.8

0.703

-0.225

0.572

0.692

Executive Function

1.769

0.451

0.692

0.142

0.713

0.692

PACC

-5.547

0.457

0.692

0.911

0.537

0.692

Global Cognition

-1.604

0.437

0.692

0.396

0.264

0.692

Verbal Episodic Memory

-1.213

0.673

0.692

0.291

0.365

0.692

Executive Function

0.687

0.71

0.692

0.47

0.132

0.692

PACC

-8.452

0.121

0.692

2.071

0.044

0.625

CpG_36 (n= 646)

CpG_37 (n= 646)

CpG_38_39 (n= 646)

CpG_41 (n= 646)

Table A7.1 CLU promoter methylation and cognitive performance in all participants table
Association between percentage methylation levels and baseline () and longitudinal ()
change in composite measures of cognition including a global cognition, verbal episodic
memory composite, executive function and Pre-clinical Alzheimer’s disease cognitive
composite (PACC) in the whole cohort (also corrected for age). P-values of nominal
significance italicised. P-values corrected for FDR = q-value. n dependent on availability of
cognitive data.
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⍺

p-value

q-value



p-value

q-value

Global Cognition

1.89

0.088

0.563

-0.059

0.783

0.675

Verbal Episodic Memory

1.509

0.175

0.563

-0.009

0.966

0.723

Executive Function

0.188

0.872

0.675

0.129

0.562

0.638

PACC

4.181

0.196

0.563

-0.646

0.272

0.563

Global Cognition

0.691

0.368

0.563

0.142

0.349

0.563

Verbal Episodic Memory

0.883

0.254

0.563

0.09

0.546

0.636

Executive Function

-0.709

0.384

0.579

-0.159

0.322

0.563

PACC

1.503

0.497

0.610

0.205

0.627

0.648

Global Cognition

0.612

0.3

0.563

0.12

0.288

0.563

Verbal Episodic Memory

0.6

0.313

0.563

0.115

0.297

0.563

Executive Function

-1.009

0.107

0.563

-0.03

0.796

0.675

PACC

1.918

0.277

0.563

-0.133

0.685

0.648

Global Cognition

-0.826

0.359

0.563

0.294

0.081

0.563

Verbal Episodic Memory

-0.959

0.291

0.563

0.254

0.126

0.563

Executive Function

0.205

0.829

0.675

-0.311

0.077

0.563

PACC

-0.558

0.833

0.675

0.652

0.172

0.563

Global Cognition

-0.828

0.578

0.648

-0.097

0.725

0.660

Verbal Episodic Memory

-0.321

0.831

0.675

-0.093

0.732

0.661

Executive Function

-1.506

0.342

0.563

0

0.999

0.724

PACC

1.006

0.817

0.675

-0.747

0.334

0.563

Global Cognition

0.181

0.883

0.675

-0.143

0.549

0.636

Verbal Episodic Memory

0.286

0.818

0.675

-0.039

0.869

0.675

Executive Function

1.088

0.405

0.587

-0.119

0.638

0.648

PACC

0.757

0.835

0.675

-0.714

0.294

0.563

Global Cognition

0.959

0.448

0.602

-0.174

0.46

0.605

Verbal Episodic Memory

0.865

0.498

0.610

-0.093

0.689

0.648

Executive Function

1.998

0.136

0.563

-0.019

0.939

0.713

PACC

7.348

0.057

0.563

-1.223

0.079

0.563

Global Cognition

0.785

0.467

0.605

-0.23

0.233

0.563

Verbal Episodic Memory

0.906

0.405

0.587

-0.224

0.239

0.563

Executive Function

1.393

0.225

0.563

-0.563

0.006

0.563

PACC

5.276

0.093

0.563

-1.231

0.021

0.563

CpG_1 (n= 450)

CpG_2_3 (n= 450)

CpG_8_9 (n= 450)

CpG_10 (n= 450)

CpG_14 (n= 450)

CpG_15 (n= 450)

CpG_16 (n= 450)

CpG_19 (n= 450)

Table A7.2 continued over next page
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Table A7.2 continued
⍺

p-value

q-value



p-value

q-value

Global Cognition

-3.124

0.113

0.563

-0.341

0.354

0.563

Verbal Episodic Memory

-2.741

0.17

0.563

-0.347

0.336

0.563

Executive Function

-1.707

0.413

0.591

0.414

0.285

0.563

PACC

-5.739

0.327

0.563

-1.871

0.098

0.563

Global Cognition

-0.276

0.843

0.675

-0.14

0.539

0.636

Verbal Episodic Memory

-0.036

0.98

0.723

-0.255

0.251

0.563

Executive Function

-0.346

0.814

0.675

-0.576

0.028

0.563

PACC

1.428

0.724

0.660

-0.83

0.2

0.563

Global Cognition

-0.071

0.979

0.723

-0.521

0.271

0.563

Verbal Episodic Memory

0.087

0.974

0.723

-0.455

0.326

0.563

Executive Function

4.469

0.108

0.563

-0.512

0.294

0.563

PACC

1.192

0.882

0.675

-2.026

0.178

0.563

Global Cognition

1.117

0.287

0.563

-0.325

0.061

0.563

Verbal Episodic Memory

1.025

0.336

0.563

-0.318

0.061

0.563

Executive Function

0.864

0.435

0.599

-0.142

0.428

0.599

PACC

1.072

0.723

0.660

-0.543

0.281

0.563

Global Cognition

-1.414

0.364

0.563

0.181

0.493

0.610

Verbal Episodic Memory

-1.72

0.275

0.563

0.303

0.24

0.563

Executive Function

1.496

0.361

0.563

0.234

0.396

0.587

PACC

2.981

0.516

0.618

-0.369

0.662

0.648

Global Cognition

0.86

0.433

0.599

-0.253

0.177

0.563

Verbal Episodic Memory

0.542

0.626

0.648

-0.141

0.444

0.602

Executive Function

-0.566

0.625

0.648

-0.074

0.702

0.655

PACC

3.723

0.246

0.563

-1.183

0.035

0.563

Global Cognition

0.242

0.808

0.675

-0.128

0.464

0.605

Verbal Episodic Memory

0.328

0.745

0.667

-0.163

0.342

0.563

Executive Function

-0.553

0.598

0.648

0.107

0.556

0.638

PACC

-1.523

0.594

0.648

0.222

0.662

0.648

Global Cognition

-0.749

0.635

0.648

-0.113

0.687

0.648

Verbal Episodic Memory

-0.818

0.608

0.648

-0.055

0.841

0.675

Executive Function

-0.278

0.867

0.675

0.378

0.195

0.563

PACC

-8.908

0.049

0.563

0.95

0.248

0.563

CpG_20_21 (n= 474)

CpG_23_24 (n= 474)

CpG_25_26_27_28 (n= 474)

CpG_29_30_31 (n= 474)

CpG_32 (n= 474)

CpG_33 (n= 474)

CpG_34 (n= 474)

CpG_36 (n= 474)

Table A7.2 continued over next page
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q-value



p-value

q-value

Global Cognition

-0.7

0.511

0.618

0.081

0.659

0.648

Verbal Episodic Memory

-0.728

0.499

0.610

0.032

0.857

0.675

Executive Function

-1.56

0.164

0.563

0.228

0.227

0.563

PACC

-0.906

0.773

0.675

0.244

0.668

0.648

Global Cognition

0.021

0.992

0.723

-0.696

0.056

0.563

Verbal Episodic Memory

-0.034

0.987

0.723

-0.674

0.059

0.563

Executive Function

2.529

0.236

0.563

-0.264

0.483

0.610

PACC

-2.612

0.683

0.648

-1.782

0.134

0.563

Global Cognition

-0.749

0.635

0.648

-0.113

0.687

0.648

Verbal Episodic Memory

-0.818

0.608

0.648

-0.055

0.841

0.675

Executive Function

-0.278

0.867

0.675

0.378

0.195

0.563

PACC

-8.908

0.049

0.563

0.95

0.248

0.563

CpG_37 (n= 474)

CpG_38_39 (n= 474)

CpG_41 (n= 474)

Table A7.2 CLU Promoter methylation and cognitive performance in Healthy Controls table
Association between percentage methylation levels and baseline () and longitudinal ()
change in composite measures of cognition including a global cognition, verbal episodic
memory composite, executive function and Pre-clinical Alzheimer’s disease cognitive
composite (PACC) in only the healthy controls (also corrected for age). P-values of nominal
significance italicised. P-values corrected for FDR = q-value. n dependent on availability of
cognitive data.
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p-value

q-value

Global Cognition

2.565

0.228

0.465

-0.339

0.41

0.498

Verbal Episodic Memory

1.981

0.342

0.498

-0.245

0.536

0.528

Executive Function

-1.218

0.572

0.528

0.59

0.165

0.465

PACC

3.256

0.613

0.530

-0.421

0.739

0.556

Global Cognition

3.016

0.02

0.309

0.028

0.911

0.590

Verbal Episodic Memory

3.381

0.009

0.278

-0.069

0.772

0.559

Executive Function

-0.113

0.932

0.595

0.055

0.834

0.561

PACC

7.8

0.047

0.465

0.226

0.77

0.559

Global Cognition

0.902

0.379

0.498

0.161

0.408

0.498

Verbal Episodic Memory

0.88

0.385

0.498

0.18

0.333

0.498

Executive Function

-1.028

0.323

0.498

0.065

0.749

0.556

PACC

2.488

0.41

0.498

0.425

0.457

0.528

Global Cognition

-1.755

0.264

0.468

0.705

0.008

0.278

Verbal Episodic Memory

-2.116

0.175

0.465

0.705

0.006

0.278

Executive Function

0.91

0.566

0.528

-0.436

0.111

0.465

PACC

5.064

0.282

0.475

1.536

0.045

0.465

Global Cognition

-0.12

0.96

0.597

0.737

0.078

0.465

Verbal Episodic Memory

0.526

0.824

0.561

0.657

0.104

0.465

Executive Function

-0.809

0.74

0.556

-0.596

0.18

0.465

PACC

2.154

0.762

0.559

1.52

0.216

0.465

Global Cognition

0.969

0.638

0.531

0.535

0.167

0.465

Verbal Episodic Memory

1.413

0.488

0.528

0.474

0.204

0.465

Executive Function

1.494

0.475

0.528

-0.183

0.648

0.531

PACC

-0.357

0.954

0.597

1.531

0.206

0.465

Global Cognition

2.598

0.185

0.465

0.083

0.811

0.561

Verbal Episodic Memory

2.529

0.194

0.465

0.218

0.515

0.528

Executive Function

3.69

0.063

0.465

0.008

0.982

0.606

PACC

11.573

0.067

0.465

-1.958

0.076

0.465

Global Cognition

2.16

0.234

0.465

0.155

0.618

0.530

Verbal Episodic Memory

2.442

0.175

0.465

0.095

0.751

0.556

Executive Function

1.518

0.414

0.498

-0.605

0.061

0.465

PACC

8.017

0.129

0.465

-0.825

0.35

0.498

CpG_1 (n= 204)

CpG_2_3 (n= 204)

CpG_8_9 (n= 204)

CpG_10 (n= 204)

CpG_14 (n= 204)

CpG_15 (n= 204)

CpG_16 (n= 204)

CpG_19 (n= 204)

Table A7.3 continued over next page

107

Table A7.3 continued
⍺

p-value

q-value



p-value

q-value

Global Cognition

-5.073

0.118

0.465

0.39

0.521

0.528

Verbal Episodic Memory

-4.146

0.201

0.465

0.202

0.729

0.556

Executive Function

1.675

0.617

0.530

0.724

0.271

0.468

PACC

-11.106

0.246

0.468

-0.432

0.836

0.561

Global Cognition

0.202

0.925

0.595

0.302

0.345

0.498

Verbal Episodic Memory

0.592

0.782

0.559

0.082

0.788

0.559

Executive Function

0.029

0.99

0.607

-1.029

0.015

0.278

PACC

-0.417

0.944

0.595

0.351

0.707

0.555

Global Cognition

2.368

0.609

0.530

0.06

0.944

0.595

Verbal Episodic Memory

2.411

0.602

0.530

0.125

0.879

0.573

Executive Function

11.884

0.013

0.278

-1.175

0.2

0.465

PACC

22.912

0.099

0.465

-5.453

0.057

0.465

Global Cognition

1.526

0.403

0.498

-0.165

0.609

0.530

Verbal Episodic Memory

1.598

0.381

0.498

-0.202

0.513

0.528

Executive Function

2.337

0.216

0.465

-0.421

0.23

0.465

PACC

1.246

0.822

0.561

-0.205

0.855

0.562

Global Cognition

-1.265

0.661

0.537

0.272

0.576

0.528

Verbal Episodic Memory

-1.809

0.529

0.528

0.405

0.384

0.498

Executive Function

3.066

0.304

0.498

0.317

0.568

0.528

PACC

3.95

0.634

0.531

-0.899

0.573

0.528

Global Cognition

2.74

0.188

0.465

-0.439

0.223

0.465

Verbal Episodic Memory

1.935

0.351

0.498

-0.222

0.521

0.528

Executive Function

1.231

0.567

0.528

-0.261

0.5

0.528

PACC

9.654

0.12

0.465

-2.171

0.07

0.465

Global Cognition

1.163

0.494

0.528

-0.226

0.48

0.528

Verbal Episodic Memory

0.786

0.643

0.531

-0.253

0.408

0.498

Executive Function

-0.457

0.795

0.559

0.21

0.542

0.528

PACC

1.036

0.829

0.561

0.758

0.467

0.528

Global Cognition

-0.523

0.848

0.561

0.489

0.318

0.498

Verbal Episodic Memory

-0.936

0.73

0.556

0.528

0.26

0.468

Executive Function

3.587

0.202

0.465

-0.199

0.704

0.555

PACC

-9.372

0.221

0.465

1.855

0.236

0.465

CpG_20_21 (n= 214)

CpG_23_24 (n= 214)

CpG_25_26_27_28 (n= 214)

CpG_29_30_31 (n= 214)

CpG_32 (n= 214)

CpG_33 (n= 214)

CpG_34 (n= 214)

CpG_36 (n= 214)
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p-value

q-value

Global Cognition

-1.374

0.425

0.505

0.268

0.358

0.498

Verbal Episodic Memory

-0.897

0.602

0.530

0.072

0.797

0.559

Executive Function

-1.597

0.372

0.498

0.417

0.18

0.465

PACC

-0.02

0.997

0.607

1.069

0.273

0.468

Global Cognition

-2.215

0.554

0.528

-0.443

0.494

0.528

Verbal Episodic Memory

-1.747

0.639

0.531

-0.704

0.257

0.468

Executive Function

6.072

0.116

0.465

-0.628

0.367

0.498

PACC

-7.672

0.511

0.528

-0.837

0.697

0.555

Global Cognition

-0.523

0.848

0.561

0.489

0.318

0.498

Verbal Episodic Memory

-0.936

0.73

0.556

0.528

0.26

0.468

Executive Function

3.587

0.202

0.465

-0.199

0.704

0.555

PACC

-9.372

0.221

0.465

1.855

0.236

0.465

CpG_37 (n= 214)

CpG_38_39 (n= 214)

CpG_41 (n= 214)

Table A7.3 CLU promoter methylation and cognitive performance in A + Healthy Controls
table
Association between percentage methylation levels and baseline () and longitudinal ()
change in composite measures of cognition including a global cognition, verbal episodic
memory composite, executive function and Pre-clinical Alzheimer’s disease cognitive
composite (PACC) in only the A+ healthy controls (also corrected for age). A+, amyloid beta
positive. P-values of nominal significance italicised. P-values corrected for FDR = q-value. n
dependent on availability of cognitive data.
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